<!DOCTYPE html>
<html id="htmlEl" lang="en"><!-- NVCGPDQCancerInfoSummaryTemplate.aspx  --><head id="header">
<meta http-equiv="content-type" content="text/html; charset=UTF-8"><meta http-equiv="X-UA-Compatible" content="IE=edge"><meta charset="utf-8"><meta name="viewport" content="width=device-width, user-scalable=yes, initial-scale=1, minimum-scale=1"><title>
	Adult Central Nervous System Tumors Treatment (PDQ®)—Health Professional Version - National Cancer Institute
</title><link rel="preconnect" crossorigin="" href="https://cdnjs.cloudflare.com/"><link rel="preconnect" crossorigin="" href="https://ajax.googleapis.com/"><link rel="preconnect" crossorigin="" href="https://fonts.gstatic.com/"><link rel="preconnect" href="https://static.cancer.gov/"><link id="gFonts" rel="stylesheet" href="Adult%20Central%20Nervous%20System%20Tumors%20Treatment%20(PDQ%C2%AE)%E2%80%94Health%20Professional%20Version%20-%20National%20Cancer%20Institute_files/css.css"><script async="" src="Adult%20Central%20Nervous%20System%20Tumors%20Treatment%20(PDQ%C2%AE)%E2%80%94Health%20Professional%20Version%20-%20National%20Cancer%20Institute_files/analytics.js"></script><script src="Adult%20Central%20Nervous%20System%20Tumors%20Treatment%20(PDQ%C2%AE)%E2%80%94Health%20Professional%20Version%20-%20National%20Cancer%20Institute_files/satelliteLib-5b3dcf1f2676c378b518a1583ef5355acd83cd3d.js">

</script><link rel="apple-touch-icon" sizes="180x180" href="https://www.cancer.gov/publishedcontent/images/images/design-elements/icons/favicons/apple-touch-icon.png?v=oLa52veKe8"><link rel="icon" type="image/png" href="https://www.cancer.gov/publishedcontent/images/images/design-elements/icons/favicons/favicon-32x32.png?v=oLa52veKe8" sizes="32x32"><link rel="icon" type="image/png" href="https://www.cancer.gov/publishedcontent/images/images/design-elements/icons/favicons/favicon-16x16.png?v=oLa52veKe8" sizes="16x16"><link rel="manifest" href="https://www.cancer.gov/publishedcontent/images/images/design-elements/icons/favicons/manifest.json?v=oLa52veKe8"><link rel="mask-icon" href="https://www.cancer.gov/publishedcontent/images/images/design-elements/icons/favicons/safari-pinned-tab.svg?v=oLa52veKe8" color="#c0143c"><link rel="shortcut icon" href="https://www.cancer.gov/publishedcontent/images/images/design-elements/icons/favicons/favicon.ico?v=oLa52veKe8"><meta name="apple-mobile-web-app-title" content="Cancer.gov"><meta name="application-name" content="Cancer.gov"><meta name="msapplication-config" content="/publishedcontent/images/images/design-elements/icons/favicons/browserconfig.xml?v=oLa52veKe8"><meta name="theme-color" content="#ffffff"><script src="Adult%20Central%20Nervous%20System%20Tumors%20Treatment%20(PDQ%C2%AE)%E2%80%94Health%20Professional%20Version%20-%20National%20Cancer%20Institute_files/jquery.js" type="text/javascript"></script><script src="Adult%20Central%20Nervous%20System%20Tumors%20Treatment%20(PDQ%C2%AE)%E2%80%94Health%20Professional%20Version%20-%20National%20Cancer%20Institute_files/jquery-ui.js" defer="defer" type="text/javascript"></script><script src="Adult%20Central%20Nervous%20System%20Tumors%20Treatment%20(PDQ%C2%AE)%E2%80%94Health%20Professional%20Version%20-%20National%20Cancer%20Institute_files/cdeConfig.js" type="text/javascript"></script><link href="Adult%20Central%20Nervous%20System%20Tumors%20Treatment%20(PDQ%C2%AE)%E2%80%94Health%20Professional%20Version%20-%20National%20Cancer%20Institute_files/Common.css" rel="stylesheet"><script src="Adult%20Central%20Nervous%20System%20Tumors%20Treatment%20(PDQ%C2%AE)%E2%80%94Health%20Professional%20Version%20-%20National%20Cancer%20Institute_files/Common.js" defer="defer" type="text/javascript"></script><script src="Adult%20Central%20Nervous%20System%20Tumors%20Treatment%20(PDQ%C2%AE)%E2%80%94Health%20Professional%20Version%20-%20National%20Cancer%20Institute_files/PDQPage.js" defer="defer" type="text/javascript"></script><link href="Adult%20Central%20Nervous%20System%20Tumors%20Treatment%20(PDQ%C2%AE)%E2%80%94Health%20Professional%20Version%20-%20National%20Cancer%20Institute_files/PDQPage.css" rel="stylesheet"><link rel="canonical" href="https://www.cancer.gov/types/brain/hp/adult-brain-treatment-pdq"><meta name="keywords" content="adult brain tumor"><meta name="description" content="Adult central nervous system tumor treatment options include surgery, radiosurgery, radiation therapy, chemotherapy, surveillance, and supportive care. Get detailed information about the types and treatment of newly diagnosed and recurrent brain and spinal tumors in this clinician summary."><meta name="content-language" content="en"><meta name="dcterms.coverage" content="nciglobal,ncienterprise"><meta name="dcterms.subject" content="Cancer Types"><meta name="dcterms.isPartOf" content="Cancer Types Landing Page"><meta name="dcterms.issued" content="01/01/1980"><meta name="english-linking-policy" content="/policies/linking"><meta name="espanol-linking-policy" content="/espanol/politicas/enlaces"><meta name="dcterms.type" content="pdqCancerInfoSummary"><meta property="og:title" content="Adult Central Nervous System Tumors Treatment"><meta property="og:description" content="Adult central nervous system tumor treatment options include surgery, radiosurgery, radiation therapy, chemotherapy, surveillance, and supportive care. Get detailed information about the types and treatment of newly diagnosed and recurrent brain and spinal tumors in this clinician summary."><meta property="og:type" content="Website"><meta property="og:site_name" content="National Cancer Institute"><meta property="og:url" content="https://www.cancer.gov/types/brain/hp/adult-brain-treatment-pdq"><meta name="twitter:card" content="summary"><link rel="schema.dcterms" href="http://purl.org/dc/terms/"><link href="https://www.cancer.gov/espanol/tipos/cerebro/pro/tratamiento-cerebro-adultos-pdq" hreflang="es" rel="alternate"><link href="https://www.cancer.gov/types/brain/hp/adult-brain-treatment-pdq" hreflang="en" rel="alternate"><script src="Adult%20Central%20Nervous%20System%20Tumors%20Treatment%20(PDQ%C2%AE)%E2%80%94Health%20Professional%20Version%20-%20National%20Cancer%20Institute_files/s-code-contents-e0fd50715ab6c34f5a371fb2d2b777dbe851f382.js"></script></head>

<body id="Body1" class="pdqcancerinfosummary" data-cde-contenttype="pdqcancerinfosummary" data-cde-pagetemplate="NVCGPDQCancerInfoSummaryTemplate" data-cde-templatetheme="default" data-cde-contentid="3240">
<div class="skip"><a title="Skip to content" href="#main">Skip to content</a></div>
<div class="wa-data-element hide" data-prop3="/types/brain/hp/adult-brain-treatment-pdq" data-prop6="Adult Central Nervous System Tumors Treatment" data-prop25="01/01/1980" data-prop44="Cancer Types Landing Page" data-evar44="Cancer Types Landing Page">

</div>
<!-- NOTIFICATION AREA -->


<!-- END NOTIFICATION AREA -->

<!-- HEADER -->
<header class="push" role="banner">
    <div id="nvcgSlSiteBanner" class="row">
	<div class="contentid-911584 slot-item only-SI nci-logo-pages large-12 columns">
		
<a href="https://www.cancer.gov/"><img src="Adult%20Central%20Nervous%20System%20Tumors%20Treatment%20(PDQ%C2%AE)%E2%80%94Health%20Professional%20Version%20-%20National%20Cancer%20Institute_files/nci-logo-full.svg" alt="National Cancer Institute" width="60%"></a>
	</div>
</div>
</header>
<!-- END HEADER -->
<!-- Begin Page -->
<div id="page">
    <!-- Global nav/utilit bar/language  -->
    <div class="fixedtotop" style="position:relative">
        <div class="headroom-area slide headroom--top headroom--not-bottom">
            <!-- LANGUAGE BAR -->
            <div class="language-bar">
                <div class="row sitewide-language">
                    <div id="LangList1" class="large-12 columns">
	<ul>
		<li><a onclick="NCIAnalytics.ClickLink(this,'Language Select Spanish');" href="https://www.cancer.gov/espanol/tipos/cerebro/pro/tratamiento-cerebro-adultos-pdq">Español</a></li>
	</ul>
</div>
                </div>
            </div><!-- end "language-bar" -->
            <!-- END LANGUAGE BAR -->

            <!-- UTILITY NAV -->
            <div id="nvcgSlUtilityBar" class="utility-background hide-for-medium-down">
	<div class="contentid-911757 slot-item only-SI row utility">
		<div class="rawHtml"><div class="large-12 columns utility">
<span><a href="https://www.cancer.gov/contact">1-800-4-CANCER</a></span>
<span><a href="https://livehelp.cancer.gov/" onclick="window.open('https://livehelp.cancer.gov/', 'LiveHelp','scrollbars=yes,resizable=yes,menubar=yes,toolbar=yes,location=yes,width=650,height=600'); return false;">Live Chat</a></span>
<span><a href="https://www.cancer.gov/publications">Publications</a></span>
<span id="utility-dictionary" class="link"> <a href="https://www.cancer.gov/publications/dictionaries/cancer-terms">Dictionary</a></span>
</div></div>
	</div>
</div>
            <!-- END UTILITY NAV -->
        </div><!-- end "headroom-area" -->
        <!-- BEGIN NAVIGATION -->
        <!-- Begin nav-search bar -->
        <div class="nav-search-bar gradient header"><div id="nvcgSlMainNav" class="row">
	<div class="contentid-113330 slot-item first-SI">
		<div class="navigation">
			<div class="mobile-menu-bar"><button type="button" class="open-panel nav-header menu-btn">Menu</button><a href="https://www.cancer.gov/global/contact" class="nav-contact">Contact</a><a href="https://www.cancer.gov/publications/dictionaries/cancer-terms" class="nav-dictionary">Dictionary</a><button type="button" class="nav-search">Search</button></div><nav id="mega-nav" role="navigation">
				<ul class="menu nav-menu">
					<li class="nav-item lvl-1 has-children item-1"><div class="nav-item-title">
						<a href="https://www.cancer.gov/about-cancer" id="accessible-megamenu-1559973650476-1" aria-haspopup="true" aria-controls="accessible-megamenu-1559973650476-2" aria-expanded="false">About Cancer</a>
					<button class="toggle" aria-expanded="false" type="button"><span class="hidden">Expand</span></button></div><ul class="mobile-item">
						<li class="lvl-2 has-children"><div class="nav-item-title">
							<a href="https://www.cancer.gov/about-cancer/understanding">Understanding Cancer</a>
						<button class="toggle" aria-expanded="false" type="button"><span class="hidden">Expand</span></button></div><ul class="mobile-item">
							<li class="lvl-3"><div class="nav-item-title">
								<a href="https://www.cancer.gov/about-cancer/understanding/what-is-cancer">What Is Cancer?</a>
							</div></li><li class="lvl-3"><div class="nav-item-title">
								<a href="https://www.cancer.gov/about-cancer/understanding/statistics">Cancer Statistics</a>
							</div></li><li class="lvl-3"><div class="nav-item-title">
								<a href="https://www.cancer.gov/about-cancer/understanding/disparities">Cancer Disparities</a>
							</div></li>
						</ul></li><li class="lvl-2 has-children"><div class="nav-item-title">
							<a href="https://www.cancer.gov/about-cancer/causes-prevention">Cancer Causes and Prevention</a>
						<button class="toggle" aria-expanded="false" type="button"><span class="hidden">Expand</span></button></div><ul class="mobile-item">
							<li class="lvl-3"><div class="nav-item-title">
								<a href="https://www.cancer.gov/about-cancer/causes-prevention/risk">Risk Factors </a>
							</div></li><li class="lvl-3"><div class="nav-item-title">
								<a href="https://www.cancer.gov/about-cancer/causes-prevention/genetics">Genetics</a>
							</div></li><li class="lvl-3"><div class="nav-item-title">
								<a href="https://www.cancer.gov/about-cancer/causes-prevention/patient-prevention-overview-pdq">Cancer Prevention Overview</a>
							</div></li><li class="lvl-3"><div class="nav-item-title">
								<a href="https://www.cancer.gov/about-cancer/causes-prevention/research">Research</a>
							</div></li>
						</ul></li><li class="lvl-2 has-children"><div class="nav-item-title">
							<a href="https://www.cancer.gov/about-cancer/screening">Cancer Screening</a>
						<button class="toggle" aria-expanded="false" type="button"><span class="hidden">Expand</span></button></div><ul class="mobile-item">
							<li class="lvl-3"><div class="nav-item-title">
								<a href="https://www.cancer.gov/about-cancer/screening/patient-screening-overview-pdq">Cancer Screening Overview</a>
							</div></li><li class="lvl-3"><div class="nav-item-title">
								<a href="https://www.cancer.gov/about-cancer/screening/screening-tests">Screening Tests</a>
							</div></li><li class="lvl-3"><div class="nav-item-title">
								<a href="https://www.cancer.gov/about-cancer/screening/research">Research</a>
							</div></li>
						</ul></li><li class="lvl-2 has-children"><div class="nav-item-title">
							<a href="https://www.cancer.gov/about-cancer/diagnosis-staging">Diagnosis and Staging</a>
						<button class="toggle" aria-expanded="false" type="button"><span class="hidden">Expand</span></button></div><ul class="mobile-item">
							<li class="lvl-3"><div class="nav-item-title">
								<a href="https://www.cancer.gov/about-cancer/diagnosis-staging/symptoms">Symptoms </a>
							</div></li><li class="lvl-3"><div class="nav-item-title">
								<a href="https://www.cancer.gov/about-cancer/diagnosis-staging/diagnosis">Diagnosis</a>
							</div></li><li class="lvl-3"><div class="nav-item-title">
								<a href="https://www.cancer.gov/about-cancer/diagnosis-staging/staging">Staging</a>
							</div></li><li class="lvl-3"><div class="nav-item-title">
								<a href="https://www.cancer.gov/about-cancer/diagnosis-staging/prognosis">Prognosis</a>
							</div></li><li class="lvl-3"><div class="nav-item-title">
								<a href="https://www.cancer.gov/about-cancer/diagnosis-staging/questions">Questions to Ask about Your Diagnosis</a>
							</div></li><li class="lvl-3"><div class="nav-item-title">
								<a href="https://www.cancer.gov/about-cancer/diagnosis-staging/research">Research</a>
							</div></li>
						</ul></li><li class="lvl-2 has-children"><div class="nav-item-title">
							<a href="https://www.cancer.gov/about-cancer/treatment">Cancer Treatment</a>
						<button class="toggle" aria-expanded="false" type="button"><span class="hidden">Expand</span></button></div><ul class="mobile-item">
							<li class="lvl-3"><div class="nav-item-title">
								<a href="https://www.cancer.gov/about-cancer/treatment/types">Types of Cancer Treatment</a>
							</div></li><li class="lvl-3"><div class="nav-item-title">
								<a href="https://www.cancer.gov/about-cancer/treatment/side-effects">Side Effects of Cancer Treatment</a>
							</div></li><li class="lvl-3"><div class="nav-item-title">
								<a href="https://www.cancer.gov/about-cancer/treatment/clinical-trials">Clinical Trials Information</a>
							</div></li><li class="lvl-3"><div class="nav-item-title">
								<a href="https://www.cancer.gov/about-cancer/treatment/drugs">A to Z List of Cancer Drugs</a>
							</div></li><li class="lvl-3"><div class="nav-item-title">
								<a href="https://www.cancer.gov/about-cancer/treatment/cam">Complementary &amp; Alternative Medicine (CAM)</a>
							</div></li><li class="lvl-3"><div class="nav-item-title">
								<a href="https://www.cancer.gov/about-cancer/treatment/questions">Questions to Ask about Your Treatment</a>
							</div></li><li class="lvl-3"><div class="nav-item-title">
								<a href="https://www.cancer.gov/about-cancer/treatment/research">Research</a>
							</div></li>
						</ul></li><li class="lvl-2 has-children"><div class="nav-item-title">
							<a href="https://www.cancer.gov/about-cancer/coping">Coping with Cancer</a>
						<button class="toggle" aria-expanded="false" type="button"><span class="hidden">Expand</span></button></div><ul class="mobile-item">
							<li class="lvl-3"><div class="nav-item-title">
								<a href="https://www.cancer.gov/about-cancer/coping/feelings">Feelings and Cancer</a>
							</div></li><li class="lvl-3"><div class="nav-item-title">
								<a href="https://www.cancer.gov/about-cancer/coping/adjusting-to-cancer">Adjusting to Cancer</a>
							</div></li><li class="lvl-3"><div class="nav-item-title">
								<a href="https://www.cancer.gov/about-cancer/coping/self-image">Self-Image &amp; Sexuality</a>
							</div></li><li class="lvl-3"><div class="nav-item-title">
								<a href="https://www.cancer.gov/about-cancer/coping/day-to-day">Day-to-Day Life</a>
							</div></li><li class="lvl-3"><div class="nav-item-title">
								<a href="https://www.cancer.gov/about-cancer/coping/caregiver-support">Support for Caregivers</a>
							</div></li><li class="lvl-3"><div class="nav-item-title">
								<a href="https://www.cancer.gov/about-cancer/coping/survivorship">Survivorship</a>
							</div></li><li class="lvl-3"><div class="nav-item-title">
								<a href="https://www.cancer.gov/about-cancer/coping/questions">Questions to Ask About Cancer</a>
							</div></li><li class="lvl-3"><div class="nav-item-title">
								<a href="https://www.cancer.gov/about-cancer/coping/research">Research</a>
							</div></li>
						</ul></li><li class="lvl-2 has-children"><div class="nav-item-title">
							<a href="https://www.cancer.gov/about-cancer/advanced-cancer">Advanced Cancer</a>
						<button class="toggle" aria-expanded="false" type="button"><span class="hidden">Expand</span></button></div><ul class="mobile-item">
							<li class="lvl-3"><div class="nav-item-title">
								<a href="https://www.cancer.gov/about-cancer/advanced-cancer/care-choices">Choices for Care</a>
							</div></li><li class="lvl-3"><div class="nav-item-title">
								<a href="https://www.cancer.gov/about-cancer/advanced-cancer/talking">Talking about Your Advanced Cancer</a>
							</div></li><li class="lvl-3"><div class="nav-item-title">
								<a href="https://www.cancer.gov/about-cancer/advanced-cancer/feelings">Coping with Your Feelings During Advanced Cancer</a>
							</div></li><li class="lvl-3"><div class="nav-item-title">
								<a href="https://www.cancer.gov/about-cancer/advanced-cancer/planning">Planning for Advanced Cancer</a>
							</div></li><li class="lvl-3"><div class="nav-item-title">
								<a href="https://www.cancer.gov/about-cancer/advanced-cancer/caregivers">Advanced Cancer and Caregivers</a>
							</div></li><li class="lvl-3"><div class="nav-item-title">
								<a href="https://www.cancer.gov/about-cancer/advanced-cancer/questions">Questions to Ask about Advanced Cancer</a>
							</div></li><li class="lvl-3"><div class="nav-item-title">
								<a href="https://www.cancer.gov/about-cancer/advanced-cancer/research">Research</a>
							</div></li>
						</ul></li><li class="lvl-2 has-children"><div class="nav-item-title">
							<a href="https://www.cancer.gov/about-cancer/managing-care">Managing Cancer Care</a>
						<button class="toggle" aria-expanded="false" type="button"><span class="hidden">Expand</span></button></div><ul class="mobile-item">
							<li class="lvl-3"><div class="nav-item-title">
								<a href="https://www.cancer.gov/about-cancer/managing-care/services">Finding Health Care Services</a>
							</div></li><li class="lvl-3"><div class="nav-item-title">
								<a href="https://www.cancer.gov/about-cancer/managing-care/track-care-costs">Costs &amp; Medical Information</a>
							</div></li><li class="lvl-3"><div class="nav-item-title">
								<a href="https://www.cancer.gov/about-cancer/managing-care/advance-directives">Advance Directives</a>
							</div></li><li class="lvl-3"><div class="nav-item-title">
								<a href="https://www.cancer.gov/about-cancer/managing-care/using-trusted-resources">Using Trusted Resources</a>
							</div></li>
						</ul></li>
					</ul><div aria-expanded="false" aria-haspopup="true" class="sub-nav-mega mega-menu-scroll" id="accessible-megamenu-1559973650476-2" role="group" aria-hidden="true" aria-labelledby="accessible-megamenu-1559973650476-1">
						<div class="sub-nav-group-wrapper"><div class="sub-nav-group-subwrapper"><ul class="sub-nav-group"><li><a href="https://www.cancer.gov/about-cancer/understanding" class="sub-nav-group-header">Understanding Cancer</a><ul><li><a href="https://www.cancer.gov/about-cancer/understanding/what-is-cancer">What Is Cancer</a></li><li><a href="https://www.cancer.gov/about-cancer/understanding/statistics">Cancer Statistics</a></li><li><a href="https://www.cancer.gov/about-cancer/understanding/disparities">Cancer Disparities</a></li></ul></li></ul><ul class="sub-nav-group"><li><a href="https://www.cancer.gov/about-cancer/causes-prevention" class="sub-nav-group-header">Causes &amp; Prevention</a><ul><li><a href="https://www.cancer.gov/about-cancer/causes-prevention/risk">Risk Factors</a></li><li><a href="https://www.cancer.gov/about-cancer/causes-prevention/genetics">Genetics</a></li><li><a href="https://www.cancer.gov/about-cancer/causes-prevention/patient-prevention-overview-pdq">Cancer Prevention Overview</a></li></ul></li></ul><ul class="sub-nav-group"><li><a href="https://www.cancer.gov/about-cancer/screening" class="sub-nav-group-header">Screening</a><ul><li><a href="https://www.cancer.gov/about-cancer/screening/patient-screening-overview-pdq">Cancer Screening Overview</a></li><li><a href="https://www.cancer.gov/about-cancer/screening/screening-tests">Screening Tests</a></li></ul></li></ul><ul class="sub-nav-group"><li><a href="https://www.cancer.gov/about-cancer/diagnosis-staging" class="sub-nav-group-header">Diagnosis &amp; Staging</a><ul><li><a href="https://www.cancer.gov/about-cancer/diagnosis-staging/symptoms">Symptoms</a></li><li><a href="https://www.cancer.gov/about-cancer/diagnosis-staging/diagnosis">Diagnosis</a></li><li><a href="https://www.cancer.gov/about-cancer/diagnosis-staging/staging">Staging</a></li><li><a href="https://www.cancer.gov/about-cancer/diagnosis-staging/prognosis">Prognosis</a></li></ul></li></ul><ul class="sub-nav-group"><li><a href="https://www.cancer.gov/about-cancer/treatment" class="sub-nav-group-header">Treatment</a><ul><li><a href="https://www.cancer.gov/about-cancer/treatment/types">Types of Treatment</a></li><li><a href="https://www.cancer.gov/about-cancer/treatment/side-effects/">Side Effects</a></li><li><a href="https://www.cancer.gov/about-cancer/treatment/clinical-trials">Clinical Trials</a></li><li><a href="https://www.cancer.gov/about-cancer/treatment/drugs">Cancer Drugs</a></li><li><a href="https://www.cancer.gov/about-cancer/treatment/cam">Complementary &amp; Alternative Medicine</a></li></ul></li></ul><ul class="sub-nav-group"><li><a href="https://www.cancer.gov/about-cancer/coping" class="sub-nav-group-header">Coping</a><ul><li><a href="https://www.cancer.gov/about-cancer/coping/feelings">Feelings &amp; Cancer</a></li><li><a href="https://www.cancer.gov/about-cancer/coping/adjusting-to-cancer">Adjusting to Cancer</a></li><li><a href="https://www.cancer.gov/about-cancer/coping/self-image">Self Image &amp; Sexuality</a></li><li><a href="https://www.cancer.gov/about-cancer/coping/day-to-day">Day to Day Life</a></li><li><a href="https://www.cancer.gov/about-cancer/coping/survivorship">Survivorship</a></li><li><a href="https://www.cancer.gov/about-cancer/coping/caregiver-support">Support for Caregivers</a></li><li><a href="https://www.cancer.gov/about-cancer/coping/questions">Questions to Ask About Cancer</a></li></ul></li></ul><ul class="sub-nav-group"><li><a href="https://www.cancer.gov/about-cancer/advanced-cancer" class="sub-nav-group-header">Advanced Cancer</a><ul><li><a href="https://www.cancer.gov/about-cancer/advanced-cancer/care-choices">Choices For Care</a></li><li><a href="https://www.cancer.gov/about-cancer/advanced-cancer/talking">Talking About Advanced Cancer</a></li><li><a href="https://www.cancer.gov/about-cancer/advanced-cancer/feelings">Coping With Your Feelings</a></li><li><a href="https://www.cancer.gov/about-cancer/advanced-cancer/planning">Planning for Advanced Cancer</a></li><li><a href="https://www.cancer.gov/about-cancer/advanced-cancer/caregivers">Advanced Cancer &amp; Caregivers</a></li></ul></li></ul><ul class="sub-nav-group"><li><a href="https://www.cancer.gov/about-cancer/managing-care" class="sub-nav-group-header">Managing Cancer Care</a><ul><li><a href="https://www.cancer.gov/about-cancer/managing-care/services">Finding Health Care Services</a></li><li><a href="https://www.cancer.gov/about-cancer/managing-care/track-care-costs">Managing Costs and Medical Information</a></li><li><a href="https://www.cancer.gov/about-cancer/managing-care/advance-directives">Advance Directives</a></li><li><a href="https://www.cancer.gov/about-cancer/managing-care/using-trusted-resources">Using Trusted Resources</a></li></ul></li></ul></div></div>
					<button class="toggle" aria-expanded="false" type="button"><span class="hidden">Expand</span></button></div></li><li class="nav-item lvl-1 contains-current has-children item-2"><div class="nav-item-title">
						<a href="https://www.cancer.gov/types" id="accessible-megamenu-1559973650499-3" aria-haspopup="true" aria-controls="accessible-megamenu-1559973650499-4" aria-expanded="false">Cancer Types</a>
					<button class="toggle" aria-expanded="true" type="button"><span class="hidden">Collapse</span></button></div><ul class="mobile-item" style="display: block;">
						<li class="lvl-2 has-children"><div class="nav-item-title">
							<a href="https://www.cancer.gov/types/aya">Adolescents and Young Adults with Cancer</a>
						<button class="toggle" aria-expanded="false" type="button"><span class="hidden">Expand</span></button></div><ul class="mobile-item">
							<li class="lvl-3"><div class="nav-item-title">
								<a href="https://www.cancer.gov/types/aya/research">Reports, Research, and Literature</a>
							</div></li>
						</ul></li><li class="lvl-2"><div class="nav-item-title">
							<a href="https://www.cancer.gov/types/by-body-location">Cancers by Body Location</a>
						</div></li><li class="lvl-2 has-children"><div class="nav-item-title">
							<a href="https://www.cancer.gov/types/childhood-cancers">Childhood Cancers</a>
						<button class="toggle" aria-expanded="false" type="button"><span class="hidden">Expand</span></button></div><ul class="mobile-item">
							<li class="lvl-3"><div class="nav-item-title">
								<a href="https://www.cancer.gov/types/childhood-cancers/late-effects-pdq">Late Effects of Childhood Cancer Treatment</a>
							</div></li><li class="lvl-3"><div class="nav-item-title">
								<a href="https://www.cancer.gov/types/childhood-cancers/pediatric-care-pdq">Pediatric Supportive Care</a>
							</div></li><li class="lvl-3"><div class="nav-item-title">
								<a href="https://www.cancer.gov/types/childhood-cancers/patient/unusual-cancers-childhood-pdq">Unusual Cancers of Childhood Treatment</a>
							</div></li><li class="lvl-3"><div class="nav-item-title">
								<a href="https://www.cancer.gov/types/childhood-cancers/pediatric-genomics-hp-pdq">Childhood Cancer Genomics</a>
							</div></li><li class="lvl-3"><div class="nav-item-title">
								<a href="https://www.cancer.gov/types/childhood-cancers/research">Study Findings</a>
							</div></li>
						</ul></li><li class="lvl-2 has-children"><div class="nav-item-title">
							<a href="https://www.cancer.gov/types/metastatic-cancer">Metastatic Cancer</a>
						<button class="toggle" aria-expanded="false" type="button"><span class="hidden">Expand</span></button></div><ul class="mobile-item">
							<li class="lvl-3"><div class="nav-item-title">
								<a href="https://www.cancer.gov/types/metastatic-cancer/research">Metastatic Cancer Research</a>
							</div></li>
						</ul></li><li class="lvl-2"><div class="nav-item-title">
							<a href="https://www.cancer.gov/types/common-cancers">Common Cancer Types</a>
						</div></li><li class="lvl-2"><div class="nav-item-title">
							<a href="https://www.cancer.gov/types/recurrent-cancer">Recurrent Cancer</a>
						</div></li>
					</ul><div aria-expanded="false" aria-haspopup="true" class="sub-nav-mega" id="accessible-megamenu-1559973650499-4" role="group" aria-hidden="true" aria-labelledby="accessible-megamenu-1559973650499-3">
						<div class="sub-nav-group-wrapper"><div class="sub-nav-group-subwrapper"><ul class="sub-nav-group cancer-types-border-container" style="height: 221.117px;"><li><a href="https://www.cancer.gov/types/common-cancers" class="sub-nav-group-header">Common Cancer Types</a><ul><li><a href="https://www.cancer.gov/types/bladder">Bladder Cancer</a></li><li><a href="https://www.cancer.gov/types/breast">Breast Cancer</a></li><li><a href="https://www.cancer.gov/types/colorectal">Colorectal Cancer</a></li><li><a href="https://www.cancer.gov/types/kidney">Kidney (Renal Cell) Cancer</a></li><li><a href="https://www.cancer.gov/types/leukemia">Leukemia</a></li></ul><ul><li><a href="https://www.cancer.gov/types/liver">Liver Cancer</a></li><li><a href="https://www.cancer.gov/types/lung">Lung Cancer</a></li><li><a href="https://www.cancer.gov/types/lymphoma">Lymphoma</a></li><li><a href="https://www.cancer.gov/types/pancreatic">Pancreatic Cancer</a></li></ul><ul><li><a href="https://www.cancer.gov/types/prostate">Prostate Cancer</a></li><li><a href="https://www.cancer.gov/types/skin">Skin Cancer</a></li><li><a href="https://www.cancer.gov/types/thyroid">Thyroid Cancer</a></li><li><a href="https://www.cancer.gov/types/uterine">Uterine Cancer</a></li></ul></li></ul><ul class="sub-nav-group"><li><a href="https://www.cancer.gov/types" class="sub-nav-group-header">All Cancer Types</a><ul><li><a href="https://www.cancer.gov/types">A to Z List of Cancers</a></li><li><a href="https://www.cancer.gov/types/by-body-location">Cancers by Body Location</a></li><li><a href="https://www.cancer.gov/types/childhood-cancers">Childhood Cancers</a></li><li><a href="https://www.cancer.gov/types/aya">Adolescent &amp; Young Adult Cancers</a></li><li><a href="https://www.cancer.gov/types/metastatic-cancer">Metastatic Cancer</a></li><li><a href="https://www.cancer.gov/types/recurrent-cancer">Recurrent Cancer</a></li></ul></li></ul></div></div>
					<button class="toggle" aria-expanded="true" type="button"><span class="hidden">Collapse</span></button></div></li><li class="nav-item lvl-1 has-children item-3"><div class="nav-item-title">
						<a href="https://www.cancer.gov/research" id="accessible-megamenu-1559973650510-5" aria-haspopup="true" aria-controls="accessible-megamenu-1559973650510-6" aria-expanded="false">Research</a>
					<button class="toggle" aria-expanded="false" type="button"><span class="hidden">Expand</span></button></div><ul class="mobile-item">
						<li class="lvl-2 has-children"><div class="nav-item-title">
							<a href="https://www.cancer.gov/research/nci-role">NCI’s Role in Cancer Research</a>
						<button class="toggle" aria-expanded="false" type="button"><span class="hidden">Expand</span></button></div><ul class="mobile-item">
							<li class="lvl-3"><div class="nav-item-title">
								<a href="https://www.cancer.gov/research/nci-role/intramural">Intramural Research</a>
							</div></li><li class="lvl-3"><div class="nav-item-title">
								<a href="https://www.cancer.gov/research/nci-role/extramural">Extramural Research</a>
							</div></li><li class="lvl-3"><div class="nav-item-title">
								<a href="https://www.cancer.gov/research/nci-role/bioinformatics">Bioinformatics, Big Data, and Cancer</a>
							</div></li><li class="lvl-3"><div class="nav-item-title">
								<a href="https://www.cancer.gov/research/nci-role/cancer-centers">NCI-Designated Cancer Centers</a>
							</div></li><li class="lvl-3"><div class="nav-item-title">
								<a href="https://www.cancer.gov/research/nci-role/fnlcr">Frederick National Laboratory for Cancer Research </a>
							</div></li><li class="lvl-3"><div class="nav-item-title">
								<a href="https://www.cancer.gov/research/nci-role/partners-collaborators">Partners &amp; Collaborators</a>
							</div></li><li class="lvl-3"><div class="nav-item-title">
								<a href="https://www.cancer.gov/research/nci-role/spotlight">Spotlight on Scientists</a>
							</div></li>
						</ul></li><li class="lvl-2 has-children"><div class="nav-item-title">
							<a href="https://www.cancer.gov/research/areas">Research Areas</a>
						<button class="toggle" aria-expanded="false" type="button"><span class="hidden">Expand</span></button></div><ul class="mobile-item">
							<li class="lvl-3"><div class="nav-item-title">
								<a href="https://www.cancer.gov/research/areas/biology">Cancer Biology Research</a>
							</div></li><li class="lvl-3"><div class="nav-item-title">
								<a href="https://www.cancer.gov/research/areas/genomics">Cancer Genomics Research</a>
							</div></li><li class="lvl-3"><div class="nav-item-title">
								<a href="https://www.cancer.gov/research/areas/causes">Research on Causes of Cancer</a>
							</div></li><li class="lvl-3"><div class="nav-item-title">
								<a href="https://www.cancer.gov/research/areas/diagnosis">Cancer Diagnosis Research </a>
							</div></li><li class="lvl-3"><div class="nav-item-title">
								<a href="https://www.cancer.gov/research/areas/prevention">Cancer Prevention Research </a>
							</div></li><li class="lvl-3"><div class="nav-item-title">
								<a href="https://www.cancer.gov/research/areas/screening">Screening &amp; Early Detection</a>
							</div></li><li class="lvl-3"><div class="nav-item-title">
								<a href="https://www.cancer.gov/research/areas/treatment">Cancer Treatment Research</a>
							</div></li><li class="lvl-3"><div class="nav-item-title">
								<a href="https://www.cancer.gov/research/areas/public-health">Cancer &amp; Public Health</a>
							</div></li><li class="lvl-3"><div class="nav-item-title">
								<a href="https://www.cancer.gov/research/areas/disparities">Cancer Health Disparities</a>
							</div></li><li class="lvl-3"><div class="nav-item-title">
								<a href="https://www.cancer.gov/research/areas/childhood">Childhood Cancers Research</a>
							</div></li><li class="lvl-3"><div class="nav-item-title">
								<a href="https://www.cancer.gov/research/areas/clinical-trials">Clinical Trials Research</a>
							</div></li><li class="lvl-3"><div class="nav-item-title">
								<a href="https://www.cancer.gov/research/areas/global-health">Global Cancer Research</a>
							</div></li>
						</ul></li><li class="lvl-2"><div class="nav-item-title">
							<a href="https://www.cancer.gov/research/key-initiatives">Key Initiatives</a>
						</div></li><li class="lvl-2 has-children"><div class="nav-item-title">
							<a href="https://www.cancer.gov/research/progress">Progress</a>
						<button class="toggle" aria-expanded="false" type="button"><span class="hidden">Expand</span></button></div><ul class="mobile-item">
							<li class="lvl-3"><div class="nav-item-title">
								<a href="https://www.cancer.gov/research/progress/annual-report-nation">Annual Report to the Nation</a>
							</div></li><li class="lvl-3"><div class="nav-item-title">
								<a href="https://www.cancer.gov/research/progress/250-years-milestones">Milestones in Cancer Research and Discovery</a>
							</div></li><li class="lvl-3"><div class="nav-item-title">
								<a href="https://www.cancer.gov/research/progress/discovery">Stories of Discovery</a>
							</div></li>
						</ul></li><li class="lvl-2 has-children"><div class="nav-item-title">
							<a href="https://www.cancer.gov/research/resources">Resources for Researchers</a>
						<button class="toggle" aria-expanded="false" type="button"><span class="hidden">Expand</span></button></div><ul class="mobile-item">
							<li class="lvl-3"><div class="nav-item-title">
								<a href="https://www.cancer.gov/research/resources/cryoem">Cryo-EM</a>
							</div></li><li class="lvl-3"><div class="nav-item-title">
								<a href="https://www.cancer.gov/research/resources/terminology">Terminology Resources</a>
							</div></li>
						</ul></li>
					</ul><div aria-expanded="false" aria-haspopup="true" class="sub-nav-mega mega-menu-scroll" id="accessible-megamenu-1559973650510-6" role="group" aria-hidden="true" aria-labelledby="accessible-megamenu-1559973650510-5">
						<div class="sub-nav-group-wrapper"><div class="sub-nav-group-subwrapper"><ul class="sub-nav-group"><li><a href="https://www.cancer.gov/research/nci-role" class="sub-nav-group-header">NCI's Role in Cancer Research</a><ul><li><a href="https://www.cancer.gov/research/nci-role/intramural">Intramural Research</a></li><li><a href="https://www.cancer.gov/research/nci-role/extramural">Extramural Research</a></li><li><a href="https://www.cancer.gov/research/nci-role/bioinformatics">Bioinformatics &amp; Big Data</a></li><li><a href="https://www.cancer.gov/research/nci-role/cancer-centers">NCI-Designated Cancer Centers</a></li><li><a href="https://www.cancer.gov/research/nci-role/fnlcr">Frederick National Lab</a></li><li><a href="https://www.cancer.gov/research/nci-role/partners-collaborators">Partners &amp; Collaborators</a></li><li><a href="https://www.cancer.gov/research/nci-role/spotlight">Spotlight on Scientists</a></li></ul></li></ul><ul class="sub-nav-group"><li><a href="https://www.cancer.gov/research/areas" class="sub-nav-group-header">NCI Research Areas</a><ul><li><a href="https://www.cancer.gov/research/areas/biology">Cancer Biology</a></li><li><a href="https://www.cancer.gov/research/areas/genomics">Cancer Genomics</a></li><li><a href="https://www.cancer.gov/research/areas/causes">Causes of Cancer</a></li><li><a href="https://www.cancer.gov/research/areas/diagnosis">Diagnosis</a></li><li><a href="https://www.cancer.gov/research/areas/prevention">Prevention</a></li><li><a href="https://www.cancer.gov/research/areas/screening">Screening &amp; Early Detection</a></li><li><a href="https://www.cancer.gov/research/areas/treatment">Treatment</a></li><li><a href="https://www.cancer.gov/research/areas/public-health">Cancer &amp; Public Health</a></li><li><a href="https://www.cancer.gov/research/areas/disparities">Cancer Health Disparities</a></li><li><a href="https://www.cancer.gov/research/areas/childhood">Childhood Cancer</a></li><li><a href="https://www.cancer.gov/research/areas/clinical-trials">Clinical Trials</a></li><li><a href="https://www.cancer.gov/research/areas/global-health">Global Health</a></li></ul></li></ul><ul class="sub-nav-group"><li><a href="https://www.cancer.gov/research/key-initiatives" class="sub-nav-group-header">Key Initiatives</a><ul><li><a href="https://www.cancer.gov/research/key-initiatives/moonshot-cancer-initiative">Cancer Moonshot</a></li><li><a href="https://www.cancer.gov/about-nci/organization/ccg/research/computational-genomics/gdc">Genomic Data Commons</a></li><li><a href="https://www.cancer.gov/research/areas/clinical-trials/nctn">National Clinical Trials Network</a></li><li><a href="https://www.cancer.gov/research/key-initiatives/ras">RAS Initiative</a></li></ul></li></ul><ul class="sub-nav-group"><li><a href="https://www.cancer.gov/research/progress" class="sub-nav-group-header">Progress</a><ul><li><a href="https://www.cancer.gov/research/progress/annual-report-nation">Annual Report to the Nation</a></li><li><a href="https://www.cancer.gov/research/progress/discovery">Stories of Discovery</a></li></ul></li><br><br><li><a href="https://www.cancer.gov/research/resources" class="sub-nav-group-header">Resources for Researchers</a></li></ul></div></div>
					<button class="toggle" aria-expanded="false" type="button"><span class="hidden">Expand</span></button></div></li><li class="nav-item lvl-1 has-children item-4"><div class="nav-item-title">
						<a href="https://www.cancer.gov/grants-training" id="accessible-megamenu-1559973650525-7" aria-haspopup="true" aria-controls="accessible-megamenu-1559973650525-8" aria-expanded="false">Grants &amp; Training</a>
					<button class="toggle" aria-expanded="false" type="button"><span class="hidden">Expand</span></button></div><ul class="mobile-item">
						<li class="lvl-2 has-children"><div class="nav-item-title">
							<a href="https://www.cancer.gov/grants-training/grants-funding">Research Grants</a>
						<button class="toggle" aria-expanded="false" type="button"><span class="hidden">Expand</span></button></div><ul class="mobile-item">
							<li class="lvl-3"><div class="nav-item-title">
								<a href="https://www.cancer.gov/grants-training/grants-funding/funding-opportunities">Research Funding Opportunities</a>
							</div></li><li class="lvl-3"><div class="nav-item-title">
								<a href="https://www.cancer.gov/grants-training/grants-funding/contacts">Research Program Contacts</a>
							</div></li><li class="lvl-3"><div class="nav-item-title">
								<a href="https://www.cancer.gov/grants-training/grants-funding/funding-strategy">Funding Strategy</a>
							</div></li>
						</ul></li><li class="lvl-2 has-children"><div class="nav-item-title">
							<a href="https://www.cancer.gov/grants-training/policies-process">Grants Policies and Process</a>
						<button class="toggle" aria-expanded="false" type="button"><span class="hidden">Expand</span></button></div><ul class="mobile-item">
							<li class="lvl-3"><div class="nav-item-title">
								<a href="https://www.cancer.gov/grants-training/policies-process/overview">Introduction to Grants Process</a>
							</div></li><li class="lvl-3"><div class="nav-item-title">
								<a href="https://www.cancer.gov/grants-training/policies-process/nci-policies">NCI Grant Policies</a>
							</div></li><li class="lvl-3"><div class="nav-item-title">
								<a href="https://www.cancer.gov/grants-training/policies-process/legal">Legal Requirements</a>
							</div></li>
						</ul></li><li class="lvl-2 has-children"><div class="nav-item-title">
							<a href="https://www.cancer.gov/grants-training/apply-grant">Apply for a Grant</a>
						<button class="toggle" aria-expanded="false" type="button"><span class="hidden">Expand</span></button></div><ul class="mobile-item">
							<li class="lvl-3"><div class="nav-item-title">
								<a href="https://www.cancer.gov/grants-training/apply-grant/development">Step 1: Application Development &amp; Submission</a>
							</div></li><li class="lvl-3"><div class="nav-item-title">
								<a href="https://www.cancer.gov/grants-training/apply-grant/receipt">Step 2: Application Receipt &amp; Assignment</a>
							</div></li><li class="lvl-3"><div class="nav-item-title">
								<a href="https://www.cancer.gov/grants-training/apply-grant/peer-review">Step 3: Peer Review and Funding Outcomes</a>
							</div></li><li class="lvl-3"><div class="nav-item-title">
								<a href="https://www.cancer.gov/grants-training/apply-grant/award-issuance">Step 4: Award Negotiation &amp; Issuance</a>
							</div></li>
						</ul></li><li class="lvl-2 has-children"><div class="nav-item-title">
							<a href="https://www.cancer.gov/grants-training/manage-award">Manage Your Award</a>
						<button class="toggle" aria-expanded="false" type="button"><span class="hidden">Expand</span></button></div><ul class="mobile-item">
							<li class="lvl-3"><div class="nav-item-title">
								<a href="https://www.cancer.gov/grants-training/manage-award/contacts">Grants Management Contacts</a>
							</div></li><li class="lvl-3"><div class="nav-item-title">
								<a href="https://www.cancer.gov/grants-training/manage-award/monitoring">Monitoring</a>
							</div></li><li class="lvl-3"><div class="nav-item-title">
								<a href="https://www.cancer.gov/grants-training/manage-award/prior-approvals">Prior Approvals</a>
							</div></li><li class="lvl-3"><div class="nav-item-title">
								<a href="https://www.cancer.gov/grants-training/manage-award/report-audit">Annual Reporting and Auditing</a>
							</div></li><li class="lvl-3"><div class="nav-item-title">
								<a href="https://www.cancer.gov/grants-training/manage-award/grant-transfer">Transfer of a Grant</a>
							</div></li><li class="lvl-3"><div class="nav-item-title">
								<a href="https://www.cancer.gov/grants-training/manage-award/grant-closeout">Grant Closeout</a>
							</div></li>
						</ul></li><li class="lvl-2 has-children"><div class="nav-item-title">
							<a href="https://www.cancer.gov/grants-training/training">Training</a>
						<button class="toggle" aria-expanded="false" type="button"><span class="hidden">Expand</span></button></div><ul class="mobile-item">
							<li class="lvl-3"><div class="nav-item-title">
								<a href="https://www.cancer.gov/grants-training/training/at-nci">Cancer Training at NCI</a>
							</div></li><li class="lvl-3"><div class="nav-item-title">
								<a href="https://www.cancer.gov/grants-training/training/resources-trainees">Resources for Trainees</a>
							</div></li><li class="lvl-3"><div class="nav-item-title">
								<a href="https://www.cancer.gov/grants-training/training/funding">Funding for Cancer Training</a>
							</div></li><li class="lvl-3"><div class="nav-item-title">
								<a href="https://www.cancer.gov/grants-training/training/idwb">Building a Diverse Workforce</a>
							</div></li><li class="lvl-3"><div class="nav-item-title">
								<a href="https://www.cancer.gov/grants-training/training/about">About Center for Cancer Training (CCT)</a>
							</div></li><li class="lvl-3"><div class="nav-item-title">
								<a href="https://www.cancer.gov/grants-training/training/contact">CCT Staff &amp; Contact</a>
							</div></li>
						</ul></li>
					</ul><div aria-expanded="false" aria-haspopup="true" class="sub-nav-mega" id="accessible-megamenu-1559973650525-8" role="group" aria-hidden="true" aria-labelledby="accessible-megamenu-1559973650525-7">
						<div class="sub-nav-group-wrapper"><div class="sub-nav-group-subwrapper"><ul class="sub-nav-group"><li><a href="https://www.cancer.gov/grants-training/grants-funding" class="sub-nav-group-header">Research Grants</a><ul><li><a href="https://www.cancer.gov/grants-training/grants-funding/funding-opportunities">Funding Opportunities</a></li><li><a href="https://www.cancer.gov/grants-training/grants-funding/contacts">Research Program Contacts</a></li><li><a href="https://www.cancer.gov/grants-training/grants-funding/funding-strategy">Funding Strategy</a></li></ul></li><br><li><a href="https://www.cancer.gov/grants-training/policies-process" class="sub-nav-group-header">Grants Policies &amp; Process</a><ul><li><a href="https://www.cancer.gov/grants-training/policies-process/overview">Introduction to Grants Process</a></li><li><a href="https://www.cancer.gov/grants-training/policies-process/legal">Legal Requirements</a></li><li><a href="https://www.cancer.gov/grants-training/policies-process/nci-policies">NCI Policies</a></li></ul></li></ul><ul class="sub-nav-group"><li><a href="https://www.cancer.gov/grants-training/apply-grant" class="sub-nav-group-header">Apply for a Grant</a><ul><li><a href="https://www.cancer.gov/grants-training/apply-grant/development">Application Development &amp; Submission</a></li><li><a href="https://www.cancer.gov/grants-training/apply-grant/receipt">Receipt &amp; Assignment</a></li><li><a href="https://www.cancer.gov/grants-training/apply-grant/peer-review">Peer Review &amp; Outcomes</a></li><li><a href="https://www.cancer.gov/grants-training/apply-grant/award-issuance">Award Issuance</a></li></ul></li></ul><ul class="sub-nav-group"><li><a href="https://www.cancer.gov/grants-training/manage-award" class="sub-nav-group-header">Manage Your Award</a><ul><li><a href="https://www.cancer.gov/grants-training/manage-award/contacts">Grants Management Contacts</a></li><li><a href="https://www.cancer.gov/grants-training/manage-award/monitoring">Monitoring</a></li><li><a href="https://www.cancer.gov/grants-training/manage-award/prior-approvals">Prior Approvals</a></li><li><a href="https://www.cancer.gov/grants-training/manage-award/report-audit">Annual Reporting &amp; Auditing</a></li><li><a href="https://www.cancer.gov/grants-training/manage-award/grant-transfer">Grant Transfer</a></li><li><a href="https://www.cancer.gov/grants-training/manage-award/grant-closeout">Grant Closeout</a></li></ul></li><br><li><a href="https://www.cancer.gov/grants-training/contracts-business" class="sub-nav-group-header">Contracts &amp; Small Business</a></li></ul><ul class="sub-nav-group"><li><a href="https://www.cancer.gov/grants-training/training" class="sub-nav-group-header">Training</a><ul><li><a href="https://www.cancer.gov/grants-training/training/at-nci">Cancer Training at NCI (Intramural)</a></li><li><a href="https://www.cancer.gov/grants-training/training/resources-trainees">Resources for Trainees</a></li><li><a href="https://www.cancer.gov/grants-training/training/funding">Funding for Cancer Training (Extramural)</a></li><li><a href="https://www.cancer.gov/grants-training/training/diversity-training">Building a Diverse Workforce</a></li><li><a href="https://www.cancer.gov/grants-training/training/contact">Training Program Contacts</a></li></ul></li></ul></div></div>
					<button class="toggle" aria-expanded="false" type="button"><span class="hidden">Expand</span></button></div></li><li class="nav-item lvl-1 has-children item-5"><div class="nav-item-title">
						<a href="https://www.cancer.gov/news-events" id="accessible-megamenu-1559973650531-9" aria-haspopup="true" aria-controls="accessible-megamenu-1559973650531-10" aria-expanded="false">News &amp; Events</a>
					<button class="toggle" aria-expanded="false" type="button"><span class="hidden">Expand</span></button></div><ul class="mobile-item">
						<li class="lvl-2"><div class="nav-item-title">
							<a href="https://www.cancer.gov/news-events/press-releases/2019">Press Releases</a>
						</div></li><li class="lvl-2 has-children"><div class="nav-item-title">
							<a href="https://www.cancer.gov/news-events/media-resources">Resources for News Media</a>
						<button class="toggle" aria-expanded="false" type="button"><span class="hidden">Expand</span></button></div><ul class="mobile-item">
							<li class="lvl-3"><div class="nav-item-title">
								<a href="https://www.cancer.gov/news-events/media-resources/contacts">Media Contacts</a>
							</div></li><li class="lvl-3"><div class="nav-item-title">
								<a href="https://www.cancer.gov/news-events/media-resources/multicultural">Multicultural Media Outreach Program</a>
							</div></li><li class="lvl-3"><div class="nav-item-title">
								<a href="https://www.cancer.gov/news-events/media-resources/reporting-fellowships">Cancer Reporting Fellowships</a>
							</div></li>
						</ul></li><li class="lvl-2 has-children"><div class="nav-item-title">
							<a href="https://www.cancer.gov/news-events/events">Events</a>
						<button class="toggle" aria-expanded="false" type="button"><span class="hidden">Expand</span></button></div><ul class="mobile-item">
							<li class="lvl-3"><div class="nav-item-title">
								<a href="https://www.cancer.gov/news-events/events/scientific-meetings">Scientific Meetings &amp; Lectures</a>
							</div></li><li class="lvl-3"><div class="nav-item-title">
								<a href="https://www.cancer.gov/news-events/events/conferences">Conferences</a>
							</div></li><li class="lvl-3"><div class="nav-item-title">
								<a href="https://www.cancer.gov/news-events/events/advisory-board-meetings">Advisory Board Meetings</a>
							</div></li><li class="lvl-3"><div class="nav-item-title">
								<a href="https://www.cancer.gov/news-events/events/social-media">Social Media Events</a>
							</div></li>
						</ul></li><li class="lvl-2"><div class="nav-item-title">
							<a href="https://www.cancer.gov/news-events/cancer-currents-blog">Cancer Currents Blog</a>
						</div></li>
					</ul><div aria-expanded="false" aria-haspopup="true" class="sub-nav-mega" id="accessible-megamenu-1559973650531-10" role="group" aria-hidden="true" aria-labelledby="accessible-megamenu-1559973650531-9">
						<div class="sub-nav-group-wrapper"><div class="sub-nav-group-subwrapper"><ul class="sub-nav-group"><li><a href="https://www.cancer.gov/news-events/press-releases/2019" class="sub-nav-group-header">All Press Releases</a><ul><li><a href="https://www.cancer.gov/news-events/press-releases/2019">2019</a></li><li><a href="https://www.cancer.gov/news-events/press-releases/2018">2018</a></li><li><a href="https://www.cancer.gov/news-events/press-releases/2017">2017</a></li><li><a href="https://www.cancer.gov/news-events/press-releases/2016">2016</a></li><li><a href="https://www.cancer.gov/news-events/press-releases/2015">2015</a></li><li><a href="https://www.cancer.gov/news-events/press-releases/2014">2014</a></li></ul></li></ul><ul class="sub-nav-group"><li><a href="https://www.cancer.gov/news-events/media-resources" class="sub-nav-group-header">Media Resources</a><ul><li><a href="https://www.cancer.gov/news-events/media-resources/contacts">Media Contacts</a></li><li><a href="https://www.cancer.gov/news-events/media-resources/multicultural">Multicultural Media</a></li></ul></li></ul><ul class="sub-nav-group"><li><a href="https://www.cancer.gov/news-events/events" class="sub-nav-group-header">Events</a><ul><li><a href="https://www.cancer.gov/news-events/events/scientific-meetings">Scientific Meetings &amp; Lectures</a></li><li><a href="https://www.cancer.gov/news-events/events/conferences">Conferences</a></li><li><a href="https://www.cancer.gov/news-events/events/advisory-board-meetings">Advisory Board Meetings</a></li><li><a href="https://www.cancer.gov/news-events/events/social-media">Social Media</a></li></ul></li></ul><ul class="sub-nav-group"><li><a href="https://www.cancer.gov/news-events/cancer-currents-blog" class="sub-nav-group-header">Cancer Currents Blog</a></li></ul></div></div>
					<button class="toggle" aria-expanded="false" type="button"><span class="hidden">Expand</span></button></div></li><li class="nav-item lvl-1 has-children item-6"><div class="nav-item-title">
						<a href="https://www.cancer.gov/about-nci" id="accessible-megamenu-1559973650541-11" aria-haspopup="true" aria-controls="accessible-megamenu-1559973650541-12" aria-expanded="false">About NCI</a>
					<button class="toggle" aria-expanded="false" type="button"><span class="hidden">Expand</span></button></div><ul class="mobile-item">
						<li class="lvl-2 has-children"><div class="nav-item-title">
							<a href="https://www.cancer.gov/about-nci/overview">NCI Overview</a>
						<button class="toggle" aria-expanded="false" type="button"><span class="hidden">Expand</span></button></div><ul class="mobile-item">
							<li class="lvl-3"><div class="nav-item-title">
								<a href="https://www.cancer.gov/about-nci/overview/history">History</a>
							</div></li><li class="lvl-3"><div class="nav-item-title">
								<a href="https://www.cancer.gov/about-nci/overview/contributing">Contributing to Cancer Research</a>
							</div></li><li class="lvl-3"><div class="nav-item-title">
								<a href="https://www.cancer.gov/about-nci/overview/strategic-planning">Strategic Planning </a>
							</div></li>
						</ul></li><li class="lvl-2 has-children"><div class="nav-item-title">
							<a href="https://www.cancer.gov/about-nci/leadership">Leadership</a>
						<button class="toggle" aria-expanded="false" type="button"><span class="hidden">Expand</span></button></div><ul class="mobile-item">
							<li class="lvl-3"><div class="nav-item-title">
								<a href="https://www.cancer.gov/about-nci/leadership/director">Director's Page</a>
							</div></li><li class="lvl-3"><div class="nav-item-title">
								<a href="https://www.cancer.gov/about-nci/leadership/previous">Previous NCI Directors</a>
							</div></li>
						</ul></li><li class="lvl-2"><div class="nav-item-title">
							<a href="https://www.cancer.gov/about-nci/organization">NCI Organization</a>
						</div></li><li class="lvl-2"><div class="nav-item-title">
							<a href="https://www.cancer.gov/about-nci/advisory-boards">Advisory Boards and Review Groups</a>
						</div></li><li class="lvl-2 has-children"><div class="nav-item-title">
							<a href="https://www.cancer.gov/about-nci/budget">Budget &amp; Appropriations</a>
						<button class="toggle" aria-expanded="false" type="button"><span class="hidden">Expand</span></button></div><ul class="mobile-item">
							<li class="lvl-3"><div class="nav-item-title">
								<a href="https://www.cancer.gov/about-nci/budget/about-annual-plan">About the Annual Plan &amp; Budget Proposal</a>
							</div></li><li class="lvl-3"><div class="nav-item-title">
								<a href="https://www.cancer.gov/about-nci/budget/congressional-justification">NCI Congressional Justification</a>
							</div></li><li class="lvl-3"><div class="nav-item-title">
								<a href="https://www.cancer.gov/about-nci/budget/fact-book">NCI Budget Fact Book</a>
							</div></li>
						</ul></li><li class="lvl-2"><div class="nav-item-title">
							<a href="https://www.cancer.gov/about-nci/careers">Careers at NCI</a>
						</div></li><li class="lvl-2"><div class="nav-item-title">
							<a href="https://www.cancer.gov/about-nci/visit">Visitor Information</a>
						</div></li><li class="lvl-2 has-children"><div class="nav-item-title">
							<a href="https://www.cancer.gov/about-nci/legislative">Legislative Activities</a>
						<button class="toggle" aria-expanded="false" type="button"><span class="hidden">Expand</span></button></div><ul class="mobile-item">
							<li class="lvl-3"><div class="nav-item-title">
								<a href="https://www.cancer.gov/about-nci/legislative/hearings">Hearings &amp; Testimonies </a>
							</div></li><li class="lvl-3"><div class="nav-item-title">
								<a href="https://www.cancer.gov/about-nci/legislative/current-congress">Current Congress </a>
							</div></li><li class="lvl-3"><div class="nav-item-title">
								<a href="https://www.cancer.gov/about-nci/legislative/history">Legislative History</a>
							</div></li><li class="lvl-3"><div class="nav-item-title">
								<a href="https://www.cancer.gov/about-nci/legislative/committees">Committees of Interest</a>
							</div></li><li class="lvl-3"><div class="nav-item-title">
								<a href="https://www.cancer.gov/about-nci/legislative/resources">Legislative Resources</a>
							</div></li><li class="lvl-3"><div class="nav-item-title">
								<a href="https://www.cancer.gov/about-nci/legislative/recent-public-laws">Recent Public Laws</a>
							</div></li><li class="lvl-3"><div class="nav-item-title">
								<a href="https://www.cancer.gov/about-nci/legislative/contact">Contact</a>
							</div></li>
						</ul></li>
					</ul><div aria-expanded="false" aria-haspopup="true" class="sub-nav-mega mega-menu-scroll" id="accessible-megamenu-1559973650541-12" role="group" aria-hidden="true" aria-labelledby="accessible-megamenu-1559973650541-11">
						<div class="sub-nav-group-wrapper"><div class="sub-nav-group-subwrapper"><ul class="sub-nav-group"><li><a href="https://www.cancer.gov/about-nci/overview" class="sub-nav-group-header">Overview &amp; Mission</a><ul><li><a href="https://www.cancer.gov/about-nci/overview/history">History of NCI</a></li><li><a href="https://www.cancer.gov/about-nci/overview/contributing">Contributing to Cancer Research</a></li><li><a href="https://www.cancer.gov/about-nci/overview/strategic-planning">Strategic Planning at NCI</a></li></ul></li></ul><ul class="sub-nav-group"><li><a href="https://www.cancer.gov/about-nci/leadership" class="sub-nav-group-header">Senior Leadership</a><ul><li><a href="https://www.cancer.gov/about-nci/leadership/director">Director</a></li><li><a href="https://www.cancer.gov/about-nci/leadership/previous">Previous Directors</a></li></ul></li></ul><ul class="sub-nav-group"><li><a href="https://www.cancer.gov/about-nci/organization" class="sub-nav-group-header">NCI Organization</a><ul><li><a href="https://www.cancer.gov/about-nci/organization">Divisions, Offices &amp; Centers</a></li></ul></li></ul><ul class="sub-nav-group"><li><a href="https://www.cancer.gov/about-nci/advisory-boards" class="sub-nav-group-header">Advisory Boards &amp; Review Groups</a></li></ul><ul class="sub-nav-group"><li><a href="https://www.cancer.gov/about-nci/budget" class="sub-nav-group-header">Budget &amp; Appropriations</a><ul><li><a href="https://www.cancer.gov/about-nci/budget/">Current Year Budget</a></li><li><a href="https://www.cancer.gov/about-nci/budget/plan">Annual Plan &amp; Budget Proposal</a></li><li><a href="https://www.cancer.gov/about-nci/budget/congressional-justification">Congressional Justification</a></li><li><a href="https://www.cancer.gov/about-nci/budget/fact-book">NCI Budget Fact Book</a></li></ul></li></ul><ul class="sub-nav-group"><li><a href="https://www.cancer.gov/about-nci/legislative" class="sub-nav-group-header">Legislative Activities</a><ul><li><a href="https://www.cancer.gov/about-nci/legislative/hearings">Hearings &amp; Testimonies</a></li><li><a href="https://www.cancer.gov/about-nci/legislative/current-congress">Current Congress</a></li><li><a href="https://www.cancer.gov/about-nci/legislative/history">Legislative History</a></li><li><a href="https://www.cancer.gov/about-nci/legislative/committees">Committees of Interest</a></li><li><a href="https://www.cancer.gov/about-nci/legislative/resources">Legislative Resources</a></li><li><a href="https://www.cancer.gov/about-nci/legislative/recent-public-laws">Recent Public Laws</a></li></ul></li></ul><ul class="sub-nav-group"><li><a href="https://www.cancer.gov/about-nci/contracts" class="sub-nav-group-header">Contracts</a></li><br><br><li><a href="https://www.cancer.gov/about-nci/careers" class="sub-nav-group-header">Careers</a></li></ul><ul class="sub-nav-group"><li><a href="https://www.cancer.gov/about-nci/visit" class="sub-nav-group-header">Visitor Information</a></li></ul></div></div>
					<button class="toggle" aria-expanded="false" type="button"><span class="hidden">Expand</span></button></div></li>
				</ul>
			</nav>
		</div>
	</div><div class="contentid-911752 slot-item last-SI">
		<div class="rawHtml"><div class="search" role="search">
	<form action="/search/results" method="post" id="siteSearchForm" name="siteSearchForm" onsubmit="NCIAnalytics.SiteWideSearch(this);">
		<label class="hidden" for="swKeyword">Search</label>
		<input placeholder="search" class="searchString ui-autocomplete-input" id="swKeyword" maxlength="255" name="swKeyword" onblur="bSearchBoxBool=false;" onfocus="bSearchBoxBool=true;" autocomplete="off" type="text" aria-autocomplete="list" aria-haspopup="true">
		<button class="searchSubmit" id="sitesearch" onclick="return siteSearchSubmit();" type="submit">
			<span class="hidden">Search</span>
		</button>
	</form>
</div>
</div>
	</div>
</div></div>
        <!-- End nav-search bar -->

        <!-- END NAVIGATION -->
    </div><!-- END Global nav/utility bar/language -->

		<!-- Begin MAIN CONTENT AREA -->
		<div class="main-content" id="content" tabindex="0">
            <div class="row general-page-body-container collapse">
                <div class="large-12 columns">
                    <div class="row">
                        <div id="cgvSlBreadcrumb" class="medium-8 columns bcrumbs">
	<div class="contentid-870117 slot-item only-SI">
		<ul class="breadcrumbs">
			<li><a href="https://www.cancer.gov/">Home</a></li><li><a href="https://www.cancer.gov/types">Cancer Types</a></li><li><a href="https://www.cancer.gov/types/brain">Brain Cancer </a></li><li class="last-breadcrumb"><a href="https://www.cancer.gov/types/brain/hp">Health Professional</a></li>
		</ul>
	</div>
</div>
                    </div><!-- END "row" -->
                </div> <!-- END "large-12 columns" -->
                <div class="row">
                    <!--    SECTION NAVIGATION -->
                    <a id="section-menu-button" href="#">Section Menu</a><div id="nvcgSlSectionNav" class="medium-3 columns local-navigation">
	<div class="contentid-939941 slot-item only-SI">
		<div class="section-nav">
			<ul>
				<li class="level-0 has-children"><div>
					<a href="https://www.cancer.gov/types/brain">Brain Cancer </a>
				</div><ul>
					<li class="level-1 has-children"><div>
						<a href="https://www.cancer.gov/types/brain">Patient</a>
					<button class="toggle" aria-expanded="false" type="button"><span class="hidden">Expand</span></button></div><ul style="display:none;">
						<li class="level-2"><div>
							<a href="https://www.cancer.gov/types/brain/patient/adult-brain-treatment-pdq">Adult Central Nervous System Tumors Treatment</a>
						</div></li><li class="level-2"><div>
							<a href="https://www.cancer.gov/types/brain/patient/child-brain-treatment-pdq">Childhood Brain &amp; Spinal Cord Tumors Treatment</a>
						</div></li><li class="level-2"><div>
							<a href="https://www.cancer.gov/types/brain/patient/child-astrocytoma-treament-pdq">Childhood Astrocytoma Treatment</a>
						</div></li><li class="level-2"><div>
							<a href="https://www.cancer.gov/types/brain/patient/child-glioma-treatment-pdq">Childhood Brain Stem Glioma Treatment</a>
						</div></li><li class="level-2"><div>
							<a href="https://www.cancer.gov/types/brain/patient/child-cns-atrt-treatment-pdq">Childhood CNS AT/RT Treatment</a>
						</div></li><li class="level-2"><div>
							<a href="https://www.cancer.gov/types/brain/patient/child-cns-embryonal-treatment-pdq">Childhood CNS Embryonal Tumors Treatment</a>
						</div></li><li class="level-2"><div>
							<a href="https://www.cancer.gov/types/brain/patient/child-cns-germ-cell-treatment-pdq">Childhood CNS Germ Cell Tumors Treatment</a>
						</div></li><li class="level-2"><div>
							<a href="https://www.cancer.gov/types/brain/patient/child-cranio-treatment-pdq">Childhood Craniopharyngioma Treatment</a>
						</div></li><li class="level-2"><div>
							<a href="https://www.cancer.gov/types/brain/patient/child-ependymoma-treatment-pdq">Childhood Ependymoma Treatment</a>
						</div></li>
					</ul></li><li class="level-1 contains-current has-children"><div>
						<a href="https://www.cancer.gov/types/brain/hp">Health Professional</a>
					<button class="toggle" aria-expanded="true" type="button"><span class="hidden">Section Menu</span></button></div><ul style="display:block;">
						<li class="level-2 contains-current"><div class="current-page">
							<a href="https://www.cancer.gov/types/brain/hp/adult-brain-treatment-pdq">Adult Central Nervous System Tumors Treatment</a>
						</div></li><li class="level-2"><div>
							<a href="https://www.cancer.gov/types/brain/hp/child-brain-treatment-pdq">Childhood Brain &amp; Spinal Cord Tumors Treatment</a>
						</div></li><li class="level-2"><div>
							<a href="https://www.cancer.gov/types/brain/hp/child-astrocytoma-treament-pdq">Childhood Astrocytomas Treatment</a>
						</div></li><li class="level-2"><div>
							<a href="https://www.cancer.gov/types/brain/hp/child-glioma-treatment-pdq">Childhood Brain Stem Glioma Treatment</a>
						</div></li><li class="level-2"><div>
							<a href="https://www.cancer.gov/types/brain/hp/child-cns-atrt-treatment-pdq">Childhood CNS AT/RT Treatment</a>
						</div></li><li class="level-2"><div>
							<a href="https://www.cancer.gov/types/brain/hp/child-cns-embryonal-treatment-pdq">Childhood CNS Embryonal Tumors Treatment</a>
						</div></li><li class="level-2"><div>
							<a href="https://www.cancer.gov/types/brain/hp/child-cns-germ-cell-treatment-pdq">Childhood CNS Germ Cell Tumors Treatment</a>
						</div></li><li class="level-2"><div>
							<a href="https://www.cancer.gov/types/brain/hp/child-cranio-treatment-pdq">Childhood Craniopharyngioma Treatment</a>
						</div></li><li class="level-2"><div>
							<a href="https://www.cancer.gov/types/brain/hp/child-ependymoma-treatment-pdq">Childhood Ependymoma Treatment</a>
						</div></li>
					</ul></li><li class="level-1"><div>
						<a href="https://www.cancer.gov/types/brain/research">Research</a>
					</div></li>
				</ul></li>
			</ul>
		</div>
	</div>
</div>
                    <!--    END SECTION NAV -->
                    <div class="medium-9 columns contentzone has-section-nav" id="main" tabindex="0" role="main">
                        <!-- ********************************* BEGIN Page Content ********************************** -->
                        <article>

                            <!-- PUBLIC ARCHIVE BANNER -->
                            <div id="cgvPublicArchiveBannerSl" class="row collapse">
	<div class="contentid-172410 slot-item only-SI large-12 columns">
		
	</div>
</div>
                            <!-- END PUBLIC ARCHIVE BANNER -->

							<div class="resize-content"> <!-- Begin resizeable area -->

								<!-- PAGE TITLE -->
								<h1><span>Adult Central Nervous System Tumors Treatment (PDQ®)–Health Professional Version</span></h1><div class="pdq-hp-patient-toggle">
    <a href="https://www.cancer.gov/types/brain/patient/adult-brain-treatment-pdq">Go to Patient Version</a>
  </div>
								
								<!-- END PAGE TITLE -->



								<div class="page-options-container">
								    <!-- PAGE OPTIONS -->
								    <div id="PageOptionsControl1" class="page-options no-resize ">
								        <ul>

								                <li class="page-options--resize">
								                    <a title="Font Resizer" aria-label="Font Resizer" href="#"></a>
								                </li>


								                <li class="page-options--print">
								                    <a title="Print" aria-label="Print" href="#"></a>
								                </li>


								                <li class="page-options--email">
								                    <a title="Email" aria-label="Email" href="#"></a>
								                </li>


								                <li class="social-share social-share--facebook">
								                    <a title="Facebook" aria-label="Facebook" href="#"></a>
								                </li>


								                <li class="social-share social-share--twitter">
								                    <a title="Twitter" aria-label="Twitter" href="#"></a>
								                </li>


								                <li class="social-share social-share--pinterest">
								                    <a title="Pinterest" aria-label="Pinterest" href="#"></a>
								                </li>

								        </ul>
								    </div>
								    <!-- END PAGE OPTIONS -->
								</div>

								<div id="cgvBody">
	<div class="contentid-3240 slot-item only-SI">
					<div class="summary-sections"><nav class="on-this-page" role="navigation"><h6>On This Page</h6><ul><li><a href="#_1">General Information About Adult  Central Nervous System (CNS) Tumors</a></li><li><a href="#_5">World Health Organization (WHO) Classification of Adult Primary CNS Tumors</a></li><li><a href="#_69">Treatment Option Overview for Adult Primary CNS Tumors</a></li><li><a href="#_792">Treatment of Primary Central Nervous System  Tumors by Tumor Type</a></li><li><a href="#_1113">Treatment of Primary Tumors of the Spinal Axis</a></li><li><a href="#_1166">Metastatic Brain Tumors</a></li><li><a href="#_687">Recurrent Adult CNS Tumors Treatment</a></li><li><a href="#_233">Changes to This Summary (05/03/2019)</a></li><li><a href="#_AboutThis_1">About This PDQ Summary</a></li></ul></nav>
								
			    			<div class="accordion"><section id="_1">
    				<h2>General Information About Adult  Central Nervous System (CNS) Tumors</h2>
    				 <div id="_section_1" class="pdq-sections"><nav class="onthispage in-this-section" role="navigation"><h6>In This Section</h6><ul><li><a href="#_619_toc">Incidence and Mortality</a></li><li><a href="#_969_toc">Anatomy</a></li><li><a href="#_895_toc">Risk Factors</a></li><li><a href="#_902_toc">Clinical Features</a></li><li><a href="#_716_toc">Diagnostic Evaluation</a><ul><li><a href="#_896_toc">Imaging tests</a></li><li><a href="#_970_toc">Biopsy</a></li></ul></li><li><a href="#_972_toc">Prognostic Factors</a></li><li><a href="#_789_toc">Related Summaries</a></li></ul></nav>
  
  <section id="_619">
    <h3 id="_619_toc">Incidence and Mortality</h3>
    <p id="_933" tabindex="-1">Brain tumors account for 85% to 90% of all primary central nervous system (CNS) tumors.[<a href="#cit/section_1.1">1</a>] Estimated new cases and deaths from brain tumors and other nervous system tumors in the United States in 2019:[<a href="#cit/section_1.2">2</a>]</p>
    <div class="pdq-content-list">
      <ul id="_934">
        <li>New cases: 23,820.</li>
        <li>Deaths: 17,760.</li>
      </ul>
    </div>
    <p id="_935" tabindex="-1">  Available registry data from the 
Surveillance, Epidemiology, and End Results (SEER) database for 2011 
indicate that the combined incidence of primary invasive CNS tumors in 
the United States is 6.4 per 100,000 persons per year, with an estimated
 mortality of 4.3 per 100,000 persons per year.[<a href="#cit/section_1.3">3</a>]
 Worldwide, approximately 256,213 new cases of brain and other CNS 
tumors were diagnosed in the year 2012, with an estimated 189,382 
deaths.[<a href="#cit/section_1.4">4</a>]</p>
    <p id="_1036" tabindex="-1">In general, the incidence of primary CNS
 tumors is higher in whites than in blacks, and mortality is higher in 
males than in females.[<a href="#cit/section_1.1">1</a>]</p>
    <p id="_1037" tabindex="-1">Primary brain tumors include the following in decreasing order of frequency:[<a href="#cit/section_1.1">1</a>]</p>
    <div class="pdq-content-list">
      <ul id="_1038">
        <li>Anaplastic astrocytomas and glioblastomas (38% of primary  brain tumors).</li>
        <li>Meningiomas and other mesenchymal tumors (27% of primary brain tumors).</li>
        <li>Pituitary tumors.</li>
        <li>Schwannomas.</li>
        <li>CNS lymphomas.</li>
        <li>Oligodendrogliomas.</li>
        <li>Ependymomas.</li>
        <li>Low-grade astrocytomas.</li>
        <li>Medulloblastomas.</li>
      </ul>
    </div>
    <p id="_1039" tabindex="-1">Primary spinal tumors include the following in decreasing order of frequency: </p>
    <div class="pdq-content-list">
      <ul id="_1040">
        <li>Schwannomas, meningiomas, and ependymomas   (79% of primary spinal tumors).</li>
        <li>Sarcomas.</li>
        <li>Astrocytomas.</li>
        <li>Vascular tumors.</li>
        <li>Chordomas.</li>
      </ul>
    </div>
    <p id="_1239" tabindex="-1">Primary brain tumors
rarely spread to other areas of the body, but they can spread to other parts of
the brain and to the spinal axis.</p>
  </section>
  <section id="_969">
    <h3 id="_969_toc">Anatomy</h3>
    <p id="_1377" tabindex="-1">
      </p><figure id="figure_1238" class="image-center">
        <a href="https://www.cancer.gov/images/cdr/live/CDR765241.jpg" target="_blank" class="article-image-enlarge">Enlarge</a>
        <img id="_1238" alt="Drawing of the inside of the brain showing the supratentorium (the upper part of the brain) and the infratentorium (the lower back part of the brain). The supratentorium includes the cerebrum, ventricles (fluid-filled spaces), choroid plexus, hypothalamus, pineal gland, pituitary gland, and optic nerve. The infratentorium includes the cerebellum and brain stem (pons and medulla). The spinal cord is also shown." title="Drawing of the inside of the brain showing the supratentorium (the upper part of the brain) and the infratentorium (the lower back part of the brain). The supratentorium includes the cerebrum, ventricles (fluid-filled spaces), choroid plexus, hypothalamus, pineal gland, pituitary gland, and optic nerve. The infratentorium includes the cerebellum and brain stem (pons and medulla). The spinal cord is also shown." src="Adult%20Central%20Nervous%20System%20Tumors%20Treatment%20(PDQ%C2%AE)%E2%80%94Health%20Professional%20Version%20-%20National%20Cancer%20Institute_files/CDR765241-750.jpg">
        <figcaption class="caption-container">Anatomy of the inside of 
the brain. The supratentorium contains the cerebrum, ventricles (with 
cerebrospinal fluid shown in blue),  choroid plexus, hypothalamus, 
pineal gland, pituitary gland, and optic nerve. The infratentorium 
contains the cerebellum and brain stem.</figcaption>
      </figure>
    <p></p>
  </section>
  <section id="_895">
    <h3 id="_895_toc">Risk Factors</h3>
    <p id="_936" tabindex="-1">Few definitive observations have been made about environmental or occupational causes of primary CNS tumors.[<a href="#cit/section_1.1">1</a>] </p>
    <p id="_1373" tabindex="-1">The following potential risk factors have been considered:</p>
    <div class="pdq-content-list">
      <ul id="_1363">
        <li>Exposure to vinyl chloride may be a risk factor for glioma.</li>
        <li>Epstein-Barr virus infection has been implicated in the etiology of primary CNS lymphoma.</li>
        <li>Transplant recipients and patients with AIDS have a substantially increased risk of primary CNS lymphoma.[<a href="#cit/section_1.1">1</a>,<a href="#cit/section_1.5">5</a>] (Refer to the PDQ summary on <a href="https://www.cancer.gov/types/lymphoma/hp/primary-cns-lymphoma-treatment-pdq">Primary CNS Lymphoma Treatment</a> for more information.)</li>
      </ul>
    </div>
    <p id="_1041" tabindex="-1">The familial tumor syndromes and related
 chromosomal abnormalities that are associated with CNS neoplasms 
include the following:[<a href="#cit/section_1.6">6</a>,<a href="#cit/section_1.7">7</a>]</p>
    <div class="pdq-content-list">
      <ul id="_1042">
        <li> Neurofibromatosis type I (17q11).</li>
        <li>Neurofibromatosis type II (22q12).</li>
        <li>von Hippel-Lindau disease (3p25-26).</li>
        <li>Tuberous sclerosis (9q34, 16p13). </li>
        <li>Li-Fraumeni syndrome (17p13). </li>
        <li>Turcot syndrome type 1 (3p21, 7p22).</li>
        <li>Turcot syndrome type 2 (5q21).</li>
        <li>Nevoid basal cell carcinoma syndrome (9q22.3).</li>
      </ul>
    </div>
  </section>
  <section id="_902">
    <h3 id="_902_toc">Clinical Features</h3>
    <p id="_941" tabindex="-1">The clinical presentation of various 
brain tumors is best appreciated by considering the relationship of 
signs and symptoms to anatomy.[<a href="#cit/section_1.1">1</a>] </p>
    <p id="_1364" tabindex="-1">General signs and symptoms include the following:</p>
    <div class="pdq-content-list">
      <ul id="_942">
        <li> Headaches.</li>
        <li> Seizures.</li>
        <li>Visual   changes.</li>
        <li>Gastrointestinal symptoms such as loss of appetite, nausea, and vomiting.</li>
        <li>Changes in personality, mood, mental capacity, and concentration.</li>
      </ul>
    </div>
    <p id="_986" tabindex="-1"> Seizures are a presenting symptom in 
approximately 20% of patients with supratentorial brain tumors and may 
antedate the clinical diagnosis by months to years in patients with 
slow-growing tumors. Among all patients with brain tumors, 70% with 
primary parenchymal tumors and 40% with metastatic brain tumors develop 
seizures at some time during the clinical course.[<a href="#cit/section_1.8">8</a>]</p>
  </section>
  <section id="_716">
    <h3 id="_716_toc">Diagnostic Evaluation</h3>
    <p id="_1240" tabindex="-1">All brain tumors, whether primary, 
metastatic, malignant, or benign, must be differentiated from other 
space-occupying lesions that can have similar clinical presentations, 
such as abscesses, arteriovenous malformations, and infarctions.[<a href="#cit/section_1.9">9</a>]</p>
    <section id="_896">
      <h4 id="_896_toc">Imaging tests</h4>
      <p id="_944" tabindex="-1">Contrast-enhanced computed tomography 
(CT) and magnetic resonance imaging (MRI) have complementary roles in 
the diagnosis of CNS neoplasms.[<a href="#cit/section_1.1">1</a>,<a href="#cit/section_1.9">9</a>,<a href="#cit/section_1.10">10</a>]</p>
      <div class="pdq-content-list">
        <ul id="_1044">
          <li> The speed of CT is desirable for evaluating clinically 
unstable patients. CT is superior for detecting calcifications, skull 
lesions, and hyperacute hemorrhages (bleeding less than 24 hours old) 
and helps direct differential diagnosis and immediate management.</li>
          <li>MRI has superior soft-tissue resolution. MRI can better 
detect isodense lesions, tumor enhancements, and associated findings 
such as edema, all phases of hemorrhagic states (except hyperacute), and
 infarctions. High-quality MRI is the diagnostic study of choice in the 
evaluation of intramedullary and extramedullary spinal cord lesions.[<a href="#cit/section_1.1">1</a>]</li>
        </ul>
      </div>
      <p id="_1045" tabindex="-1">In posttherapy imaging, single-photon 
emission computed tomography (SPECT) and positron emission tomography 
(PET) may be useful in differentiating tumor recurrence from radiation 
necrosis.[<a href="#cit/section_1.9">9</a>]</p>
    </section>
    <section id="_970">
      <h4 id="_970_toc">Biopsy</h4>
      <p id="_945" tabindex="-1">Biopsy confirmation to corroborate the 
suspected diagnosis of a primary brain tumor is critical, whether before
 surgery by needle biopsy or at the time of surgical resection. Cases in
 which the clinical and radiologic picture clearly point to a benign 
tumor, which could potentially be managed with active surveillance 
without biopsy or treatment, are the exception.  For other cases, 
radiologic patterns may be misleading, and a definitive biopsy is needed
 to rule out other causes of space-occupying lesions, such as metastatic
 cancer or infection.</p>
      <p id="_1046" tabindex="-1">CT- or MRI-guided stereotactic 
techniques can be used to place a needle safely and accurately into 
almost all locations in the brain.</p>
    </section>
  </section>
  <section id="_972">
    <h3 id="_972_toc">Prognostic Factors</h3>
    <p id="_1341" tabindex="-1">Several genetic alterations have emerged
 in recent years as powerful prognostic factors in diffuse glioma 
(astrocytoma, oligodendroglioma, mixed glioma, and glioblastoma), and 
these alterations may guide patient management. Specific alterations 
include the following:</p>
    <div class="pdq-content-list">
      <ul id="_1365">
        <li>DNA methylation of the O6-methylguanine-DNA methyltransferase (MGMT) gene promoter.</li>
        <li>Mutation of isocitrate dehydrogenase (IDH) 1 (<em>IDH1</em>) or <em>IDH2</em> genes.</li>
        <li>Codeletion of chromosomes 1p and 19q. </li>
      </ul>
    </div>
    <p id="_1384" tabindex="-1">	Other prognostic factors that confer poor prognosis  include the following:[<a href="#cit/section_1.11">11</a>,<a href="#cit/section_1.12">12</a>]</p>
    <div class="pdq-content-list">
      <ul id="_1385">
        <li>	Age older than 40 years.</li>
        <li>	Progressive disease. </li>
        <li>Tumor size larger than 5 cm. </li>
        <li>Tumor crossing the midline. </li>
        <li>Contrast enhancement on MRI.</li>
        <li>World Health Organization performance status (≥1). </li>
        <li>Neurological symptoms. </li>
        <li>Less than a gross total resection. </li>
      </ul>
    </div>
    <p id="_1386" tabindex="-1">In an exploratory analysis of 318 
patients with low-grade glioma treated with either radiation therapy 
alone or temozolomide chemotherapy alone, a combination of these 
prognostic factors demonstrated the following:[<a href="#cit/section_1.11">11</a>] </p>
    <div class="pdq-content-list">
      <ol id="_1387">
        <li>Longer progression-free survival (PFS) in patients with an <em>IDH</em>
 mutation without codeletion of 1p/19q when treated with radiation 
therapy (hazard ratio, 1.86; 95% confidence interval, 1.21–2.87; 
log-rank, <em>P</em> = .0043). </li>
        <li>No significant treatment-dependent differences in PFS for patients with an <em>IDH</em> mutation with codeletion of 1p/19q and <em>IDH</em> wild-type tumors. </li>
        <li>Patients with wild-type <em>IDH</em> tumors had the worst prognosis independent of treatment type. </li>
        <li>Patients with <em>IDH</em>-mutated tumors with codeletion of 1p/19q had the best prognosis.</li>
        <li>The O6-methylguanine-DNA methyltransferase (MGMT)  promoter status in low-grade tumors was methylated in:<div class="pdq-content-list"><ul id="_1388"><li>All <em>IDH</em> mutations with codeletion of 1p/19q (45/45).</li><li>Most, but not all (86%, 62/72), of the <em>IDH</em> mutations without codeletion of 1p/19q.</li><li>Fifty-six percent (5/9) of the <em>IDH</em> wild-type cases. </li></ul></div></li>
      </ol>
    </div>
    <p id="_1366" tabindex="-1">(Refer to the <a href="https://www.cancer.gov/types/brain/hp/adult-brain-treatment-pdq#link/_792">Treatment of Primary Central Nervous System Tumors by Tumor Type</a> section of this summary  for more information.)</p>
  </section>
  <section id="_789">
    <h3 id="_789_toc">Related Summaries</h3>
    <p id="_957" tabindex="-1">Refer to the following PDQ summaries for more information:</p>
    <div class="pdq-content-list">
      <ul id="_1367">
        <li>
          <a href="https://www.cancer.gov/types/lymphoma/hp/primary-cns-lymphoma-treatment-pdq">Primary CNS Lymphoma Treatment</a>.</li>
        <li>
          <a href="https://www.cancer.gov/types/brain/hp/child-brain-treatment-pdq">Childhood Brain and Spinal Cord Tumors Treatment Overview</a> (treatment of brain tumors in children).</li>
      </ul>
    </div>
  </section>
  <h6 do-not-show="toc">References</h6>
  <ol>
    <li id="section_1.1">Mehta M, Vogelbaum  MA, Chang S, et al.: 
Neoplasms of the central nervous system. In: DeVita VT Jr, Lawrence TS, 
Rosenberg SA: Cancer: Principles and Practice of Oncology. 9th ed. 
Philadelphia, Pa: Lippincott Williams &amp; Wilkins, 2011, pp 1700-49.</li>
    <li id="section_1.2">American Cancer Society: Cancer Facts and Figures 2019. Atlanta, Ga: American Cancer Society, 2019. <a href="https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2019/cancer-facts-and-figures-2019.pdf" title="https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2019/cancer-facts-and-figures-2019.pdf">Available online</a><a class="icon-exit-notification" title="Exit Disclaimer" href="https://www.cancer.gov/policies/linking"><span class="hidden">Exit Disclaimer</span></a>. Last accessed January 23, 2019.</li>
    <li id="section_1.3">Howlader N, Noone AM, Krapcho M, et al., eds.: 
SEER Cancer Statistics Review, 1975-2011. Bethesda, Md: National Cancer 
Institute, 2014. <a href="http://seer.cancer.gov/csr/1975_2011/" title="http://seer.cancer.gov/csr/1975_2011/">Also available online</a>. Last accessed February 22, 2019.</li>
    <li id="section_1.4">Ferlay J, Soerjomataram  I, Ervik M, et al.: 
GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide. Lyon, 
France: International Agency for Research on Cancer, 2013. IARC 
CancerBase No. 11. <a href="http://globocan.iarc.fr/Default.aspx" title="http://globocan.iarc.fr/Default.aspx">Available online</a><a class="icon-exit-notification" title="Exit Disclaimer" href="https://www.cancer.gov/policies/linking"><span class="hidden">Exit Disclaimer</span></a>. Last accessed February 1, 2019.</li>
    <li id="section_1.5">Schabet M: Epidemiology of primary CNS lymphoma. J Neurooncol 43 (3): 199-201, 1999.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10563423&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10563423&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_1.6">Behin A, Hoang-Xuan K, Carpentier AF, et al.: Primary brain tumours in adults. Lancet 361 (9354): 323-31, 2003.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12559880&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12559880&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_1.7">Kleihues P, Cavenee WK, eds.: Pathology and 
Genetics of Tumours of the Nervous System. Lyon, France: International 
Agency for Research on Cancer, 2000.</li>
    <li id="section_1.8">Cloughesy T, Selch MT, Liau L: Brain. In: 
Haskell CM: Cancer Treatment. 5th ed. Philadelphia, Pa: WB Saunders Co, 
2001, pp 1106-42.</li>
    <li id="section_1.9">Hutter A, Schwetye KE, Bierhals AJ, et al.: 
Brain neoplasms: epidemiology, diagnosis, and prospects for 
cost-effective imaging. Neuroimaging Clin N Am 13 (2): 237-50, x-xi, 
2003.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=13677804&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=13677804&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_1.10">Ricci PE: Imaging of adult brain tumors. Neuroimaging Clin N Am 9 (4): 651-69, 1999.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10517938&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10517938&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_1.11">Baumert BG, Hegi ME, van den Bent MJ, et al.: 
Temozolomide chemotherapy versus radiotherapy in high-risk low-grade 
glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup
 study. Lancet Oncol 17 (11): 1521-1532, 2016.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=27686946&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=27686946&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_1.12">Reijneveld JC, Taphoorn MJ, Coens C, et al.: 
Health-related quality of life in patients with high-risk low-grade 
glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup
 study. Lancet Oncol 17 (11): 1533-1542, 2016.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=27686943&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=27686943&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
  </ol>
</div>
    			</section><section id="_5">
    				<h2>World Health Organization (WHO) Classification of Adult Primary CNS Tumors</h2>
    				 <div id="_section_5" class="pdq-sections"><nav class="onthispage in-this-section" role="navigation"><h6>In This Section</h6><ul><li><a href="#_1047_toc">Genomic Alterations</a></li></ul></nav>
  <p id="_257" tabindex="-1">This classification is based on the World Health Organization (WHO)  classification of central nervous system (CNS) tumors.[<a href="#cit/section_2.1">1</a>]
 The WHO approach incorporates and interrelates morphology, 
cytogenetics, molecular genetics, and immunologic markers in an attempt 
to construct a cellular  classification that is universally applicable 
and prognostically valid.  Earlier attempts to develop a TNM-based  
classification were dropped for the following reasons:[<a href="#cit/section_2.2">2</a>]</p>
  <div class="pdq-content-list">
    <ul id="_1049">
      <li>Tumor size (T) is less relevant than are tumor histology and location.</li>
      <li>Nodal status (N) does not apply because the brain and spinal cord have no lymphatics. </li>
      <li>Metastatic spread (M) rarely applies because most patients 
with CNS neoplasms do not live long enough to develop metastatic 
disease.</li>
    </ul>
  </div>
  <p id="_258" tabindex="-1">The WHO grading of CNS tumors establishes a malignancy scale based on histologic features of the tumor.[<a href="#cit/section_2.3">3</a>] The histologic grades are as follows:</p>
  <div class="pdq-content-list">
    <ul id="_980">
      <li>
        <strong>WHO grade I</strong> includes lesions with low 
proliferative potential, a frequently discrete nature, and the 
possibility of cure following surgical resection alone. </li>
      <li>
        <strong>WHO grade II</strong> includes lesions that are 
generally infiltrating and low in mitotic activity but recur more 
frequently than do grade I malignant tumors after local therapy. Some 
tumor types tend to progress to higher grades of malignancy.</li>
      <li>
        <strong>WHO grade III</strong> includes lesions with histologic 
evidence of malignancy, including nuclear atypia and increased mitotic 
activity. These lesions have anaplastic histology and infiltrative 
capacity.  They are usually treated with aggressive adjuvant therapy.</li>
      <li>
        <strong>WHO grade IV</strong> includes lesions that are 
mitotically active, necrosis prone, and generally associated with a 
rapid preoperative and postoperative progression and fatal outcomes.  
The lesions are usually treated with aggressive adjuvant therapy.</li>
    </ul>
  </div>
  <p id="_719" tabindex="-1">Table 1 lists  the tumor types and grades.[<a href="#cit/section_2.4">4</a>]
 Tumors limited to the peripheral nervous system are not included.  
Histopathology, grading methods, incidence, and what is known about 
etiology specific to each tumor type have been described in detail 
elsewhere.[<a href="#cit/section_2.4">4</a>,<a href="#cit/section_2.5">5</a>]</p>
  <div style="height: 1px;"></div><figure class="table"><figcaption id="_768_cap">Table 1.  WHO Grades of CNS Tumors<span class="sup">a</span></figcaption><div class="scrollable"><div><table id="_768" class="table-default expandable-container" aria-labelledby="_768_cap">
    
    <colgroup>
      <col width="31.19%">
      <col width="19.57%">
      <col width="18.50%">
      <col width="15.29%">
      <col width="15.44%">
    </colgroup>
    <thead>
      <tr>
        <th>&nbsp;</th>
        <th scope="col" align="Center">I</th>
        <th scope="col" align="Center">II</th>
        <th scope="col" align="Center">III</th>
        <th scope="col" align="Center">IV</th>
      </tr>
    </thead>
    <tfoot class="pdq-footer">
      <tr>
        <td colspan="5">
          <span class="sup">a</span>Reprinted with permission from Louis, DN, Ohgaki H, Wiestler, OD, Cavenee, WK. <em>World Health Organization Classification of Tumours of the Central Nervous System</em>. IARC, Lyon, 2007.</td>
      </tr>
    </tfoot>
    <tbody>
      <tr>
        <td colspan="5">
          <strong>Astrocytic tumors</strong>
        </td>
      </tr>
      <tr>
        <td>Subependymal giant cell astrocytoma</td>
        <td scope="col" align="Center">X</td>
        <td>&nbsp;</td>
        <td>&nbsp;</td>
        <td>&nbsp;</td>
      </tr>
      <tr>
        <td>Pilocytic astrocytoma</td>
        <td scope="col" align="Center">X</td>
        <td>&nbsp;</td>
        <td>&nbsp;</td>
        <td>&nbsp;</td>
      </tr>
      <tr>
        <td>Pilomyxoid astrocytoma</td>
        <td>&nbsp;</td>
        <td scope="col" align="Center">X</td>
        <td>&nbsp;</td>
        <td>&nbsp;</td>
      </tr>
      <tr>
        <td>Diffuse astrocytoma</td>
        <td>&nbsp;</td>
        <td scope="col" align="Center">X</td>
        <td>&nbsp;</td>
        <td>&nbsp;</td>
      </tr>
      <tr>
        <td>Pleomorphic xanthoastrocytoma</td>
        <td>&nbsp;</td>
        <td scope="col" align="Center">X</td>
        <td>&nbsp;</td>
        <td>&nbsp;</td>
      </tr>
      <tr>
        <td>Anaplastic astrocytoma</td>
        <td>&nbsp;</td>
        <td>&nbsp;</td>
        <td scope="col" align="Center">X</td>
        <td>&nbsp;</td>
      </tr>
      <tr>
        <td>Glioblastoma</td>
        <td>&nbsp;</td>
        <td>&nbsp;</td>
        <td>&nbsp;</td>
        <td scope="col" align="Center">X</td>
      </tr>
      <tr>
        <td>Giant cell glioblastoma</td>
        <td>&nbsp;</td>
        <td>&nbsp;</td>
        <td>&nbsp;</td>
        <td scope="col" align="Center">X</td>
      </tr>
      <tr>
        <td>Gliosarcoma</td>
        <td>&nbsp;</td>
        <td>&nbsp;</td>
        <td>&nbsp;</td>
        <td scope="col" align="Center">X</td>
      </tr>
      <tr>
        <td colspan="5">
          <strong>Oligodendroglial tumors</strong>
        </td>
      </tr>
      <tr>
        <td>Oligodendroglioma</td>
        <td>&nbsp;</td>
        <td scope="col" align="Center">X</td>
        <td>&nbsp;</td>
        <td>&nbsp;</td>
      </tr>
      <tr>
        <td>Anaplastic oligodendroglioma</td>
        <td>&nbsp;</td>
        <td>&nbsp;</td>
        <td scope="col" align="Center">X</td>
        <td>&nbsp;</td>
      </tr>
      <tr>
        <td colspan="5">
          <strong>Oligoastrocytic tumors</strong>
        </td>
      </tr>
      <tr>
        <td>Oligoastrocytoma</td>
        <td>&nbsp;</td>
        <td scope="col" align="Center">X</td>
        <td>&nbsp;</td>
        <td>&nbsp;</td>
      </tr>
      <tr>
        <td>Anaplastic oligoastrocytoma</td>
        <td>&nbsp;</td>
        <td>&nbsp;</td>
        <td scope="col" align="Center">X</td>
        <td>&nbsp;</td>
      </tr>
      <tr>
        <td colspan="5">
          <strong>Ependymal tumors</strong>
        </td>
      </tr>
      <tr>
        <td>Subependymoma</td>
        <td scope="col" align="Center">X</td>
        <td>&nbsp;</td>
        <td>&nbsp;</td>
        <td>&nbsp;</td>
      </tr>
      <tr>
        <td>Myxopapillary ependymoma</td>
        <td scope="col" align="Center">X</td>
        <td>&nbsp;</td>
        <td>&nbsp;</td>
        <td>&nbsp;</td>
      </tr>
      <tr>
        <td>Ependymoma</td>
        <td>&nbsp;</td>
        <td scope="col" align="Center">X</td>
        <td>&nbsp;</td>
        <td>&nbsp;</td>
      </tr>
      <tr>
        <td>Anaplastic ependymoma</td>
        <td>&nbsp;</td>
        <td>&nbsp;</td>
        <td scope="col" align="Center">X</td>
        <td>&nbsp;</td>
      </tr>
      <tr>
        <td colspan="5">
          <strong>Choroid plexus tumors</strong>
        </td>
      </tr>
      <tr>
        <td>Choroid plexus papilloma</td>
        <td scope="col" align="Center">X</td>
        <td>&nbsp;</td>
        <td>&nbsp;</td>
        <td>&nbsp;</td>
      </tr>
      <tr>
        <td>Atypical choroid plexus papilloma</td>
        <td>&nbsp;</td>
        <td scope="col" align="Center">X</td>
        <td>&nbsp;</td>
        <td>&nbsp;</td>
      </tr>
      <tr>
        <td>Choroid plexus carcinoma</td>
        <td>&nbsp;</td>
        <td>&nbsp;</td>
        <td scope="col" align="Center">X</td>
        <td>&nbsp;</td>
      </tr>
      <tr>
        <td colspan="5">
          <strong>Other neuroepithelial tumors</strong>
        </td>
      </tr>
      <tr>
        <td>Angiocentric glioma</td>
        <td scope="col" align="Center">X</td>
        <td>&nbsp;</td>
        <td>&nbsp;</td>
        <td>&nbsp;</td>
      </tr>
      <tr>
        <td>Chordoid glioma of the third ventricle</td>
        <td>&nbsp;</td>
        <td scope="col" align="Center">X</td>
        <td>&nbsp;</td>
        <td>&nbsp;</td>
      </tr>
      <tr>
        <td colspan="5">
          <strong>Neuronal and mixed neuronal-glial tumors</strong>
        </td>
      </tr>
      <tr>
        <td>Gangliocytoma</td>
        <td scope="col" align="Center">X</td>
        <td>&nbsp;</td>
        <td>&nbsp;</td>
        <td>&nbsp;</td>
      </tr>
      <tr>
        <td>Ganglioglioma</td>
        <td scope="col" align="Center">X</td>
        <td>&nbsp;</td>
        <td>&nbsp;</td>
        <td>&nbsp;</td>
      </tr>
      <tr>
        <td>Anaplastic ganglioma</td>
        <td>&nbsp;</td>
        <td>&nbsp;</td>
        <td scope="col" align="Center">X</td>
        <td>&nbsp;</td>
      </tr>
      <tr>
        <td>Desmoplastic infantile astrocytoma and ganglioglioma</td>
        <td scope="col" align="Center">X</td>
        <td>&nbsp;</td>
        <td>&nbsp;</td>
        <td>&nbsp;</td>
      </tr>
      <tr>
        <td>Dysembryoplastic neuroepithelial tumor</td>
        <td scope="col" align="Center">X</td>
        <td>&nbsp;</td>
        <td>&nbsp;</td>
        <td>&nbsp;</td>
      </tr>
      <tr>
        <td>Central neurocytoma</td>
        <td>&nbsp;</td>
        <td scope="col" align="Center">X</td>
        <td>&nbsp;</td>
        <td>&nbsp;</td>
      </tr>
      <tr>
        <td>Extraventricular neurocytoma</td>
        <td>&nbsp;</td>
        <td scope="col" align="Center">X</td>
        <td>&nbsp;</td>
        <td>&nbsp;</td>
      </tr>
      <tr>
        <td>Cerebellar liponeurocytoma</td>
        <td>&nbsp;</td>
        <td scope="col" align="Center">X</td>
        <td>&nbsp;</td>
        <td>&nbsp;</td>
      </tr>
      <tr>
        <td>Paraganglioma of the spinal cord</td>
        <td scope="col" align="Center">X</td>
        <td>&nbsp;</td>
        <td>&nbsp;</td>
        <td>&nbsp;</td>
      </tr>
      <tr>
        <td>Papillary glioneuronal tumor</td>
        <td scope="col" align="Center">X</td>
        <td>&nbsp;</td>
        <td>&nbsp;</td>
        <td>&nbsp;</td>
      </tr>
      <tr>
        <td>Rosette-forming glioneural tumor of the fourth ventricle</td>
        <td scope="col" align="Center">X</td>
        <td>&nbsp;</td>
        <td>&nbsp;</td>
        <td>&nbsp;</td>
      </tr>
      <tr>
        <td>
          <strong>Pineal tumors</strong>
        </td>
        <td>&nbsp;</td>
        <td>&nbsp;</td>
        <td>&nbsp;</td>
        <td>&nbsp;</td>
      </tr>
      <tr>
        <td>Pineocytoma</td>
        <td scope="col" align="Center">X</td>
        <td>&nbsp;</td>
        <td>&nbsp;</td>
        <td>&nbsp;</td>
      </tr>
      <tr>
        <td>Pineal parenchymal tumor of intermediate differentiation</td>
        <td>&nbsp;</td>
        <td scope="col" align="Center">X</td>
        <td scope="col" align="Center">X</td>
        <td>&nbsp;</td>
      </tr>
      <tr>
        <td>Pineoblastoma</td>
        <td>&nbsp;</td>
        <td>&nbsp;</td>
        <td>&nbsp;</td>
        <td scope="col" align="Center">X</td>
      </tr>
      <tr>
        <td>Papillary tumor of the pineal region</td>
        <td>&nbsp;</td>
        <td scope="col" align="Center">X</td>
        <td scope="col" align="Center">X</td>
        <td>&nbsp;</td>
      </tr>
      <tr>
        <td colspan="5">
          <strong>Embryonal tumors</strong>
        </td>
      </tr>
      <tr>
        <td>Medulloblastoma</td>
        <td>&nbsp;</td>
        <td>&nbsp;</td>
        <td>&nbsp;</td>
        <td scope="col" align="Center">X</td>
      </tr>
      <tr>
        <td>CNS primitive neuroectodermal tumor </td>
        <td>&nbsp;</td>
        <td>&nbsp;</td>
        <td>&nbsp;</td>
        <td scope="col" align="Center">X</td>
      </tr>
      <tr>
        <td>Atypical teratoid/rhabdoid tumor</td>
        <td>&nbsp;</td>
        <td>&nbsp;</td>
        <td>&nbsp;</td>
        <td scope="col" align="Center">X</td>
      </tr>
      <tr>
        <td colspan="5">
          <strong>Tumors of the cranial and paraspinal nerves</strong>
        </td>
      </tr>
      <tr>
        <td>Schwannoma</td>
        <td scope="col" align="Center">X</td>
        <td>&nbsp;</td>
        <td>&nbsp;</td>
        <td>&nbsp;</td>
      </tr>
      <tr>
        <td>Neurofibroma</td>
        <td scope="col" align="Center">X</td>
        <td>&nbsp;</td>
        <td>&nbsp;</td>
        <td>&nbsp;</td>
      </tr>
      <tr>
        <td>Perineurioma</td>
        <td scope="col" align="Center">X</td>
        <td scope="col" align="Center">X</td>
        <td scope="col" align="Center">X</td>
        <td>&nbsp;</td>
      </tr>
      <tr>
        <td>Malignant peripheral nerve sheath tumor </td>
        <td>&nbsp;</td>
        <td scope="col" align="Center">X</td>
        <td scope="col" align="Center">X</td>
        <td scope="col" align="Center">X</td>
      </tr>
      <tr>
        <td colspan="5">
          <strong>Meningeal tumors</strong>
        </td>
      </tr>
      <tr>
        <td>Meningioma</td>
        <td scope="col" align="Center">X</td>
        <td>&nbsp;</td>
        <td>&nbsp;</td>
        <td>&nbsp;</td>
      </tr>
      <tr>
        <td>Atypical meningioma</td>
        <td>&nbsp;</td>
        <td scope="col" align="Center">X</td>
        <td>&nbsp;</td>
        <td>&nbsp;</td>
      </tr>
      <tr>
        <td>Anaplastic/malignant meningioma</td>
        <td>&nbsp;</td>
        <td>&nbsp;</td>
        <td scope="col" align="Center">X</td>
        <td>&nbsp;</td>
      </tr>
      <tr>
        <td> Hemangiopericytoma</td>
        <td>&nbsp;</td>
        <td scope="col" align="Center">X</td>
        <td scope="col" align="Center">&nbsp;</td>
        <td>&nbsp;</td>
      </tr>
      <tr>
        <td>Anaplastic hemangiopericytoma</td>
        <td>&nbsp;</td>
        <td>&nbsp;</td>
        <td scope="col" align="Center">X</td>
        <td>&nbsp;</td>
      </tr>
      <tr>
        <td>Hemangioblastoma</td>
        <td scope="col" align="Center">X</td>
        <td>&nbsp;</td>
        <td>&nbsp;</td>
        <td>&nbsp;</td>
      </tr>
      <tr>
        <td colspan="5">
          <strong>Tumors of the sellar region</strong>
        </td>
      </tr>
      <tr>
        <td>Craniopharyngioma</td>
        <td scope="col" align="Center">X</td>
        <td>&nbsp;</td>
        <td>&nbsp;</td>
        <td>&nbsp;</td>
      </tr>
      <tr>
        <td>Granular cell tumor of the neurohypophysis</td>
        <td scope="col" align="Center">X</td>
        <td>&nbsp;</td>
        <td>&nbsp;</td>
        <td>&nbsp;</td>
      </tr>
      <tr>
        <td>Pituicytoma</td>
        <td scope="col" align="Center">X</td>
        <td>&nbsp;</td>
        <td>&nbsp;</td>
        <td>&nbsp;</td>
      </tr>
      <tr>
        <td>Spindle cell oncocytoma of the adenohypophysis</td>
        <td scope="col" align="Center">X</td>
        <td>&nbsp;</td>
        <td>&nbsp;</td>
        <td>&nbsp;</td>
      </tr>
    </tbody>
  </table></div></div></figure>
  <section id="_1047">
    <h3 id="_1047_toc">Genomic Alterations</h3>
    <p id="_1342" tabindex="-1">Recently discovered alterations in the <em>BRAF</em> and <em>isocitrate dehydrogenase  (IDH) 1</em>  and <em>IDH2</em>
 genes, and genomic 1p/19q codeletion, appear to be hallmark aberrations
 in particular glioma subtypes. Assessment for the presence of these 
mutations aids diagnosis and prognosis and, with regard to 1p/19q 
codeletion, predicts for response to chemotherapy.  </p>
    <p id="_1343" tabindex="-1">In pilocytic astrocytomas (WHO grade I), tandem duplication at 7q34 leading to a fusion between <em>KIAA1549</em> and <em>BRAF</em> is found in approximately 70% of pilocytic astrocytomas.[<a href="#cit/section_2.6">6</a>-<a href="#cit/section_2.8">8</a>] An activating point mutation in <em>BRAF</em> (V600E) is found in an additional 5% to 9% of these tumors and in general, <em>RAF</em> alterations occur in approximately 80% of pilocytic astrocytomas.</p>
    <p id="_1344" tabindex="-1">
      <em>BRAF </em> V600E mutations are observed (in about 60%) of 
other benign glioma variants, including pleomorphic xanthoastrocytoma 
and ganglioglioma, while <em>BRAF</em> tandem duplications are not found in these variant glioma tumors.[<a href="#cit/section_2.9">9</a>-<a href="#cit/section_2.11">11</a>]</p>
    <p id="_1345" tabindex="-1">The majority of WHO grade II and III 
diffuse gliomas (astrocytomas, oligodendrogliomas, and 
oligoastrocytomas) and 5% to 10% of glioblastomas (WHO grade IV) harbor 
point mutations in the <em>R132</em> position of (<em>IDH1</em>) or, rarely, the analogous codon in <em>IDH2 </em>(R172).[<a href="#cit/section_2.12">12</a>-<a href="#cit/section_2.16">16</a>] The presence of an <em>IDH1</em> or <em>IDH2</em>
 mutation is a strong prognostic factor. Patients with these mutant 
tumors have significantly longer survival independent of WHO grade or 
histologic subtype.</p>
    <p id="_1346" tabindex="-1">Deletion of chromosomes 1p and 19q occurs through a translocation event [<a href="#cit/section_2.17">17</a>]
 and is common in oligodendrogliomas. 1p/19q codeletion is a powerful 
prognostic factor and may predict for response to chemotherapy.  (Refer 
to the  <a href="https://www.cancer.gov/types/brain/hp/adult-brain-treatment-pdq#link/_1144">Anaplastic oligodendrogliomas  treatment</a> section of this summary  for more information.)</p>
    <p id="_1347" tabindex="-1">These genetic alterations have potential diagnostic utility. Presence of the <em>IDH1</em> and <em>IDH2</em> mutations may distinguish diffuse gliomas from other glioma variants, which often have <em>BRAF</em> genetic alterations, and non-neoplastic reactive astrocytosis.[<a href="#cit/section_2.18">18</a>]  Most (90%) <em>IDH</em> mutations in gliomas result in an <em>R132H</em>
 substitution, which can be detected with a highly sensitive and 
specific monoclonal antibody. A rapid immunohistochemical analysis using
 the mutant-specific <em>IDH1</em> antibody can aid diagnostic analysis.[<a href="#cit/section_2.19">19</a>]</p>
    <p id="_1048" tabindex="-1">Other CNS tumors are associated with 
characteristic patterns of altered oncogenes, altered tumor suppressor 
genes, and chromosomal abnormalities. Familial tumor syndromes with 
defined chromosomal abnormalities are associated with gliomas.</p>
  </section>
  <h6 do-not-show="toc">References</h6>
  <ol>
    <li id="section_2.1">Kleihues P, Cavenee WK, eds.: Pathology and 
Genetics of Tumours of the Nervous System. Lyon, France: International 
Agency for Research on Cancer, 2000.</li>
    <li id="section_2.2">Brain and Spinal Cord. In: Amin MB, Edge SB, 
Greene FL, et al., eds.: AJCC Cancer Staging Manual. 8th ed. New York, 
NY: Springer, 2017, pp. 857–69.</li>
    <li id="section_2.3">Kleihues P, Burger PC, Scheithauer BW: The new WHO classification of brain tumours. Brain Pathol 3 (3): 255-68, 1993.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8293185&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8293185&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_2.4">Louis DN, Ohgaki H, Wiestler OD, et al.: The 
2007 WHO classification of tumours of the central nervous system. Acta 
Neuropathol 114 (2): 97-109, 2007.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17618441&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17618441&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_2.5">Louis DN, Ohgaki H, Wiestler OD, et al., eds.: 
WHO Classification of Tumours of the Central Nervous System. 4th ed. 
Lyon, France: IARC Press, 2007.</li>
    <li id="section_2.6">Sievert AJ, Jackson EM, Gai X, et al.: 
Duplication of 7q34 in pediatric low-grade astrocytomas detected by 
high-density single-nucleotide polymorphism-based genotype arrays 
results in a novel BRAF fusion gene. Brain Pathol 19 (3): 449-58, 
2009.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19016743&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19016743&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_2.7">Pfister S, Janzarik WG, Remke M, et al.: BRAF 
gene duplication constitutes a mechanism of MAPK pathway activation in 
low-grade astrocytomas. J Clin Invest 118 (5): 1739-49, 2008.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18398503&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18398503&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_2.8">Jones DT, Kocialkowski S, Liu L, et al.: Tandem
 duplication producing a novel oncogenic BRAF fusion gene defines the 
majority of pilocytic astrocytomas. Cancer Res 68 (21): 8673-7, 
2008.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18974108&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18974108&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_2.9">Dias-Santagata D, Lam Q, Vernovsky K, et al.: 
BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: 
diagnostic and therapeutic implications. PLoS One 6 (3): e17948, 
2011.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21479234&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21479234&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_2.10">MacConaill LE, Campbell CD, Kehoe SM, et al.: 
Profiling critical cancer gene mutations in clinical tumor samples. PLoS
 One 4 (11): e7887, 2009.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19924296&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19924296&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_2.11">Parsons DW, Jones S, Zhang X, et al.: An 
integrated genomic analysis of human glioblastoma multiforme. Science 
321 (5897): 1807-12, 2008.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18772396&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18772396&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_2.12">Yan H, Parsons DW, Jin G, et al.: IDH1 and IDH2 mutations in gliomas. N Engl J Med 360 (8): 765-73, 2009.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19228619&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19228619&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_2.13">Dubbink HJ, Taal W, van Marion R, et al.: IDH1
 mutations in low-grade astrocytomas predict survival but not response 
to temozolomide. Neurology 73 (21): 1792-5, 2009.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19933982&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19933982&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_2.14">Sanson M, Marie Y, Paris S, et al.: Isocitrate
 dehydrogenase 1 codon 132 mutation is an important prognostic biomarker
 in gliomas. J Clin Oncol 27 (25): 4150-4, 2009.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19636000&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19636000&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_2.15">Hartmann C, Hentschel B, Wick W, et al.: 
Patients with IDH1 wild type anaplastic astrocytomas exhibit worse 
prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status 
accounts for the unfavorable prognostic effect of higher age: 
implications for classification of gliomas. Acta Neuropathol 120 (6): 
707-18, 2010.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21088844&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21088844&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_2.16">Hartmann C, Meyer J, Balss J, et al.: Type and
 frequency of IDH1 and IDH2 mutations are related to astrocytic and 
oligodendroglial differentiation and age: a study of 1,010 diffuse 
gliomas. Acta Neuropathol 118 (4): 469-74, 2009.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19554337&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19554337&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_2.17">Jenkins RB, Blair H, Ballman KV, et al.: A 
t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and 
predicts a better prognosis of patients with oligodendroglioma. Cancer 
Res 66 (20): 9852-61, 2006.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17047046&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17047046&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_2.18">Camelo-Piragua S, Jansen M, Ganguly A, et al.:
 A sensitive and specific diagnostic panel to distinguish diffuse 
astrocytoma from astrocytosis: chromosome 7 gain with mutant isocitrate 
dehydrogenase 1 and p53. J Neuropathol Exp Neurol 70 (2): 110-5, 
2011.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21343879&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21343879&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_2.19">Capper D, Weissert S, Balss J, et al.: 
Characterization of R132H mutation-specific IDH1 antibody binding in 
brain tumors. Brain Pathol 20 (1): 245-54, 2010.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19903171&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19903171&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
  </ol>
</div>
    			</section><section id="_69">
    				<h2>Treatment Option Overview for Adult Primary CNS Tumors</h2>
    				 <div id="_section_69" class="pdq-sections"><nav class="onthispage in-this-section" role="navigation"><h6>In This Section</h6><ul><li><a href="#_720_toc">Primary CNS Tumors</a><ul><li><a href="#_724_toc">Surgery</a></li><li><a href="#_730_toc">Radiation therapy</a></li><li><a href="#_740_toc">Chemotherapy</a></li><li><a href="#_974_toc">Active surveillance</a></li><li><a href="#_1065_toc">Supportive therapy</a></li></ul></li></ul></nav>
  <section id="_720">
    <h3 id="_720_toc">Primary CNS Tumors</h3>
    <p id="_1050" tabindex="-1">This section discusses general treatment modalities for primary central nervous system (CNS) tumors. (Refer to  the <a href="https://www.cancer.gov/types/brain/hp/adult-brain-treatment-pdq#link/_792">Treatment of Primary Central Nervous System Tumors by Tumor Type</a> section of this summary for a description of specific treatment options for each tumor type.)</p>
    <p id="_1051" tabindex="-1"> Radiation therapy and chemotherapy 
options vary according to histology and anatomic site of the CNS tumor. 
 For glioblastoma, combined modality therapy with resection, radiation, 
and chemotherapy is standard. Anaplastic astrocytomas, anaplastic 
oligodendrogliomas, and anaplastic oligoastrocytomas represent only a 
small proportion of CNS gliomas; therefore, phase III randomized trials 
restricted to these tumor types are not generally practical.   The 
natural histories of these tumors are variable, depending on 
histological and molecular factors; therefore, treatment guidelines are 
evolving. Therapy involving surgically implanted carmustine-impregnated 
polymer wafers combined with postoperative external-beam radiation 
therapy (EBRT) may play a role in the treatment of high-grade (grades 
III and IV) gliomas  in some patients.[<a href="#cit/section_3.1">1</a>]</p>
    <p id="_987" tabindex="-1">Standard treatment options for primary CNS tumors include the following:</p>
    <div class="pdq-content-list">
      <ol id="_988">
        <li>
          <a href="https://www.cancer.gov/types/brain/hp/adult-brain-treatment-pdq#link/_724">Surgery</a>.</li>
        <li>
          <a href="https://www.cancer.gov/types/brain/hp/adult-brain-treatment-pdq#link/_730">Radiation therapy</a>.</li>
        <li>
          <a href="https://www.cancer.gov/types/brain/hp/adult-brain-treatment-pdq#link/_740">Chemotherapy</a>.</li>
        <li>
          <a href="https://www.cancer.gov/types/brain/hp/adult-brain-treatment-pdq#link/_974">Active surveillance</a>.</li>
        <li>
          <a href="https://www.cancer.gov/types/brain/hp/adult-brain-treatment-pdq#link/_1065">Supportive therapy</a>.</li>
      </ol>
    </div>
    <section id="_724">
      <h4 id="_724_toc">Surgery</h4>
      <p id="_725" tabindex="-1">For most types of CNS tumors   in most
locations, complete or near-complete surgical removal is generally 
attempted,  within the constraints of
preserving neurologic function and the patient's underlying health.  
This practice is based on observational evidence that survival is better
 in patients who undergo tumor resection than in those who have closed 
biopsy alone.[<a href="#cit/section_3.2">2</a>,<a href="#cit/section_3.3">3</a>]
 The benefit of resection has not been tested in randomized trials.  
Selection bias can enter into observational studies despite attempts to 
adjust for patient differences that guide the decision to resect the 
tumor; therefore, the actual difference in outcome between radical 
surgery and biopsy alone may not be as large as noted in the 
retrospective studies.[<a href="#cit/section_3.3">3</a>]</p>
      <p id="_873" tabindex="-1"> An exception to the use of resection 
is the case of 
deep-seated tumors such as pontine gliomas, which are diagnosed on
clinical evidence and  treated without initial surgery approximately 50%
 of the time.  In most cases, however, diagnosis by biopsy is preferred.
 
Stereotactic biopsy can be used for lesions that are difficult to reach 
and
resect.
</p>
      <p id="_726" tabindex="-1">The primary goals of surgical resection include the following:[<a href="#cit/section_3.4">4</a>]</p>
      <div class="pdq-content-list">
        <ul id="_1241">
          <li>To establish a histologic diagnosis.</li>
          <li>To reduce intracranial pressure by removing as much tumor as is safely possible to preserve neurological function.</li>
        </ul>
      </div>
      <p id="_728" tabindex="-1"> Total elimination of primary malignant
 intraparenchymal tumors by surgery alone is rarely achievable.  
Therefore, intraoperative techniques have been developed to reach a 
balance between removing as much tumor as is practical and preserving  
functional status.  For example, craniotomies with stereotactic 
resections of primary gliomas can be performed in cooperative patients 
while they are awake, with real-time assessment of neurologic function.[<a href="#cit/section_3.5">5</a>] Examples of intraoperative neurologic assessment include the following:</p>
      <div class="pdq-content-list">
        <ul id="_1052">
          <li>  Resection proceeds until either the magnetic resonance 
imaging (MRI) signal abnormality being used to monitor the extent of 
surgery is completely removed or subtle neurologic dysfunction appears 
(e.g., a slight decrease in rapid alternating motor movement or anomia).
  </li>
          <li>	When the tumor is located in or near language centers in 
the cortex, intraoperative language mapping can be performed by 
electrode discharge-induced speech arrest while the patient is asked to 
count or read.[<a href="#cit/section_3.6">6</a>]</li>
        </ul>
      </div>
      <p id="_729" tabindex="-1">As is the case with several other specialized operations [<a href="#cit/section_3.7">7</a>,<a href="#cit/section_3.8">8</a>]
 in which postoperative mortality has been associated with the number of
 procedures performed, postoperative mortality after surgery for primary
 brain tumors may be associated with hospital and/or surgeon volume.[<a href="#cit/section_3.9">9</a>]
  Using the Nationwide Inpatient Sample hospital discharge database for 
the years 1988 to 2000, which represented 20% of inpatient admissions to
 nonfederal U.S. hospitals, investigators observed the following:[<a href="#cit/section_3.9">9</a>]</p>
      <div class="pdq-content-list">
        <ul id="_1236">
          <li> Large-volume hospitals had lower in-hospital mortality 
rates after craniotomies for primary brain tumors (odds ratio [OR], 0.75
 for a tenfold higher caseload; 95% confidence interval [CI], 0.62–0.90)
 and after needle biopsies (OR, 0.54; 95% CI, 0.35–0.83).</li>
          <li>Although there was no specific sharp threshold in 
all-cause mortality outcomes between low-volume hospitals   and 
high-volume hospitals, craniotomy-associated in-hospital mortality was 
4.5% for hospitals with 5 or fewer procedures per year and 1.5% for 
hospitals with at least 42 procedures per year.</li>
          <li>In-hospital mortality rates decreased over the study years
 (perhaps because the proportion of elective nonemergent operations 
increased from 45% to 57%), but the decrease was more rapid in 
high-volume hospitals  than in low-volume hospitals.  </li>
          <li>High-volume surgeons had lower in-hospital patient mortality rates after craniotomy (OR, 0.60; 95% CI, 0.45–0.79).</li>
        </ul>
      </div>
      <p id="_1242" tabindex="-1">As with any study of volume-outcome 
associations, these results may not be causal because of residual 
confounding factors such as referral patterns, private insurance, and 
patient selection, despite multivariable adjustment.  </p>
    </section>
    <section id="_730">
      <h4 id="_730_toc">Radiation therapy</h4>
      <section id="_731">
        <h5 id="_731_toc">High-grade tumors</h5>
        <p id="_732" tabindex="-1">Radiation therapy has a major role in the treatment of patients with high-grade gliomas.  </p>
        <p id="_1056" tabindex="-1">Evidence (postoperative radiation therapy [PORT]):</p>
        <div class="pdq-content-list">
          <ol id="_1057">
            <li>A systematic review and meta-analysis of five randomized
 trials (plus one trial with allocation by birth date) comparing PORT 
with no radiation therapy showed a statistically significant survival 
advantage with radiation (risk ratio,  0.81; 95% CI, 0.74–0.88).[<a href="#cit/section_3.10">10</a>][<a href="https://www.cancer.gov/Common/PopUps/popDefinition.aspx?id=335125&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000335125&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence: 1iiA</a>]  </li>
            <li>A randomized trial comparing 60 Gy (in 30 fractions over
 6 weeks) with 45 Gy (in 25 fractions over 4 weeks) showed superior 
survival in the first group (12 months vs. 9 months median survival; 
hazard ratio [HR], 0.81; 95% CI, 0.66–0.99). The accepted standard dose 
of EBRT for malignant gliomas is 60 Gy.[<a href="#cit/section_3.11">11</a>][<a href="https://www.cancer.gov/Common/PopUps/popDefinition.aspx?id=335125&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000335125&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence: 1iiA</a>]</li>
          </ol>
        </div>
        <p id="_868" tabindex="-1">EBRT using either 3-dimensional 
conformal radiation therapy (3D-CRT) or intensity-modulated radiation 
therapy (IMRT) is considered an acceptable technique in radiation 
therapy delivery. Typically used are 2- to 3-cm margins on the MRI-based
 volumes (T1-weighted and fluid-attenuated inversion recovery [FLAIR]) 
to create the planning target volume. </p>
        <p id="_788" tabindex="-1">Dose escalation using radiosurgery 
has not improved outcomes. A randomized trial tested radiosurgery as a 
boost added to standard EBRT, but the trial found no improvement in 
survival, quality of life, or patterns of relapse compared with EBRT 
without the boost.[<a href="#cit/section_3.12">12</a>,<a href="#cit/section_3.13">13</a>] </p>
        <p id="_735" tabindex="-1">Brachytherapy has been used to 
deliver high doses of radiation locally to the tumor while sparing 
normal brain tissue.  However, this approach is technically demanding 
and has fallen out of favor with the advent of 3D-CRT and IMRT.</p>
      </section>
      <section id="_736">
        <h5 id="_736_toc">Low-grade tumors</h5>
        <p id="_737" tabindex="-1">Treatment options for patients with  
low-grade gliomas (i.e., low-grade astrocytomas, oligodendrogliomas, and
 mixed oligoastrocytomas) are not as clear as in the case of high-grade 
tumors and include observation, PORT, and chemotherapy with 
temozolomide.  </p>
        <p id="_1058" tabindex="-1">Evidence (PORT versus observation):</p>
        <div class="pdq-content-list">
          <ol id="_1059">
            <li>The European Organisation for Research and Treatment of 
Cancer (EORTC)  randomly assigned 311 patients with low-grade gliomas to
 undergo either radiation or observation in the EORTC-22845 (MRC BR04) 
trial.[<a href="#cit/section_3.14">14</a>,<a href="#cit/section_3.15">15</a>]
 On review of central pathology, about 25% of patients in the trial were
 reported to have high-grade tumors. Most of the control patients 
received radiation therapy at the time of progression.<div class="pdq-content-list"><ul id="_1060"><li>After
 a median follow-up of 93 months, median progression-free survival (PFS)
 was 5.3 years in the radiation arm versus 3.4 years in the control arm 
(HR,  0.59; 95% CI, 0.45–0.77).[<a href="#cit/section_3.14">14</a>,<a href="#cit/section_3.15">15</a>][<a href="https://www.cancer.gov/Common/PopUps/popDefinition.aspx?id=335131&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000335131&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence: 1iiDiii</a>]</li><li>There
 was no difference in the overall survival (OS) rate (median survival = 
7.4 years in the radiation arm vs. 7.2 years in the control arm; HR, 
0.97; 95% CI, 0.71–1.34; <em>P</em> = .87).[<a href="#cit/section_3.14">14</a>,<a href="#cit/section_3.15">15</a>][<a href="https://www.cancer.gov/Common/PopUps/popDefinition.aspx?id=335125&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000335125&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence: 1iiA</a>]  This was caused by a  longer survival after progression in the control arm (3.4 years) than in the radiation arm (1.0 year) (<em>P</em> &lt; .0001).</li><li>The
 investigators did not collect reliable quality-of-life measurements, so
 it is not clear whether the delay in initial relapse in the radiation 
therapy arm translated into improved function or quality of life.  </li></ul></div></li>
          </ol>
        </div>
        <p id="_1381" tabindex="-1">Evidence (PORT versus temozolomide 
for patients with low-grade World Health Organization (WHO) grade II 
tumors with at least one high-risk feature):</p>
        <div class="pdq-content-list">
          <ol id="_1382">
            <li>The <a href="https://www.cancer.gov/clinicaltrials/NCT00182819">EORTC 22033-26033</a>
 [NCT00182819] trial randomly assigned 707 patients with low-grade 
glioma (WHO grade II astrocytoma, oligoastrocytoma, or 
oligodendroglioma) and at least one high-risk feature (age &gt;40 years,
 progressive disease, tumor size &gt;5 cm, tumor crossing the midline, 
or neurological symptoms) to receive either radiation therapy (n = 240) 
or temozolomide chemotherapy (n = 237).  Radiation therapy consisted of 
conformal treatment (up to 50.4 Gy; 28 doses of 1.8 Gy daily, 5 days a 
week, for up to 6.5 weeks). Chemotherapy was dose-dense oral 
temozolomide (75 mg/m<span class="sup">2</span> daily for 21 days, repeated every 28 days [one cycle], for a maximum of 12 cycles).[<a href="#cit/section_3.16">16</a>,<a href="#cit/section_3.17">17</a>]<div class="pdq-content-list"><ol id="_1389" class="lower-alpha"><li>There was no significant difference in PFS (primary endpoint) or health-related quality of life (HR-QOL) (secondary endpoint).</li><li>At
 a median follow-up of 48 months (intraquartile range [IQR], 31–56), 
median PFS was 39 months (95% CI, 35–44) in the temozolomide group and 
46 months (95% CI, 40–56) in the radiation therapy group (unadjusted HR,
 1.16; 95% CI, 0.9–1.5; <em>P</em> = .22).[<a href="#cit/section_3.16">16</a>][<a href="https://www.cancer.gov/Common/PopUps/popDefinition.aspx?id=335131&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000335131&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence: 1iiDiii</a>] </li><li>An exploratory analysis of 318 molecularly defined patients found that patients with  an isocitrate dehydrogenase  (<em>IDH</em>
 gene) mutation without codeletion of 1p/19q displayed a significantly 
longer PFS when treated with radiation therapy (HR, 1.86; 95% CI, 
1.21–2.87; log-rank, <em>P</em> = .0043).</li><li>There were no significant treatment-dependent differences in PFS for patients with <em>IDH</em> mutation with codeletion of 1p/19q and <em>IDH</em> wild-type tumors. </li><li>Patients with wild-type <em>IDH</em> tumors had the worst prognosis independent of treatment type.</li><li>Patients with <em>IDH</em>-mutated tumors with codeletion of 1p/19q had the best prognosis.</li><li>The O6-methylguanine-DNA methyltransferase (MGMT)  promoter status was methylated in: <div class="pdq-content-list"><ul id="_1390"><li>All <em>IDH</em> mutations with codeletion of 1p/19q (45/45).</li><li>Most, but not all (86%, 62/72), of the <em>IDH</em> mutations without codeletion of 1p/19q.</li><li>Fifty-six percent (5/9) of the <em>IDH</em> wild-type cases. </li></ul></div></li></ol></div></li>
          </ol>
        </div>
      </section>
      <section id="_738">
        <h5 id="_738_toc">Disease progression, subsequent neoplasms, or recurrences</h5>
        <p id="_739" tabindex="-1">There are no randomized trials to 
delineate the role of repeat radiation after disease progression or the 
development of radiation-induced cancers.  The literature is limited to 
small retrospective case series, which makes interpretation difficult.[<a href="#cit/section_3.18">18</a>]
 The decision to repeat radiation must be made carefully because of the 
risk of neurocognitive deficits and radiation-induced necrosis.  One 
advantage of radiosurgery  is the ability to deliver therapeutic doses 
to recurrent tumors that may require the re-irradiation of previously 
irradiated brain tissue beyond tolerable dose limits.</p>
      </section>
    </section>
    <section id="_740">
      <h4 id="_740_toc">Chemotherapy</h4>
      <section id="_741">
        <h5 id="_741_toc">Systemic chemotherapy</h5>
        <p id="_780" tabindex="-1">For many years, the nitrosourea 
carmustine ([bis-chloroethylnitrosourea] BCNU) was the standard 
chemotherapy agent added to surgery and radiation therapy for malignant 
gliomas, based on the Radiation Therapy Oncology Group's (RTOG's)  
randomized trial  (RTOG-8302).[<a href="#cit/section_3.19">19</a>][<a href="https://www.cancer.gov/Common/PopUps/popDefinition.aspx?id=335125&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000335125&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence: 1iiA</a>]
 A modest impact on survival with the use of nitrosourea-containing 
chemotherapy regimens for malignant gliomas was confirmed in a 
patient-level meta-analysis of 12 randomized trials (combined HR<sub>death</sub>, 0.85; 95% CI,  0.78–0.91).[<a href="#cit/section_3.20">20</a>]  </p>
        <p id="_743" tabindex="-1">A large multicenter trial (<a href="https://www.cancer.gov/clinicaltrials/NCT00006353">NCT00006353</a>)
 of glioblastoma patients conducted by the EORTC-National Cancer 
Institute of Canada  reported a survival advantage with the use of 
temozolomide in addition to radiation therapy.[<a href="#cit/section_3.21">21</a>,<a href="#cit/section_3.22">22</a>][<a href="https://www.cancer.gov/Common/PopUps/popDefinition.aspx?id=335125&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000335125&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence: 1iiA</a>]
   On the basis of these results, the oral agent temozolomide has 
replaced BCNU as the standard systemic chemotherapy for malignant 
gliomas.  (Refer to the  <a href="https://www.cancer.gov/types/brain/hp/adult-brain-treatment-pdq#link/_1100">Glioblastomas treatment</a> section of this summary for more information.) </p>
        <p id="_1348" tabindex="-1">Long-term results of randomized trials in high-risk, low-grade (WHO grade II) gliomas [<a href="#cit/section_3.23">23</a>][<a href="https://www.cancer.gov/Common/PopUps/popDefinition.aspx?id=335125&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000335125&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence: 1iiA</a>] and anaplastic (WHO grade III) oligodendroglial tumors [<a href="#cit/section_3.24">24</a>,<a href="#cit/section_3.25">25</a>][<a href="https://www.cancer.gov/Common/PopUps/popDefinition.aspx?id=335125&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000335125&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence: 1iiA</a>]
 have demonstrated that the addition of procarbazine, lomustine (CCNU), 
and vincristine (PCV) chemotherapy to radiation therapy after surgery 
extends survival. Radiation and PCV chemotherapy should be considered 
for patients deemed appropriate for therapy.  (Refer to the <a href="https://www.cancer.gov/types/brain/hp/adult-brain-treatment-pdq#link/_792">Treatment of Primary Central Nervous System Tumors by Tumor Type</a> section of this summary for more information.)</p>
        <section id="_744">
          <h6 id="_744_toc">Localized chemotherapy (carmustine wafer)</h6>
          <p id="_745" tabindex="-1">The concept of delivering high 
doses of chemotherapy while avoiding systemic toxicity is attractive 
because malignant glioma–related deaths are nearly always the result of 
an inability to control intracranial disease rather than the result of 
distant metastases.  A biodegradable carmustine wafer  has been 
developed for that purpose.  The wafers contain 3.85% carmustine, and up
 to eight wafers are implanted into the tumor bed lining at the time of 
open resection, with an intended total dose of about 7.7 mg per wafer 
(61.6 mg maximum per patient) over a period of 2 to 3 weeks.  </p>
          <p id="_1243" tabindex="-1">Two randomized, placebo-controlled
 trials of this focal drug-delivery method have shown an OS advantage 
associated with the carmustine wafers versus radiation therapy alone. In
  both trials, the  upper age limit for patients was  65 years.  </p>
          <p id="_1061" tabindex="-1">Evidence (carmustine wafer):</p>
          <div class="pdq-content-list">
            <ol id="_1062">
              <li>A small trial was closed because of a lack of 
continued availability of the carmustine wafers after 32 patients with 
high-grade gliomas had been entered.[<a href="#cit/section_3.26">26</a>]<div class="pdq-content-list"><ul id="_1063"><li>Although OS was better in the carmustine-wafer group (median 58.1 vs. 39.9 weeks; <em>P</em>
 = .012), there was an imbalance in the study arms (only 11 of 16 
patients in the carmustine-wafer group vs. 16 of the 16 patients in the 
placebo-wafer group had grade IV glioblastoma tumors).</li></ul></div></li>
              <li>A multicenter study of 240 patients with primary malignant gliomas, 207 of whom had glioblastoma, was more informative.[<a href="#cit/section_3.27">27</a>,<a href="#cit/section_3.28">28</a>]
 At initial surgery, patients received either carmustine wafers or 
placebo wafers, followed by radiation therapy (55–60 Gy). Systemic 
therapy was not allowed until recurrence, except in the case of 
anaplastic oligodendrogliomas (n = 9).  Unlike the initial trial, 
patient characteristics were well balanced between the study arms.<div class="pdq-content-list"><ul id="_1064"><li>
  Median survival in the two groups was 13.8 months in patients treated 
with carmustine wafers versus 11.6 months in placebo-treated patients  
(HR, 0.73; 95% CI, 0.56–0.96; <em>P</em> = .017).</li></ul></div></li>
              <li>A systematic review combining both studies [<a href="#cit/section_3.26">26</a>-<a href="#cit/section_3.28">28</a>] estimated an HR for overall mortality of 0.65; 95% CI, 0.48–0.86; <em>P</em> = .003.[<a href="#cit/section_3.29">29</a>][<a href="https://www.cancer.gov/Common/PopUps/popDefinition.aspx?id=335106&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000335106&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence: 1iA</a>]</li>
            </ol>
          </div>
        </section>
      </section>
    </section>
    <section id="_974">
      <h4 id="_974_toc">Active surveillance</h4>
      <p id="_1055" tabindex="-1">Active surveillance is appropriate in 
some circumstances.  With the increasing use of sensitive neuroimaging 
tools, detection of asymptomatic low-grade meningiomas has increased; 
most appear to show minimal growth and can often be safely observed, 
with therapy deferred until the detection of tumor growth or the 
development of symptoms.[<a href="#cit/section_3.30">30</a>,<a href="#cit/section_3.31">31</a>]</p>
    </section>
    <section id="_1065">
      <h4 id="_1065_toc">Supportive therapy</h4>
      <p id="_1066" tabindex="-1">Dexamethasone, mannitol, and 
furosemide are used to treat the peritumoral edema associated with brain
 tumors. The use of anticonvulsants is mandatory for patients with 
seizures.[<a href="#cit/section_3.4">4</a>]</p>
    </section>
  </section>
  <h6 do-not-show="toc">References</h6>
  <ol>
    <li id="section_3.1">Lallana EC, Abrey LE: Update on the therapeutic
 approaches to brain tumors. Expert Rev Anticancer Ther 3 (5): 655-70, 
2003.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14599089&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14599089&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_3.2">Laws ER, Parney IF, Huang W, et al.: Survival 
following surgery and prognostic factors for recently diagnosed 
malignant glioma: data from the Glioma Outcomes Project. J Neurosurg 99 
(3): 467-73, 2003.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12959431&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12959431&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_3.3">Chang SM, Parney IF, Huang W, et al.: Patterns 
of care for adults with newly diagnosed malignant glioma. JAMA 293 (5): 
557-64, 2005.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15687310&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15687310&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_3.4">Cloughesy T, Selch MT, Liau L: Brain. In: 
Haskell CM: Cancer Treatment. 5th ed. Philadelphia, Pa: WB Saunders Co, 
2001, pp 1106-42.</li>
    <li id="section_3.5">Meyer FB, Bates LM, Goerss SJ, et al.: Awake 
craniotomy for aggressive resection of primary gliomas located in 
eloquent brain. Mayo Clin Proc 76 (7): 677-87, 2001.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11444399&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11444399&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_3.6">Sanai N, Mirzadeh Z, Berger MS: Functional 
outcome after language mapping for glioma resection. N Engl J Med 358 
(1): 18-27, 2008.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18172171&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18172171&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_3.7">Begg CB, Cramer LD, Hoskins WJ, et al.: Impact 
of hospital volume on operative mortality for major cancer surgery. JAMA
 280 (20): 1747-51, 1998.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9842949&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9842949&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_3.8">Birkmeyer JD, Finlayson EV, Birkmeyer CM: 
Volume standards for high-risk surgical procedures: potential benefits 
of the Leapfrog initiative. Surgery 130 (3): 415-22, 2001.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11562662&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11562662&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_3.9">Barker FG 2nd, Curry WT Jr, Carter BS: Surgery 
for primary supratentorial brain tumors in the United States, 1988 to 
2000: the effect of provider caseload and centralization of care. Neuro 
Oncol 7 (1): 49-63, 2005.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15701282&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15701282&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_3.10">Laperriere N, Zuraw L, Cairncross G, et al.: 
Radiotherapy for newly diagnosed malignant glioma in adults: a 
systematic review. Radiother Oncol 64 (3): 259-73, 2002.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12242114&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12242114&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_3.11">Bleehen NM, Stenning SP: A Medical Research 
Council trial of two radiotherapy doses in the treatment of grades 3 and
 4 astrocytoma. The Medical Research Council Brain Tumour Working Party.
 Br J Cancer 64 (4): 769-74, 1991.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1654987&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1654987&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_3.12">Tsao MN, Mehta MP, Whelan TJ, et al.: The 
American Society for Therapeutic Radiology and Oncology (ASTRO) 
evidence-based review of the role of radiosurgery for malignant glioma. 
Int J Radiat Oncol Biol Phys 63 (1): 47-55, 2005.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16111571&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16111571&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_3.13">Souhami L, Seiferheld W, Brachman D, et al.: 
Randomized comparison of stereotactic radiosurgery followed by 
conventional radiotherapy with carmustine to conventional radiotherapy 
with carmustine for patients with glioblastoma multiforme: report of 
Radiation Therapy Oncology Group 93-05 protocol. Int J Radiat Oncol Biol
 Phys 60 (3): 853-60, 2004.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15465203&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15465203&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_3.14">Karim AB, Afra D, Cornu P, et al.: Randomized 
trial on the efficacy of radiotherapy for cerebral low-grade glioma in 
the adult: European Organization for Research and Treatment of Cancer 
Study 22845 with the Medical Research Council study BRO4: an interim 
analysis. Int J Radiat Oncol Biol Phys 52 (2): 316-24, 2002.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11872276&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11872276&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_3.15">van den Bent MJ, Afra D, de Witte O, et al.: 
Long-term efficacy of early versus delayed radiotherapy for low-grade 
astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised 
trial. Lancet 366 (9490): 985-90, 2005.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16168780&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16168780&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_3.16">Baumert BG, Hegi ME, van den Bent MJ, et al.: 
Temozolomide chemotherapy versus radiotherapy in high-risk low-grade 
glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup
 study. Lancet Oncol 17 (11): 1521-1532, 2016.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=27686946&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=27686946&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_3.17">Reijneveld JC, Taphoorn MJ, Coens C, et al.: 
Health-related quality of life in patients with high-risk low-grade 
glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup
 study. Lancet Oncol 17 (11): 1533-1542, 2016.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=27686943&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=27686943&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_3.18">Paulino AC, Mai WY, Chintagumpala M, et al.: 
Radiation-induced malignant gliomas: is there a role for reirradiation? 
Int J Radiat Oncol Biol Phys 71 (5): 1381-7, 2008.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18262733&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18262733&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_3.19">Walker MD, Green SB, Byar DP, et al.: 
Randomized comparisons of radiotherapy and nitrosoureas for the 
treatment of malignant glioma after surgery. N Engl J Med 303 (23): 
1323-9, 1980.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7001230&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7001230&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_3.20">Stewart LA: Chemotherapy in adult high-grade 
glioma: a systematic review and meta-analysis of individual patient data
 from 12 randomised trials. Lancet 359 (9311): 1011-8, 2002.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11937180&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11937180&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_3.21">Stupp R, Mason WP, van den Bent MJ, et al.: 
Radiotherapy plus concomitant and adjuvant temozolomide for 
glioblastoma. N Engl J Med 352 (10): 987-96, 2005.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15758009&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15758009&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_3.22">Stupp R, Hegi ME, Mason WP, et al.: Effects of
 radiotherapy with concomitant and adjuvant temozolomide versus 
radiotherapy alone on survival in glioblastoma in a randomised phase III
 study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10 (5): 
459-66, 2009.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19269895&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19269895&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_3.23">Buckner JC, Pugh SL, Shaw EG, et al.: Phase 
III study of radiation therapy with or without procarbazine, CCNU, and 
vincristine (PCV) in low-grade glioma: RTOG 9802 with Alliance, ECOG, 
and SWOG. [Abstract] J Clin Oncol  32 (Suppl 5): A-2000, 2014.</li>
    <li id="section_3.24">van den Bent MJ, Brandes AA, Taphoorn MJ, et 
al.: Adjuvant procarbazine, lomustine, and vincristine chemotherapy in 
newly diagnosed anaplastic oligodendroglioma: long-term follow-up of 
EORTC brain tumor group study 26951. J Clin Oncol 31 (3): 344-50, 
2013.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23071237&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23071237&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_3.25">Cairncross G, Wang M, Shaw E, et al.: Phase 
III trial of chemoradiotherapy for anaplastic oligodendroglioma: 
long-term results of RTOG 9402. J Clin Oncol 31 (3): 337-43, 2013.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23071247&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23071247&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_3.26">Valtonen S, Timonen U, Toivanen P, et al.: 
Interstitial chemotherapy with carmustine-loaded polymers for high-grade
 gliomas: a randomized double-blind study. Neurosurgery 41 (1): 44-8; 
discussion 48-9, 1997.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9218294&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9218294&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_3.27">Westphal M, Hilt DC, Bortey E, et al.: A phase
 3 trial of local chemotherapy with biodegradable carmustine (BCNU) 
wafers (Gliadel wafers) in patients with primary malignant glioma. 
Neuro-oncol 5 (2): 79-88, 2003.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12672279&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12672279&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_3.28">Westphal M, Ram Z, Riddle V, et al.: Gliadel 
wafer in initial surgery for malignant glioma: long-term follow-up of a 
multicenter controlled trial. Acta Neurochir (Wien) 148 (3): 269-75; 
discussion 275, 2006.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16482400&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16482400&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_3.29">Hart MG, Grant R, Garside R, et al.: 
Chemotherapeutic wafers for high grade glioma. Cochrane Database Syst 
Rev  (3): CD007294, 2008.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18646178&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18646178&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_3.30">Nakamura M, Roser F, Michel J, et al.: The 
natural history of incidental meningiomas. Neurosurgery 53 (1): 62-70; 
discussion 70-1, 2003.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12823874&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12823874&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_3.31">Yano S, Kuratsu J; Kumamoto Brain Tumor 
Research Group: Indications for surgery in patients with asymptomatic 
meningiomas based on an extensive experience. J Neurosurg 105 (4): 
538-43, 2006.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17044555&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17044555&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
  </ol>
</div>
    			</section><section id="_792">
    				<h2>Treatment of Primary Central Nervous System  Tumors by Tumor Type</h2>
    				 <div id="_section_792" class="pdq-sections"><nav class="onthispage in-this-section" role="navigation"><h6>In This Section</h6><ul><li><a href="#_1067_toc">Astrocytic Tumors Treatment</a><ul><li><a href="#_1068_toc">Brain stem gliomas treatment</a></li><li><a href="#_1073_toc">Pineal astrocytic tumors treatment</a></li><li><a href="#_1078_toc">Pilocytic astrocytomas treatment</a></li><li><a href="#_1083_toc">Diffuse astrocytomas treatment</a></li><li><a href="#_1089_toc">Anaplastic astrocytomas treatment</a></li><li><a href="#_1100_toc">Glioblastomas treatment</a></li></ul></li><li><a href="#_1137_toc">Oligodendroglial Tumors Treatment</a><ul><li><a href="#_1138_toc">Oligodendrogliomas treatment</a></li><li><a href="#_1144_toc">Anaplastic oligodendrogliomas treatment</a></li></ul></li><li><a href="#_831_toc">Mixed Gliomas Treatment</a></li><li><a href="#_835_toc">Ependymal Tumors Treatment</a></li><li><a href="#_844_toc">Embryonal Cell Tumors (Medulloblastomas) Treatment</a><ul><li><a href="#_1312_toc">Treatment options under clinical evaluation for medulloblastomas</a></li></ul></li><li><a href="#_851_toc">Pineal Parenchymal Tumors Treatment</a></li><li><a href="#_855_toc">Meningeal Tumors Treatment</a></li><li><a href="#_682_toc">Germ Cell Tumors Treatment</a></li><li><a href="#_684_toc">Treatment of Tumors of the Sellar Region</a></li><li><a href="#_1108_toc">Treatment Options Under Clinical Evaluation for Primary CNS Tumors</a></li><li><a href="#_TrialSearch_792_sid_4_toc">Current Clinical Trials</a></li></ul></nav>
  <div style="height: 1px;"></div><figure class="table"><figcaption id="_989_cap">Table 2.  Treatment of Primary Central Nervous System  Tumors by Tumor Type</figcaption><div class="scrollable"><div><table id="_989" class="table-default expandable-container" aria-labelledby="_989_cap">
    
    <colgroup>
      <col width="50.00%">
      <col width="50.00%">
    </colgroup>
    <thead>
      <tr>
        <th scope="col" align="Center">Tumor Type</th>
        <th scope="col" align="Center">Standard Treatment Options</th>
      </tr>
    </thead>
    <tbody>
      <tr>
        <td>Astrocytic tumors</td>
        <td>&nbsp;</td>
      </tr>
      <tr>
        <td>—Brain stem gliomas</td>
        <td>
          <a href="https://www.cancer.gov/types/brain/hp/adult-brain-treatment-pdq#link/_1336">Radiation therapy</a>
        </td>
      </tr>
      <tr>
        <td rowspan="2">—Pineal astrocytic tumors</td>
        <td>
          <a href="https://www.cancer.gov/types/brain/hp/adult-brain-treatment-pdq#link/_1249">Surgery plus radiation therapy</a>
        </td>
      </tr>
      <tr>
        <td>
          <a href="https://www.cancer.gov/types/brain/hp/adult-brain-treatment-pdq#link/_1249">Surgery plus radiation therapy and chemotherapy for higher-grade tumors</a>
        </td>
      </tr>
      <tr>
        <td rowspan="2">—Pilocytic astrocytomas</td>
        <td>
          <a href="https://www.cancer.gov/types/brain/hp/adult-brain-treatment-pdq#link/_1252">Surgery alone </a>
        </td>
      </tr>
      <tr>
        <td>
          <a href="https://www.cancer.gov/types/brain/hp/adult-brain-treatment-pdq#link/_1252">Surgery followed by radiation therapy </a>
        </td>
      </tr>
      <tr>
        <td rowspan="2">—Diffuse astrocytomas (WHO grade II)</td>
        <td>
          <a href="https://www.cancer.gov/types/brain/hp/adult-brain-treatment-pdq#link/_1255">Surgery with or without radiation therapy</a>
        </td>
      </tr>
      <tr>
        <td>
          <a href="https://www.cancer.gov/types/brain/hp/adult-brain-treatment-pdq#link/_1255">Surgery followed by radiation therapy and chemotherapy</a>
        </td>
      </tr>
      <tr>
        <td rowspan="2">—Anaplastic astrocytomas (WHO grade III)</td>
        <td>
          <a href="https://www.cancer.gov/types/brain/hp/adult-brain-treatment-pdq#link/_1259">Surgery plus radiation therapy with or without chemotherapy</a>
        </td>
      </tr>
      <tr>
        <td>
          <a href="https://www.cancer.gov/types/brain/hp/adult-brain-treatment-pdq#link/_1259">Surgery plus chemotherapy</a>
        </td>
      </tr>
      <tr>
        <td rowspan="4">—Glioblastomas</td>
        <td>
          <a href="https://www.cancer.gov/types/brain/hp/adult-brain-treatment-pdq#link/_1267">Surgery plus radiation therapy and chemotherapy</a>
        </td>
      </tr>
      <tr>
        <td>
          <a href="https://www.cancer.gov/types/brain/hp/adult-brain-treatment-pdq#link/_1267">Surgery plus radiation therapy</a>
        </td>
      </tr>
      <tr>
        <td>
          <a href="https://www.cancer.gov/types/brain/hp/adult-brain-treatment-pdq#link/_1267">Carmustine-impregnated polymer implant</a>
        </td>
      </tr>
      <tr>
        <td>
          <a href="https://www.cancer.gov/types/brain/hp/adult-brain-treatment-pdq#link/_1267">Radiation therapy and concurrent chemotherapy</a>
        </td>
      </tr>
      <tr>
        <td colspan="2">Oligodendroglial tumors</td>
      </tr>
      <tr>
        <td rowspan="2" scope="col" align="Left">—Oligodendrogliomas</td>
        <td>
          <a href="https://www.cancer.gov/types/brain/hp/adult-brain-treatment-pdq#link/_1286">Surgery with or without radiation therapy</a>
        </td>
      </tr>
      <tr>
        <td>
          <a href="https://www.cancer.gov/types/brain/hp/adult-brain-treatment-pdq#link/_1286">Surgery with radiation therapy and chemotherapy</a>
        </td>
      </tr>
      <tr>
        <td>—Anaplastic oligodendrogliomas</td>
        <td>
          <a href="https://www.cancer.gov/types/brain/hp/adult-brain-treatment-pdq#link/_1291">Surgery plus radiation therapy with or without chemotherapy</a>
        </td>
      </tr>
      <tr>
        <td>Mixed gliomas</td>
        <td>
          <a href="https://www.cancer.gov/types/brain/hp/adult-brain-treatment-pdq#link/_1301">Surgery plus radiation therapy with or without chemotherapy</a>
        </td>
      </tr>
      <tr>
        <td colspan="2">Ependymal tumors</td>
      </tr>
      <tr>
        <td rowspan="2">—Grades I and II ependymal tumors</td>
        <td>
          <a href="https://www.cancer.gov/types/brain/hp/adult-brain-treatment-pdq#link/_1305">Surgery alone</a>
        </td>
      </tr>
      <tr>
        <td>
          <a href="https://www.cancer.gov/types/brain/hp/adult-brain-treatment-pdq#link/_1305">Surgery followed by radiation therapy</a>
        </td>
      </tr>
      <tr>
        <td>—Anaplastic ependymoma</td>
        <td>
          <a href="https://www.cancer.gov/types/brain/hp/adult-brain-treatment-pdq#link/_1308">Surgery plus radiation therapy</a>
        </td>
      </tr>
      <tr>
        <td colspan="2">Embryonal cell tumors</td>
      </tr>
      <tr>
        <td>—Medulloblastomas</td>
        <td>
          <a href="https://www.cancer.gov/types/brain/hp/adult-brain-treatment-pdq#link/_1311">Surgery plus craniospinal radiation therapy</a>
        </td>
      </tr>
      <tr>
        <td rowspan="2">Pineal parenchymal tumors</td>
        <td>
          <a href="https://www.cancer.gov/types/brain/hp/adult-brain-treatment-pdq#link/_1318">Surgery plus radiation therapy</a> (for pineocytoma)</td>
      </tr>
      <tr>
        <td>
          <a href="https://www.cancer.gov/types/brain/hp/adult-brain-treatment-pdq#link/_1318">Surgery plus radiation therapy and chemotherapy</a> (for pineoblastoma)</td>
      </tr>
      <tr>
        <td colspan="2">Meningeal tumors</td>
      </tr>
      <tr>
        <td rowspan="5">—Grade I meningiomas</td>
        <td>
          <a href="https://www.cancer.gov/types/brain/hp/adult-brain-treatment-pdq#link/_1321">Active surveillance with deferred treatment</a>
        </td>
      </tr>
      <tr>
        <td>
          <a href="https://www.cancer.gov/types/brain/hp/adult-brain-treatment-pdq#link/_1321">Surgery</a>
        </td>
      </tr>
      <tr>
        <td>
          <a href="https://www.cancer.gov/types/brain/hp/adult-brain-treatment-pdq#link/_1321">Stereotactic radiosurgery</a>
        </td>
      </tr>
      <tr>
        <td>
          <a href="https://www.cancer.gov/types/brain/hp/adult-brain-treatment-pdq#link/_1321">Surgery plus radiation therapy</a>
        </td>
      </tr>
      <tr>
        <td>
          <a href="https://www.cancer.gov/types/brain/hp/adult-brain-treatment-pdq#link/_1321">Fractionated radiation therapy</a>
        </td>
      </tr>
      <tr>
        <td>—Grades II and III meningiomas and hemangiopericytomas</td>
        <td>
          <a href="https://www.cancer.gov/types/brain/hp/adult-brain-treatment-pdq#link/_1324">Surgery plus radiation therapy</a>
        </td>
      </tr>
      <tr>
        <td>Germ cell tumors</td>
        <td>
          <a href="https://www.cancer.gov/types/brain/hp/adult-brain-treatment-pdq#link/_683">Depends on multiple factors</a>
        </td>
      </tr>
      <tr>
        <td colspan="2">Tumors of the sellar region</td>
      </tr>
      <tr>
        <td rowspan="2">—Craniopharyngiomas</td>
        <td>
          <a href="https://www.cancer.gov/types/brain/hp/adult-brain-treatment-pdq#link/_1327">Surgery alone</a>
        </td>
      </tr>
      <tr>
        <td>
          <a href="https://www.cancer.gov/types/brain/hp/adult-brain-treatment-pdq#link/_1327">Debulking surgery plus radiation therapy</a>
        </td>
      </tr>
    </tbody>
  </table></div></div></figure>
  <section id="_1067">
    <h3 id="_1067_toc">Astrocytic Tumors Treatment</h3>
    <section id="_1068">
      <h4 id="_1068_toc">Brain stem gliomas treatment</h4>
      <p id="_1244" tabindex="-1">Patients with brain stem gliomas have relatively poor prognoses that correlate with
histology (when biopsies are performed), location, and extent of tumor.  The
overall median survival time of patients in studies has been 44 to 74
weeks.</p>
      <p id="_1245" tabindex="-1">Standard treatment options for brain stem gliomas include the following:</p>
      <div class="pdq-content-list">
        <ol id="_1336">
          <li>Radiation therapy.</li>
        </ol>
      </div>
    </section>
    <section id="_1073">
      <h4 id="_1073_toc">Pineal astrocytic tumors treatment</h4>
      <p id="_1247" tabindex="-1">Depending on the degree of anaplasia, patients with pineal astrocytomas have variable prognoses. 
Patients with higher-grade tumors have worse prognoses.
</p>
      <p id="_1248" tabindex="-1">Standard treatment options for pineal astrocytic tumors include the following:</p>
      <div class="pdq-content-list">
        <ol id="_1249">
          <li>Surgery plus radiation therapy for pineal astrocytoma.</li>
          <li>Surgery plus radiation therapy and chemotherapy for higher-grade tumors.</li>
        </ol>
      </div>
    </section>
    <section id="_1078">
      <h4 id="_1078_toc">Pilocytic astrocytomas treatment</h4>
      <p id="_1250" tabindex="-1">This astrocytic tumor is classified as a World Health Organization (WHO) grade I tumor and is often curable.</p>
      <p id="_1251" tabindex="-1">Standard treatment options for pilocytic astrocytomas include the following:</p>
      <div class="pdq-content-list">
        <ol id="_1252">
          <li>Surgery alone if the tumor is totally resectable.
</li>
          <li>Surgery followed by radiation therapy to known or suspected residual
tumor.</li>
        </ol>
      </div>
    </section>
    <section id="_1083">
      <h4 id="_1083_toc">Diffuse astrocytomas treatment</h4>
      <p id="_1253" tabindex="-1">This WHO grade II astrocytic tumor is less often curable than is a pilocytic astrocytoma.</p>
      <p id="_1254" tabindex="-1">Standard treatment options for diffuse astrocytomas (WHO grade II) include the following:</p>
      <div class="pdq-content-list">
        <ol id="_1255">
          <li>Surgery with or without radiation therapy.</li>
          <li>Surgery followed by radiation therapy and chemotherapy.</li>
        </ol>
      </div>
      <p id="_1368" tabindex="-1">Controversy exists about the timing of radiation therapy after surgery. (Refer to  <a href="https://www.cancer.gov/types/brain/hp/adult-brain-treatment-pdq#link/_736">Low-grade tumors</a> in the <a href="https://www.cancer.gov/types/brain/hp/adult-brain-treatment-pdq#link/_730">Radiation therapy</a> section of the <a href="https://www.cancer.gov/types/brain/hp/adult-brain-treatment-pdq#link/_69">Treatment Option Overview for Adult Central Nervous System Tumors Treatment</a> section in this summary for more information.) </p>
      <div class="pdq-content-list">
        <ul id="_1369">
          <li>Radiation therapy  improved  progression-free survival 
(PFS) in patients who received early radiation therapy in the European 
Organisation for Research and Treatment of Cancer (EORTC) (EORTC-22845) 
trial. (Refer to <a href="https://www.cancer.gov/types/brain/hp/adult-brain-treatment-pdq#link/_1138">Oligodendrogliomas treatment</a> in the  <a href="https://www.cancer.gov/types/brain/hp/adult-brain-treatment-pdq#link/_1137">Oligodendroglial Tumors Treatment</a> section of the <a href="https://www.cancer.gov/types/brain/hp/adult-brain-treatment-pdq#link/_792">Treatment of Primary Central Nervous System Tumors by Tumor Type</a> section of this summary for more information.)[<a href="#cit/section_4.1">1</a>]<a href="https://www.cancer.gov/Common/PopUps/popDefinition.aspx?id=335125&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000335125&amp;version=HealthProfessional&amp;language=English'); return(false);">[Level of evidence: 1iiA]</a> </li>
          <li>In the same trial, there was no difference in overall 
survival (OS) between patients who had radiation therapy after surgery 
and those who were treated with radiation therapy at the time of 
progression.[<a href="#cit/section_4.1">1</a>]<a href="https://www.cancer.gov/Common/PopUps/popDefinition.aspx?id=335125&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000335125&amp;version=HealthProfessional&amp;language=English'); return(false);">[Level of evidence: 1iiA]</a></li>
        </ul>
      </div>
      <p id="_1370" tabindex="-1">Some
physicians use surgery alone if a patient has clinical factors that are 
considered low risk, such as age less than 40 years and the lack of 
contrast enhancement on a computed
tomographic scan.[<a href="#cit/section_4.2">2</a>]</p>
      <p id="_1351" tabindex="-1">Evidence (surgery followed by radiation therapy and chemotherapy):</p>
      <div class="pdq-content-list">
        <ol id="_1352">
          <li>For patients with low-grade (WHO grade II) tumors, which are considered <em>high risk</em>,
 radiation therapy followed by six cycles of vincristine (PCV) 
chemotherapy is a recommended option based on the long-term follow-up 
results of the Radiation Therapy Oncology Group's (RTOG's) 
1986-initiated randomized trial (<a href="https://www.cancer.gov/clinicaltrials/NCT00003375">RTOG 9802</a> [NCT00003375]).[<a href="#cit/section_4.3">3</a>][<a href="https://www.cancer.gov/Common/PopUps/popDefinition.aspx?id=335125&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000335125&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence: 1iiA</a>]
  In this trial, high-risk, low-grade glioma patients, defined as 
patients aged 18 to 39 years with biopsy or subtotal resection, or 
patients aged 40 years or older, were randomly assigned to either 54 Gy 
of radiation therapy or radiation therapy followed by six cycles of PCV 
chemotherapy.<div class="pdq-content-list"><ol id="_1361" class="lower-alpha"><li>The addition of PCV to radiation therapy increased median PFS from 4.0 years to 10.4 years (<em>P</em> = .002; hazard ratio [HR], 0.50) and median OS from 7.8 years to 13.3 years (<em>P</em> = .03; HR, 0.59).</li><li>Notably,
 the RTOG 9802 study enrolled patients with a variety of tumors, 
including astrocytomas, oligodendrogliomas, and mixed oligoastrocytomas.<div class="pdq-content-list"><ul id="_1362"><li>
 In a risk-adjusted multivariate analysis, patients treated with PCV and
 patients  with an oligodendroglial histology had better survival 
outcomes. A subset analysis of histologic type suggested that the 
addition of PCV mainly benefited patients with oligodendroglial tumors, 
although this data is yet to be validated.[<a href="#cit/section_4.4">4</a>]</li><li> Median OS for PCV versus the control arm was not reached versus 10.8 years for oligodendrogliomas (<em>P</em> = .008), 11.4 years versus 5.9 years  for oligoastrocytomas (<em>P</em> = .05), and 7.7 years versus 4.4 years  for astrocytomas (<em>P</em> = .31).</li></ul></div></li></ol></div></li>
        </ol>
      </div>
      <p id="_1371" tabindex="-1">The discovery of the <em>isocitrate dehydrogenase (IDH) 1 </em> and <em>IDH2</em> mutations in diffuse gliomas has greatly helped to identify patients who are considered <em>high risk</em>.  A number of large, retrospective studies has demonstrated that the <em>IDH1</em> and <em>IDH2</em> mutation is a powerful independent prognostic factor for improved survival.[<a href="#cit/section_4.5">5</a>-<a href="#cit/section_4.9">9</a>] The  majority of WHO grade II and III gliomas harbor the <em>IDH1</em> and <em>IDH2</em> mutation,[<a href="#cit/section_4.6">6</a>,<a href="#cit/section_4.10">10</a>,<a href="#cit/section_4.11">11</a>] and, therefore, the presence of the  <em>IDH1</em> and <em>IDH2</em> mutation should be included in the assessment of <em>high risk</em>.
 Molecular correlative data from the RTOG 98-02 trial, which would be 
informative about which patients benefited the most from the addition of
 PCV, have not yet been reported.</p>
    </section>
    <section id="_1089">
      <h4 id="_1089_toc">Anaplastic astrocytomas treatment</h4>
      <p id="_1257" tabindex="-1">Patients with anaplastic astrocytomas (WHO grade III) have a low cure rate with standard
local treatment.</p>
      <p id="_1258" tabindex="-1">Standard treatment options for anaplastic astrocytomas include the following:</p>
      <div class="pdq-content-list">
        <ol id="_1259">
          <li>Surgery plus radiation therapy with or without chemotherapy.</li>
          <li>Surgery plus chemotherapy.</li>
        </ol>
      </div>
      <p id="_1260" tabindex="-1">A subset of anaplastic astrocytomas is
 aggressive;  these tumors are frequently managed  in the same way as 
glioblastomas, with surgery and radiation, and often  with chemotherapy.
 However, the optimal treatment for these tumors is not established. Two
 phase III randomized trials restricted to patients with anaplastic 
gliomas (<a href="https://www.cancer.gov/clinicaltrials/NCT00626990">NCT00626990</a> and <a href="https://www.cancer.gov/clinicaltrials/NCT00887146">NCT00887146</a>)
 are currently enrolling patients, but efficacy data are not available. 
It is not known whether the improved survival of patients with 
chemotherapy-treated glioblastoma can be extrapolated to patients with 
anaplastic astrocytomas. </p>
      <p id="_1372" tabindex="-1">The <em>IDH1</em> and <em>IDH2</em> 
mutation is present in 50% to 70% of anaplastic astrocytomas and is 
independently associated with significantly improved survival.[<a href="#cit/section_4.6">6</a>,<a href="#cit/section_4.9">9</a>]  Assessment of the <em>IDH1</em> and <em>IDH2</em> mutation status may guide decisions about treatment options.</p>
      <p id="_1261" tabindex="-1">Evidence (surgery plus radiation therapy or chemotherapy):</p>
      <div class="pdq-content-list">
        <ol id="_1262">
          <li>Postoperative radiation alone has been compared with 
postoperative chemotherapy alone in patients with anaplastic gliomas 
(i.e., 144 astrocytomas, 91 oligoastrocytomas, and 39 
oligodendrogliomas), with crossover to the other modality at the time of
 tumor progression. Of the 139  patients randomly assigned to undergo 
radiation therapy, 135 were randomly assigned to receive chemotherapy, 
with a 32-week course of either PCV or single-agent temozolomide (2:1:1 
randomization).[<a href="#cit/section_4.12">12</a>][Levels of evidence: <a href="https://www.cancer.gov/Common/PopUps/popDefinition.aspx?id=335125&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000335125&amp;version=HealthProfessional&amp;language=English'); return(false);">1iiA</a> and <a href="https://www.cancer.gov/Common/PopUps/popDefinition.aspx?id=632558&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000632558&amp;version=HealthProfessional&amp;language=English'); return(false);">1iiD</a>] <div class="pdq-content-list"><ul id="_1263"><li>The order of the modalities did not affect time-to-treatment failure (TTF) or OS.</li><li>Neither TTF nor OS differed across the treatment arms.</li></ul></div></li>
        </ol>
      </div>
      <p id="_1264" tabindex="-1">Patients with anaplastic astrocytomas are appropriate candidates for clinical
trials designed to improve local control by adding newer forms of treatment to
standard treatment. Information about ongoing clinical trials is available from the <a href="https://www.cancer.gov/about-cancer/treatment/clinical-trials" title="https://www.cancer.gov/about-cancer/treatment/clinical-trials">NCI website</a>.</p>
    </section>
    <section id="_1100">
      <h4 id="_1100_toc">Glioblastomas treatment</h4>
      <p id="_1265" tabindex="-1">For patients with glioblastoma (WHO grade IV), the cure rate is very low with standard local
treatment.</p>
      <p id="_1354" tabindex="-1">Methylation of the promoter of the O6-methylguanine-DNA methyltransferase (<em>MGMT</em>) DNA repair enzyme gene is an independent prognostic factor for improved survival in newly diagnosed glioblastoma.[<a href="#cit/section_4.13">13</a>,<a href="#cit/section_4.14">14</a>] <em>MGMT</em>
 promoter methylation and concomitant inactivation of the DNA repair 
enzyme activities may also predict for response to temozolomide 
chemotherapy.[<a href="#cit/section_4.13">13</a>] However, the clinical data that  <em>MGMT</em> promoter methylation is a predictive marker is less certain. (Refer to <a href="https://www.cancer.gov/types/brain/hp/adult-brain-treatment-pdq#link/_1100">Glioblastomas treatment</a> in the <a href="https://www.cancer.gov/types/brain/hp/adult-brain-treatment-pdq#link/_1067">Astrocytic Tumors Treatment</a> section of the <a href="https://www.cancer.gov/types/brain/hp/adult-brain-treatment-pdq#link/_792">Treatment of Primary Central Nervous System Tumors by Tumor Type</a> section of this summary for more information about the <a href="https://www.cancer.gov/clinicaltrials/NCT00304031">RTOG-0525</a> [NCT00304031] trial.) </p>
      <p id="_1266" tabindex="-1">Standard treatment options for patients with newly diagnosed glioblastoma include the following:</p>
      <div class="pdq-content-list">
        <ol id="_1267">
          <li>Surgery plus radiation therapy and chemotherapy.</li>
          <li>Surgery plus radiation therapy.</li>
          <li>Carmustine-impregnated polymer implanted during initial surgery.</li>
          <li>Radiation therapy and concurrent chemotherapy.</li>
        </ol>
      </div>
      <p id="_1268" tabindex="-1">The standard  treatment for patients 
with newly diagnosed glioblastoma is surgery followed by concurrent 
radiation therapy and daily temozolomide, and then followed by six 
cycles of temozolomide. The addition of bevacizumab to radiation therapy
 and temozolomide did not improve OS.</p>
      <p id="_1270" tabindex="-1">Evidence (Surgery plus radiation therapy  and chemotherapy):</p>
      <div class="pdq-content-list">
        <ol id="_1271">
          <li>Standard therapy is based on a large, multicenter, randomized trial (<a href="https://www.cancer.gov/clinicaltrials/NCT00006353">NCT00006353</a>)
 conducted by the EORTC and National Cancer Institute of Canada 
(NCIC).This trial reported a survival benefit with concurrent radiation 
therapy and temozolomide, compared with radiation therapy alone.[<a href="#cit/section_4.15">15</a>,<a href="#cit/section_4.16">16</a>][<a href="https://www.cancer.gov/Common/PopUps/popDefinition.aspx?id=335125&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000335125&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence: 1iiA</a>]
 In this study, 573 patients with glioblastoma were randomly assigned to
 receive standard radiation to the tumor volume with a 2- to 3-cm margin
 (60 Gy, 2 Gy per fraction, over 6 weeks) alone or with temozolomide (75
 mg/m<span class="sup">2</span> orally per day during radiation therapy 
for up to 49 days, followed by a 4-week break and then up to six cycles 
of five daily doses every 28 days at a dose of 150 mg/m<span class="sup">2</span>, increasing to 200 mg/m<span class="sup">2</span> after the first cycle). <div class="pdq-content-list"><ol id="_1272" class="lower-alpha"><li>OS was statistically significantly better in the combined radiation therapy–temozolomide group (HR<sub>death</sub>,
 0.6; 95% confidence interval [CI], 0.5–0.7; OS at 3 years was 16.0% for
 the radiation therapy–temozolomide group  vs. 4.4% radiation 
therapy–alone group).</li><li>A companion molecular correlation subset 
study to the EORTC-NCIC trial provided strong evidence that epigenetic 
silencing of the <em>MGMT</em> DNA-repair gene by promoter DNA methylation was associated with increased OS in patients with newly diagnosed glioblastoma.[<a href="#cit/section_4.13">13</a>]<div class="pdq-content-list"><ul id="_1273"><li><em>MGMT</em> promoter methylation was an independent favorable prognostic factor (<em>P</em> &lt; .001 by the log-rank test; HR, 0.45; 95% CI, 0.32–0.61). </li><li>The median OS for patients with <em>MGMT</em> methylation was 18.2 months (95% CI, 15.5–22.0), compared with 12.2 months (95% CI, 11.4–13.5) for patients without <em>MGMT</em> methylation.</li></ul></div></li></ol></div></li>
          <li>To test whether protracted (dose-dense) temozolomide 
enhances treatment response in patients with newly diagnosed 
glioblastoma, a multicenter, randomized, phase III trial conducted by 
the RTOG, EORTC, and the  North Central Cancer Therapy Group, <a href="https://www.cancer.gov/clinicaltrials/NCT00304031">RTOG 0525</a>
 (NCT00304031), compared standard adjuvant temozolomide treatment (days 
1–5 of a 28-day cycle) with a dose-dense schedule (days 1–21 of a 28-day
 cycle). All patients were treated with surgery followed by radiation 
therapy and concurrent daily temozolomide. Patients were then randomly 
assigned to receive either standard adjuvant temozolomide or dose-dense 
temozolomide.[<a href="#cit/section_4.14">14</a>][<a href="https://www.cancer.gov/Common/PopUps/popDefinition.aspx?id=335125&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000335125&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence: 1iiA</a>]<div class="pdq-content-list"><ul id="_1274"><li>Among
 833 randomly assigned patients, no statistically significant difference
 between standard and dose-dense temozolomide was observed for median OS
 (16.6 months for standard temozolomide vs. 14.9 months for dose-dense 
temozolomide; HR, 1.03; <em>P</em> = .63) or for median PFS (5.5 vs. 6.7 months; HR, 0.87; <em>P</em> = .06). </li><li>	Protracted temozolomide, which depletes intracellular <em>MGMT</em>, was predicted to have greater efficacy in tumors with <em>MGMT</em>-promoter
 methylation. To test this retrospectively, MGMT status was determined 
in 86% of randomly assigned patients. No difference in efficacy was 
observed in either the <em>MGMT</em>-methylated or <em>MGMT</em>-unmethylated
 subsets. There was no survival advantage for the use of dose-dense 
temozolomide versus standard-dose temozolomide in newly diagnosed 
glioblastoma patients, regardless of <em>MGMT</em> status. However, this study confirmed the strong prognostic effect of <em>MGMT</em>
 methylation because the median OS was 21.2 months (95% CI, 17.9–24.8) 
for patients with methylation versus 14 months  (HR, 1.74; 95% CI, 
12.9–14.7; <em>P</em> &lt; .001) for patients without methylation. </li><li>The efficacy of dose-dense temozolomide for patients who have recurrent glioblastoma, however, is yet  to be determined.</li></ul></div></li>
        </ol>
      </div>
      <p id="_1275" tabindex="-1">Evidence (surgery and chemoradiation with or without bevacizumab):</p>
      <p id="_1276" tabindex="-1">In 2013, final data from two 
multicenter, phase III, randomized, double-blind, placebo-controlled 
trials of bevacizumab in patients who had newly diagnosed glioblastoma 
were reported: <a href="https://www.cancer.gov/clinicaltrials/NCT00884741">RTOG 0825</a> (NCT00884741) and the Roche-sponsored <a href="https://www.cancer.gov/clinicaltrials/NCT00943826">AVAglio</a> (NCT00943826).[<a href="#cit/section_4.17">17</a>,<a href="#cit/section_4.18">18</a>][<a href="https://www.cancer.gov/Common/PopUps/popDefinition.aspx?id=335106&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000335106&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence: 1iA</a>] Bevacizumab did not improve OS in either trial. </p>
      <p id="_1277" tabindex="-1">There was significant crossover in 
both trials. Approximately 40% of RTOG 0825 patients and approximately 
30% of AVAglio patients received bevacizumab at the first sign of 
disease progression.</p>
      <div class="pdq-content-list">
        <ol id="_1278">
          <li>
            <a href="https://www.cancer.gov/clinicaltrials/NCT00884741">RTOG 0825</a>
 (NCT00884741): Patients were randomly assigned to receive standard 
therapy (chemoradiation with temozolomide) or standard therapy plus 
bevacizumab. OS and PFS were coprimary endpoints.[<a href="#cit/section_4.17">17</a>][<a href="https://www.cancer.gov/Common/PopUps/popDefinition.aspx?id=335106&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000335106&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence: 1iA</a>]<div class="pdq-content-list"><ul id="_1279"><li>Bevacizumab
 did not improve OS  (median OS was 16–17 months for each arm); however,
 it increased median PFS (10.7 months in the bevacizumab arm vs. 7.3 
months in the placebo arm; HR, 0.79; <em>P</em> = .007).</li><li>The PFS result in the RTOG 0825 trial did not meet the prespecified significance level (<em>P</em> = .004). </li></ul></div>   </li>
          <li>
            <a href="https://www.cancer.gov/clinicaltrials/NCT00943826">AVAglio</a>
 (NCT00943826): Patients were randomly assigned to receive standard 
therapy (chemoradiation with temozolomide) or standard therapy plus 
bevacizumab. OS and PFS were coprimary endpoints.[<a href="#cit/section_4.18">18</a>][<a href="https://www.cancer.gov/Common/PopUps/popDefinition.aspx?id=335106&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000335106&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence: 1iA</a>]   <div class="pdq-content-list"><ul id="_1280"><li>Bevacizumab
 did not improve OS  (median OS was 16–17 months for each arm); however,
 it increased median PFS (10.6 months in the bevacizumab arm vs. 6.2 
months in the placebo arm; HR,  0.64; <em>P</em> &lt; .0001).</li><li>The
 PFS result  was statistically significant and associated with clinical 
benefit because bevacizumab-treated patients remained functionally 
independent longer (9.0 months in the bevacizumab arm vs. 6.0 months in 
the standard therapy arm) and had a longer time until their Karnofsky 
Performance status deteriorated (HR, 0.65; <em>P</em> &lt; .0001). </li><li>Bevacizumab-treated patients also had delayed initiation of corticosteroids (12.3 months vs. 3.7 months; HR, 0.71; <em>P</em>
 = .002), and more patients were able to discontinue corticosteroids if 
they were already taking them (66% in the bevacizumab arm vs. 47% in the
 standard therapy arm).  </li></ul></div></li>
        </ol>
      </div>
      <p id="_1281" tabindex="-1">The two trials had contradictory 
results in health-related quality of life (HRQoL) and neurocognitive 
outcomes studies. In the mandatory HRQoL studies in the AVAglio trial, 
bevacizumab-treated patients experienced improved HRQoL, but 
bevacizumab-treated patients in the elective RTOG 0825 studies showed 
more decline in patient-reported HRQoL and neurocognitive function. The 
reasons for these discrepancies are unclear.</p>
      <p id="_1282" tabindex="-1">On the basis of  these results, there 
is no definite evidence that the addition of bevacizumab to standard 
therapy is beneficial for all newly diagnosed glioblastoma patients. 
Certain subgroups may benefit from the addition of bevacizumab, but this
 is not yet known.</p>
      <p id="_1283" tabindex="-1">Glioblastoma patients are appropriate candidates for clinical trials
designed to improve local control by adding newer forms of treatment to
standard treatment.
Information about ongoing clinical trials is available from the <a href="https://www.cancer.gov/about-cancer/treatment/clinical-trials" title="https://www.cancer.gov/about-cancer/treatment/clinical-trials">NCI website</a>.</p>
    </section>
  </section>
  <section id="_1137">
    <h3 id="_1137_toc">Oligodendroglial Tumors Treatment</h3>
    <section id="_1138">
      <h4 id="_1138_toc">Oligodendrogliomas treatment</h4>
      <p id="_1284" tabindex="-1">Patients who have oligodendrogliomas 
(WHO grade II) generally have better prognoses than do patients who have
 diffuse astrocytomas. In particular, patients who have 
oligodendrogliomas with 1p/19q codeletion have a much longer survival.[<a href="#cit/section_4.3">3</a>] Most of the oligodendrogliomas eventually progress.</p>
      <p id="_1285" tabindex="-1">Standard treatment options for oligodendrogliomas include the following:</p>
      <div class="pdq-content-list">
        <ol id="_1286">
          <li>Surgery with  or without radiation therapy.</li>
          <li>Surgery with radiation therapy and chemotherapy.</li>
        </ol>
      </div>
      <p id="_1287" tabindex="-1">Controversy exists concerning the 
timing of radiation therapy after surgery. A study (EORTC-22845) of 300 
patients with low-grade gliomas who had surgery and were randomly 
assigned to either radiation therapy or watchful waiting, did not show a
 difference in OS between the two groups.[<a href="#cit/section_4.1">1</a>]<a href="https://www.cancer.gov/Common/PopUps/popDefinition.aspx?id=335125&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000335125&amp;version=HealthProfessional&amp;language=English'); return(false);">[Level of evidence: 1iiA]</a> (Refer to  <a href="https://www.cancer.gov/types/brain/hp/adult-brain-treatment-pdq#link/_736">Low-grade tumors</a> in the <a href="https://www.cancer.gov/types/brain/hp/adult-brain-treatment-pdq#link/_730">Radiation Therapy</a> section of the <a href="https://www.cancer.gov/types/brain/hp/adult-brain-treatment-pdq#link/_69">Treatment Option Overview for Adult Central Nervous System Tumors Treatment</a> section of this summary for more information.)</p>
      <p id="_1355" tabindex="-1">For low-grade (WHO grade II) tumors that are considered <em>high risk</em>,
 radiation therapy followed by six cycles of PCV chemotherapy is a 
recommended option based on the long-term follow-up results of 
RTOG-9802, a randomized trial for high-risk, low-grade gliomas.[<a href="#cit/section_4.3">3</a>][<a href="https://www.cancer.gov/Common/PopUps/popDefinition.aspx?id=335125&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000335125&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence: 1iiA</a>] (Refer to  <a href="https://www.cancer.gov/types/brain/hp/adult-brain-treatment-pdq#link/_1083">Diffuse astrocytomas treatment</a> in the <a href="https://www.cancer.gov/types/brain/hp/adult-brain-treatment-pdq#link/_1067">Astrocytic Tumors Treatment</a> section of the <a href="https://www.cancer.gov/types/brain/hp/adult-brain-treatment-pdq#link/_792">Treatment of Primary Central Nervous System Tumors by Tumor Type</a> section  of this summary for more information.)</p>
      <p id="_1356" tabindex="-1">Notably, the RTOG-9802 study enrolled 
patients with a mixed variety of tumors, including astrocytomas, 
oligodendrogliomas, and mixed oligoastrocytomas; in a retrospective 
subset analysis, only the oligodendroglial tumors appeared to benefit 
from the addition of PCV.[<a href="#cit/section_4.4">4</a>] (Refer to  <a href="https://www.cancer.gov/types/brain/hp/adult-brain-treatment-pdq#link/_1083">Diffuse astrocytomas treatment</a> in the <a href="https://www.cancer.gov/types/brain/hp/adult-brain-treatment-pdq#link/_1067">Astrocytic Tumors Treatment</a> section of the <a href="https://www.cancer.gov/types/brain/hp/adult-brain-treatment-pdq#link/_792">Treatment of Primary Central Nervous System Tumors by Tumor Type</a> section  of this summary for more information.)</p>
      <p id="_1357" tabindex="-1">The discovery of the <em>IDH1</em> and <em>IDH2</em>
 mutations, which are independent prognostic factors for significantly 
improved survival in diffuse gliomas, has greatly helped to identify 
patients who are considered <em>high risk</em>. (Refer to  <a href="https://www.cancer.gov/types/brain/hp/adult-brain-treatment-pdq#link/_1083">Diffuse astrocytomas treatment</a> in the <a href="https://www.cancer.gov/types/brain/hp/adult-brain-treatment-pdq#link/_1067">Astrocytic Tumors Treatment</a> section of the <a href="https://www.cancer.gov/types/brain/hp/adult-brain-treatment-pdq#link/_792">Treatment of Primary Central Nervous System Tumors by Tumor Type</a>
 section  of this summary for more information.) In addition, a high 
proportion of WHO grade II oligodendrogliomas have 1p/19q codeletion, 
which is a powerful prognostic factor for improved survival.[<a href="#cit/section_4.19">19</a>-<a href="#cit/section_4.21">21</a>] Therefore, the presence of the <em>IDH1</em> and <em>IDH2</em>
 mutation and 1p/19q codeletion should be included in the assessment of 
high-risk patients. Molecular correlative data from the RTOG-9802 trial,
 which would be informative about which patients benefited most from the
 addition of PCV, have not yet been reported.</p>
    </section>
    <section id="_1144">
      <h4 id="_1144_toc">Anaplastic oligodendrogliomas treatment</h4>
      <p id="_1288" tabindex="-1">Patients with anaplastic 
oligodendrogliomas (WHO grade III) have a low cure rate with
standard local treatment, but their prognoses are generally better than 
are the prognoses of patients with anaplastic astrocytomas. Prognoses 
are particularly better for patients with 1p/19q codeletion, which 
occurs in a majority of these tumors. Two phase III randomized trials 
restricted to patients with anaplastic gliomas  (<a href="https://www.cancer.gov/clinicaltrials/NCT00626990">NCT00626990</a> and <a href="https://www.cancer.gov/clinicaltrials/NCT00887146">NCT00887146</a>) are currently enrolling patients; however, efficacy data are not yet available. (Refer to <a href="https://www.cancer.gov/types/brain/hp/adult-brain-treatment-pdq#link/_1089">Anaplastic astrocytomas treatment</a> in the   <a href="https://www.cancer.gov/types/brain/hp/adult-brain-treatment-pdq#link/_1067">Astrocytic Tumors Treatment</a> section of the <a href="https://www.cancer.gov/types/brain/hp/adult-brain-treatment-pdq#link/_792">Treatment of Primary Central Nervous System Tumors by Tumor Type</a> section of this summary for more information.) These patients are appropriate candidates for
clinical trials designed to improve local control by adding newer forms of
treatment. </p>
      <p id="_1289" tabindex="-1">Information about ongoing clinical trials is available from the <a href="https://www.cancer.gov/about-cancer/treatment/clinical-trials" title="https://www.cancer.gov/about-cancer/treatment/clinical-trials">NCI website</a>.</p>
      <p id="_1290" tabindex="-1">Standard treatment options for anaplastic oligodendrogliomas include the following:</p>
      <div class="pdq-content-list">
        <ol id="_1291">
          <li>Surgery plus radiation with or without chemotherapy.[<a href="#cit/section_4.22">22</a>]</li>
        </ol>
      </div>
      <p id="_1292" tabindex="-1">Evidence (surgery followed by radiation therapy with or without chemotherapy):</p>
      <div class="pdq-content-list">
        <ol id="_1293">
          <li>Mature results from the EORTC <a href="https://www.cancer.gov/clinicaltrials/NCT00002840">Brain Tumor Group Study 26951</a>
 (NCT00002840), a phase III, randomized study with 11.7 years of  
follow-up, demonstrated increased OS and PFS  in patients with 
anaplastic oligodendroglial tumors with six cycles of adjuvant PCV 
chemotherapy after radiation therapy, compared with radiation therapy 
alone.[<a href="#cit/section_4.23">23</a>][<a href="https://www.cancer.gov/Common/PopUps/popDefinition.aspx?id=335125&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000335125&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence: 1iiA</a>]<div class="pdq-content-list"><ul id="_1294"><li>OS was significantly longer in the radiation therapy and PCV arm (42.3 months vs. 30.6 months; HR, 0.75; 95% CI, 0.60–0.95). </li><li>Patients
 with 1p/19q-codeleted tumors derived more benefit from adjuvant PCV 
chemotherapy than did those with non–1p/19q-deleted tumors.[<a href="#cit/section_4.23">23</a>]</li></ul></div></li>
          <li>In contrast, the RTOG trial (<a href="https://www.cancer.gov/clinicaltrials/NCT00002569">RTOG-9402</a>
 [NCT00002569]) demonstrated no differences in median survival by 
treatment arm between an 8-week, intensive PCV chemotherapy regimen 
followed by immediate involved-field-plus-radiation therapy and 
radiation therapy alone.[<a href="#cit/section_4.24">24</a>]<div class="pdq-content-list"><ul id="_1295"><li>In
 an unplanned subgroup analysis, patients with 1p/19q-codeleted 
anaplastic oligodendrogliomas and mixed anaplastic astrocytomas 
demonstrated a median survival of 14.7 years versus 7.3 years (HR, 0.59;
 95% CI, 0.37–0.95; <em>P</em> = .03).</li><li>For patients with 
non-codeleted tumors, there was no difference in median survival by 
treatment arm (2.6 vs. 2.7 years; HR, 0.85; 95% CI, 0.58–1.23; <em>P</em> = .39).[<a href="#cit/section_4.24">24</a>][<a href="https://www.cancer.gov/Common/PopUps/popDefinition.aspx?id=335125&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000335125&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence: 1iiA</a>]</li></ul></div></li>
          <li>Postoperative radiation therapy alone has been compared 
with postoperative chemotherapy alone in patients with anaplastic 
gliomas (including 144 astrocytomas, 91 oligoastrocytomas, and 39 
oligodendrogliomas) with crossover to the other modality at the time of 
tumor progression. Of the 139 patients randomly assigned to undergo 
radiation therapy, 135 were randomly assigned to receive chemotherapy, 
with a 32-week course of either PCV or single-agent temozolomide (2:1:1 
randomization).[<a href="#cit/section_4.12">12</a>][Levels of evidence: <a href="https://www.cancer.gov/Common/PopUps/popDefinition.aspx?id=335125&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000335125&amp;version=HealthProfessional&amp;language=English'); return(false);">1iiA</a> and <a href="https://www.cancer.gov/Common/PopUps/popDefinition.aspx?id=632558&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000632558&amp;version=HealthProfessional&amp;language=English'); return(false);">1iiD</a>].<div class="pdq-content-list"><ul id="_1296"><li>TTF or OS did not differ across the treatment arms and were  not affected by the order of the modalities.</li></ul></div> </li>
        </ol>
      </div>
      <p id="_1297" tabindex="-1">On the basis of these data, <a href="https://www.cancer.gov/clinicaltrials/NCT00887146">CODEL</a>
 (NCT00887146), a study  that randomly assigned patients to receive 
radiation therapy alone (control arm), radiation therapy with 
temozolomide, and temozolomide alone (exploratory arm), was halted 
because radiation therapy alone was no longer considered adequate 
treatment in patients with anaplastic oligodendroglioma with 
1p/19q-codeletions.[<a href="#cit/section_4.25">25</a>] Temozolomide and
 PCV chemotherapy in anaplastic oligodendroglioma have not been 
compared, although in the setting of grade 3 anaplastic gliomas, no 
survival difference was seen between PCV chemotherapy and temozolomide.[<a href="#cit/section_4.12">12</a>,<a href="#cit/section_4.26">26</a>]</p>
      <p id="_1298" tabindex="-1">The combination of radiation and chemotherapy is not known to be superior in outcome to sequential modality therapy.</p>
      <p id="_1358" tabindex="-1">A high proportion of anaplastic oligodendrogliomas have the <em>IDH1</em> and<em>IDH2</em> mutation and 1p/19q codeletion, both powerful prognostic factors for improved survival. (Refer to <a href="https://www.cancer.gov/types/brain/hp/adult-brain-treatment-pdq#link/_1083">Diffuse astrocytomas treatment</a> in the <a href="https://www.cancer.gov/types/brain/hp/adult-brain-treatment-pdq#link/_1067">Astrocytic Tumors Treatment</a> section of the <a href="https://www.cancer.gov/types/brain/hp/adult-brain-treatment-pdq#link/_792">Treatment of Primary Central Nervous System Tumors by Tumor Type</a> of this summary for more information.)[<a href="#cit/section_4.23">23</a>,<a href="#cit/section_4.24">24</a>]
 In addition, PCV chemotherapy has been shown to be predictive in a 
retrospective analysis of the phase III trials described earlier. 
Therefore, assessment of these molecular markers may aid management 
decisions for anaplastic oligodendrogliomas.</p>
    </section>
  </section>
  <section id="_831">
    <h3 id="_831_toc">Mixed Gliomas Treatment</h3>
    <p id="_1299" tabindex="-1">Patients with mixed glial tumors, which 
include oligoastrocytoma (WHO grade II) and anaplastic oligoastrocytoma 
(WHO grade III), have highly variable prognoses based upon their status 
of the <em>IDH1</em> and <em>IDH2</em> genes and 1p/19q chromosomes.[<a href="#cit/section_4.27">27</a>-<a href="#cit/section_4.29">29</a>]
 Therefore, the optimal treatment for these tumors as a group is 
uncertain. Often, they are treated similarly to astrocytic tumors 
because a subset of tumors may have outcomes similar to WHO grade III 
astrocytic or WHO grade IV glioblastoma tumors. Testing for these known,
 strong, prognostic molecular markers should be performed, which may 
help to guide the assessment of risk and subsequent management.</p>
    <p id="_1300" tabindex="-1">Standard treatment options for mixed gliomas include the following:</p>
    <div class="pdq-content-list">
      <ol id="_1301">
        <li>Surgery plus radiation therapy with or without chemotherapy.</li>
      </ol>
    </div>
    <p id="_1302" tabindex="-1">(Refer to the <a href="https://www.cancer.gov/types/brain/hp/adult-brain-treatment-pdq#link/_1067">Astrocytic Tumors</a> section in the <a href="https://www.cancer.gov/types/brain/hp/adult-brain-treatment-pdq#link/_792">Treatment of Primary Central Nervous System Tumors by Tumor Type</a> section of this summary for more information about astrocytic tumors.)</p>
  </section>
  <section id="_835">
    <h3 id="_835_toc">Ependymal Tumors Treatment</h3>
    <p id="_1303" tabindex="-1">Ependymal tumors (WHO grade I) and 
ependymomas (WHO grade II)—i.e., subependymomas and myxopapillary 
ependymomas—are often curable.
</p>
    <p id="_1304" tabindex="-1">Standard treatment options for grades I and II ependymal tumors include the following:</p>
    <div class="pdq-content-list">
      <ol id="_1305">
        <li>Surgery alone if the tumor is totally resectable.</li>
        <li>Surgery followed by radiation therapy to known or suspected residual
tumor.</li>
      </ol>
    </div>
    <p id="_1306" tabindex="-1">Patients with anaplastic ependymomas (WHO grade III) have variable prognoses that depend on the location and
extent of disease.  Frequently, but not invariably, patients with anaplastic ependymomas have
worse prognoses than do those patients with lower-grade ependymal tumors.</p>
    <p id="_1307" tabindex="-1">Standard treatment options for anaplastic ependymomas include the following:</p>
    <div class="pdq-content-list">
      <ol id="_1308">
        <li>Surgery plus radiation therapy.[<a href="#cit/section_4.30">30</a>]</li>
      </ol>
    </div>
  </section>
  <section id="_844">
    <h3 id="_844_toc">Embryonal Cell Tumors (Medulloblastomas) Treatment</h3>
    <p id="_1309" tabindex="-1">Medulloblastoma occurs primarily in children, but may also occur  in adults.[<a href="#cit/section_4.31">31</a>]  (Refer to the PDQ summary on <a href="https://www.cancer.gov/types/brain/hp/child-cns-embryonal-treatment-pdq">Childhood Central Nervous System Embryonal Tumors Treatment</a> for more information.)</p>
    <p id="_1310" tabindex="-1">Standard treatment options for medulloblastomas include the following:</p>
    <div class="pdq-content-list">
      <ol id="_1311">
        <li>Surgery plus craniospinal radiation therapy for good-risk patients.[<a href="#cit/section_4.32">32</a>]</li>
      </ol>
    </div>
    <section id="_1312">
      <h4 id="_1312_toc">Treatment options under clinical evaluation for medulloblastomas</h4>
      <p id="_1313" tabindex="-1">Treatment options under clinical evaluation include the following:</p>
      <div class="pdq-content-list">
        <ol id="_1314">
          <li>Surgery plus craniospinal radiation therapy and various chemotherapy regimens are being evaluated for poor-risk patients.[<a href="#cit/section_4.32">32</a>]</li>
        </ol>
      </div>
    </section>
  </section>
  <section id="_851">
    <h3 id="_851_toc">Pineal Parenchymal Tumors Treatment</h3>
    <p id="_1315" tabindex="-1">Pineocytomas (WHO grade II), 
pineoblastomas (WHO grade IV), and pineal parenchymal tumors of 
intermediate differentiation are diverse tumors that require special 
consideration. Pineocytomas are slow-growing tumors  and prognosis 
varies. </p>
    <p id="_1316" tabindex="-1">Pineoblastomas grow more rapidly  and 
patients with these tumors have worse prognoses.  Pineal parenchymal 
tumors of intermediate differentiation have unpredictable growth and 
clinical behavior.</p>
    <p id="_1317" tabindex="-1">Standard treatment options for pineal parenchymal tumors include the following:</p>
    <div class="pdq-content-list">
      <ol id="_1318">
        <li>
          <a href="https://www.cancer.gov/types/brain/hp/adult-brain-treatment-pdq#link/_851">Surgery plus radiation therapy for pineocytoma.</a>
        </li>
        <li>
          <a href="https://www.cancer.gov/types/brain/hp/adult-brain-treatment-pdq#link/_851">Surgery plus radiation therapy and chemotherapy for pineoblastoma.</a>
</li>
      </ol>
    </div>
  </section>
  <section id="_855">
    <h3 id="_855_toc">Meningeal Tumors Treatment</h3>
    <p id="_1319" tabindex="-1">WHO grade I meningiomas are usually 
curable when they are resectable. With the increasing use of sensitive 
neuroimaging tools, there has been more detection of asymptomatic 
low-grade meningiomas. Most appear to show minimal growth and can often 
be safely observed while therapy is deferred until growth or the 
development of symptoms.[<a href="#cit/section_4.33">33</a>,<a href="#cit/section_4.34">34</a>]</p>
    <p id="_1320" tabindex="-1">Standard treatment options for meningeal tumors include the following:</p>
    <div class="pdq-content-list">
      <ol id="_1321">
        <li>Active surveillance with deferred treatment, especially for incidentally discovered asymptomatic tumors.[<a href="#cit/section_4.33">33</a>,<a href="#cit/section_4.34">34</a>].</li>
        <li>Surgery.</li>
        <li>Stereotactic radiosurgery for tumors smaller than 3 cm.</li>
        <li>Surgery plus radiation therapy in selected cases, such as for patients with
known or suspected residual disease or with recurrence after previous
surgery.</li>
        <li>Fractionated radiation therapy for patients with unresectable tumors.[<a href="#cit/section_4.35">35</a>]</li>
      </ol>
    </div>
    <p id="_1322" tabindex="-1">The prognoses for patients with  WHO 
grade II meningiomas (atypical, clear cell, and chordoid),  WHO grade 
III meningiomas (anaplastic/malignant, rhabdoid, and papillary), and 
hemangiopericytomas  are worse than the prognoses for patients with 
low-grade meningiomas because complete resections are less commonly 
feasible, and
the proliferative capacity is greater.</p>
    <p id="_1323" tabindex="-1">Standard treatment options for grades II and III meningiomas and hemangiopericytomas include the following:</p>
    <div class="pdq-content-list">
      <ol id="_1324">
        <li>Surgery plus radiation therapy.</li>
      </ol>
    </div>
  </section>
  <section id="_682">
    <h3 id="_682_toc">Germ Cell Tumors Treatment</h3>
    <p id="_683" tabindex="-1">The prognoses and treatment of patients 
with germ cell tumors—which include germinomas, embryonal carcinomas, 
choriocarcinomas, and teratomas—depend on tumor histology,
tumor location, presence and amount of biological markers, and surgical
resectability.</p>
  </section>
  <section id="_684">
    <h3 id="_684_toc">Treatment of Tumors of the Sellar Region</h3>
    <p id="_1325" tabindex="-1">Craniopharyngiomas (WHO grade I) are often curable. </p>
    <p id="_1326" tabindex="-1">Standard treatment options for craniopharyngiomas include the following:</p>
    <div class="pdq-content-list">
      <ol id="_1327">
        <li>Surgery alone if the tumor is totally resectable.</li>
        <li>Debulking surgery plus radiation therapy if the tumor is unresectable.</li>
      </ol>
    </div>
  </section>
  <section id="_1108">
    <h3 id="_1108_toc">Treatment Options Under Clinical Evaluation for Primary CNS Tumors</h3>
    <p id="_1109" tabindex="-1">Patients who have CNS tumors that are 
either infrequently curable or unresectable should be considered 
candidates for clinical trials. Information about ongoing clinical 
trials is available from the <a href="https://www.cancer.gov/about-cancer/treatment/clinical-trials" title="https://www.cancer.gov/about-cancer/treatment/clinical-trials">NCI website</a>.</p>
    <p id="_1110" tabindex="-1">Heavy-particle radiation, such as 
proton-beam therapy, carries the theoretical advantage of delivering 
high doses of ionizing radiation to the tumor bed while sparing 
surrounding brain tissue.  The data are preliminary for this 
investigational technique, and are not widely available.</p>
    <p id="_1111" tabindex="-1">Novel biologic therapies under clinical evaluation for patients with CNS tumors include the following:[<a href="#cit/section_4.36">36</a>]</p>
    <div class="pdq-content-list">
      <ul id="_1112">
        <li>Dendritic cell vaccination.[<a href="#cit/section_4.37">37</a>]</li>
        <li>Tyrosine kinase receptor inhibitors.[<a href="#cit/section_4.38">38</a>]</li>
        <li>Farnesyl transferase inhibitors.</li>
        <li>Viral-based gene therapy.[<a href="#cit/section_4.39">39</a>,<a href="#cit/section_4.40">40</a>]</li>
        <li>Oncolytic viruses.</li>
        <li>Epidermal growth factor-receptor inhibitors.</li>
        <li>Vascular endothelial growth factor inhibitors.[<a href="#cit/section_4.36">36</a>]</li>
        <li>Other antiangiogenesis agents.</li>
      </ul>
    </div>
  </section>
  <section id="_TrialSearch_792_sid_4">
    <h3 id="_TrialSearch_792_sid_4_toc">Current Clinical Trials</h3>
    <p id="_TrialSearch_792_22" tabindex="-1">Use our <a href="https://www.cancer.gov/about-cancer/treatment/clinical-trials/advanced-search" title="https://www.cancer.gov/about-cancer/treatment/clinical-trials/advanced-search">advanced clinical trial search</a>
 to find NCI-supported cancer clinical trials that are now enrolling 
patients. The search can be narrowed by location of the trial, type of 
treatment, name of the drug, and other criteria. <a href="https://www.cancer.gov/about-cancer/treatment/clinical-trials/" title="https://www.cancer.gov/about-cancer/treatment/clinical-trials/">General information</a> about clinical trials is also available.</p>
  </section>
  <h6 do-not-show="toc">References</h6>
  <ol>
    <li id="section_4.1">van den Bent MJ, Afra D, de Witte O, et al.: 
Long-term efficacy of early versus delayed radiotherapy for low-grade 
astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised 
trial. Lancet 366 (9490): 985-90, 2005.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16168780&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16168780&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_4.2">Kaye AH, Walker DG: Low grade astrocytomas: controversies in management. J Clin Neurosci 7 (6): 475-83, 2000.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11029226&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11029226&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_4.3">Buckner JC, Pugh SL, Shaw EG, et al.: Phase III
 study of radiation therapy with or without procarbazine, CCNU, and 
vincristine (PCV) in low-grade glioma: RTOG 9802 with Alliance, ECOG, 
and SWOG. [Abstract] J Clin Oncol  32 (Suppl 5): A-2000, 2014.</li>
    <li id="section_4.4">Buckner JC, Shaw E, Pugh S, et al.: R9802: 
Phase III study of radiation therapy with or without procarbazine, CCNU,
 and vincristine (PCV) in low-grade glioma: Results by histologic type. 
[Abstract] Neuro-Oncology  16 (Suppl 5): A-AT-13, v11, 2014.</li>
    <li id="section_4.5">Parsons DW, Jones S, Zhang X, et al.: An 
integrated genomic analysis of human glioblastoma multiforme. Science 
321 (5897): 1807-12, 2008.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18772396&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18772396&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_4.6">Yan H, Parsons DW, Jin G, et al.: IDH1 and IDH2 mutations in gliomas. N Engl J Med 360 (8): 765-73, 2009.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19228619&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19228619&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_4.7">Dubbink HJ, Taal W, van Marion R, et al.: IDH1 
mutations in low-grade astrocytomas predict survival but not response to
 temozolomide. Neurology 73 (21): 1792-5, 2009.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19933982&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19933982&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_4.8">Sanson M, Marie Y, Paris S, et al.: Isocitrate 
dehydrogenase 1 codon 132 mutation is an important prognostic biomarker 
in gliomas. J Clin Oncol 27 (25): 4150-4, 2009.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19636000&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19636000&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_4.9">Hartmann C, Hentschel B, Wick W, et al.: 
Patients with IDH1 wild type anaplastic astrocytomas exhibit worse 
prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status 
accounts for the unfavorable prognostic effect of higher age: 
implications for classification of gliomas. Acta Neuropathol 120 (6): 
707-18, 2010.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21088844&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21088844&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_4.10">Hartmann C, Meyer J, Balss J, et al.: Type and
 frequency of IDH1 and IDH2 mutations are related to astrocytic and 
oligodendroglial differentiation and age: a study of 1,010 diffuse 
gliomas. Acta Neuropathol 118 (4): 469-74, 2009.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19554337&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19554337&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_4.11">Watanabe T, Nobusawa S, Kleihues P, et al.: 
IDH1 mutations are early events in the development of astrocytomas and 
oligodendrogliomas. Am J Pathol 174 (4): 1149-53, 2009.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19246647&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19246647&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_4.12">Wick W, Hartmann C, Engel C, et al.: NOA-04 
randomized phase III trial of sequential radiochemotherapy of anaplastic
 glioma with procarbazine, lomustine, and vincristine or temozolomide. J
 Clin Oncol 27 (35): 5874-80, 2009.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19901110&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19901110&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_4.13">Hegi ME, Diserens AC, Gorlia T, et al.: MGMT 
gene silencing and benefit from temozolomide in glioblastoma. N Engl J 
Med 352 (10): 997-1003, 2005.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15758010&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15758010&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_4.14">Gilbert MR, Wang M, Aldape KD, et al.: 
Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized 
phase III clinical trial. J Clin Oncol 31 (32): 4085-91, 2013.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24101040&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24101040&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_4.15">Stupp R, Mason WP, van den Bent MJ, et al.: 
Radiotherapy plus concomitant and adjuvant temozolomide for 
glioblastoma. N Engl J Med 352 (10): 987-96, 2005.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15758009&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15758009&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_4.16">Stupp R, Hegi ME, Mason WP, et al.: Effects of
 radiotherapy with concomitant and adjuvant temozolomide versus 
radiotherapy alone on survival in glioblastoma in a randomised phase III
 study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10 (5): 
459-66, 2009.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19269895&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19269895&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_4.17">Gilbert MR, Dignam JJ, Armstrong TS, et al.: A
 randomized trial of bevacizumab for newly diagnosed glioblastoma. N 
Engl J Med 370 (8): 699-708, 2014.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24552317&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24552317&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_4.18">Chinot OL, Wick W, Mason W, et al.: 
Bevacizumab plus radiotherapy-temozolomide for newly diagnosed 
glioblastoma. N Engl J Med 370 (8): 709-22, 2014.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24552318&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24552318&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_4.19">Fallon KB, Palmer CA, Roth KA, et al.: 
Prognostic value of 1p, 19q, 9p, 10q, and EGFR-FISH analyses in 
recurrent oligodendrogliomas. J Neuropathol Exp Neurol 63 (4): 314-22, 
2004.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15099021&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15099021&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_4.20">Smith JS, Perry A, Borell TJ, et al.: 
Alterations of chromosome arms 1p and 19q as predictors of survival in 
oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin 
Oncol 18 (3): 636-45, 2000.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10653879&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10653879&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_4.21">Okamoto Y, Di Patre PL, Burkhard C, et al.: 
Population-based study on incidence, survival rates, and genetic 
alterations of low-grade diffuse astrocytomas and oligodendrogliomas. 
Acta Neuropathol 108 (1): 49-56, 2004.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15118874&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15118874&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_4.22">van den Bent MJ, Chinot O, Boogerd W, et al.: 
Second-line chemotherapy with temozolomide in recurrent 
oligodendroglioma after PCV (procarbazine, lomustine and vincristine) 
chemotherapy: EORTC Brain Tumor Group phase II study 26972. Ann Oncol 14
 (4): 599-602, 2003.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12649108&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12649108&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_4.23">van den Bent MJ, Brandes AA, Taphoorn MJ, et 
al.: Adjuvant procarbazine, lomustine, and vincristine chemotherapy in 
newly diagnosed anaplastic oligodendroglioma: long-term follow-up of 
EORTC brain tumor group study 26951. J Clin Oncol 31 (3): 344-50, 
2013.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23071237&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23071237&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_4.24">Cairncross G, Wang M, Shaw E, et al.: Phase 
III trial of chemoradiotherapy for anaplastic oligodendroglioma: 
long-term results of RTOG 9402. J Clin Oncol 31 (3): 337-43, 2013.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23071247&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23071247&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_4.25">Gilbert MR: Minding the Ps and Qs: 
perseverance and quality studies lead to major advances in patients with
 anaplastic oligodendroglioma. J Clin Oncol 31 (3): 299-300, 2013.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23071223&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23071223&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_4.26">Brada M, Stenning S, Gabe R, et al.: 
Temozolomide versus procarbazine, lomustine, and vincristine in 
recurrent high-grade glioma. J Clin Oncol 28 (30): 4601-8, 2010.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20855843&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20855843&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_4.27">Jiao Y, Killela PJ, Reitman ZJ, et al.: 
Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification 
of malignant gliomas. Oncotarget 3 (7): 709-22, 2012.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22869205&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22869205&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_4.28">Killela PJ, Reitman ZJ, Jiao Y, et al.: TERT 
promoter mutations occur frequently in gliomas and a subset of tumors 
derived from cells with low rates of self-renewal. Proc Natl Acad Sci U S
 A 110 (15): 6021-6, 2013.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23530248&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23530248&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_4.29">Killela PJ, Pirozzi CJ, Healy P, et al.: 
Mutations in IDH1, IDH2, and in the TERT promoter define clinically 
distinct subgroups of adult malignant gliomas. Oncotarget 5 (6): 
1515-25, 2014.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24722048&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24722048&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_4.30">Oya N, Shibamoto Y, Nagata Y, et al.: 
Postoperative radiotherapy for intracranial ependymoma: analysis of 
prognostic factors and patterns of failure. J Neurooncol 56 (1): 87-94, 
2002.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11949831&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11949831&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_4.31">Brandes AA, Ermani M, Amista P, et al.: The 
treatment of adults with medulloblastoma: a prospective study. Int J 
Radiat Oncol Biol Phys 57 (3): 755-61, 2003.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14529781&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14529781&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_4.32">Brandes AA, Franceschi E, Tosoni A, et al.: 
Long-term results of a prospective study on the treatment of 
medulloblastoma in adults. Cancer 110 (9): 2035-41, 2007.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17823910&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17823910&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_4.33">Nakamura M, Roser F, Michel J, et al.: The 
natural history of incidental meningiomas. Neurosurgery 53 (1): 62-70; 
discussion 70-1, 2003.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12823874&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12823874&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_4.34">Yano S, Kuratsu J; Kumamoto Brain Tumor 
Research Group: Indications for surgery in patients with asymptomatic 
meningiomas based on an extensive experience. J Neurosurg 105 (4): 
538-43, 2006.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17044555&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17044555&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_4.35">Debus J, Wuendrich M, Pirzkall A, et al.: High
 efficacy of fractionated stereotactic radiotherapy of large 
base-of-skull meningiomas: long-term results. J Clin Oncol 19 (15): 
3547-53, 2001.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11481362&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11481362&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_4.36">Fine HA: Promising new therapies for malignant gliomas. Cancer J 13 (6): 349-54, 2007 Nov-Dec.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18032970&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18032970&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_4.37">Fecci PE, Mitchell DA, Archer GE, et al.: The 
history, evolution, and clinical use of dendritic cell-based 
immunization strategies in the therapy of brain tumors. J Neurooncol 64 
(1-2): 161-76, 2003 Aug-Sep.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12952297&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12952297&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_4.38">Newton HB: Molecular neuro-oncology and 
development of targeted therapeutic strategies for brain tumors. Part 1:
 Growth factor and Ras signaling pathways. Expert Rev Anticancer Ther 3 
(5): 595-614, 2003.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14599084&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14599084&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_4.39">Kew Y, Levin VA: Advances in gene therapy and immunotherapy for brain tumors. Curr Opin Neurol 16 (6): 665-70, 2003.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14624074&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14624074&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_4.40">Chiocca EA, Aghi M, Fulci G: Viral therapy for glioblastoma. Cancer J 9 (3): 167-79, 2003 May-Jun.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12952302&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12952302&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
  </ol>
</div>
    			</section><section id="_1113">
    				<h2>Treatment of Primary Tumors of the Spinal Axis</h2>
    				 <div id="_section_1113" class="pdq-sections">
  <p id="_1114" tabindex="-1">Surgery and radiation therapy are the 
primary modalities used to treat tumors of the spinal axis; therapeutic 
options vary according to the histology of the tumor.[<a href="#cit/section_5.1">1</a>]
 The experience with chemotherapy for primary spinal cord tumors is  
limited; no reports of controlled clinical trials are available  for 
these types of tumors.[<a href="#cit/section_5.1">1</a>,<a href="#cit/section_5.2">2</a>]
 Chemotherapy is indicated for most patients with leptomeningeal 
involvement from a primary or metastatic tumor and positive 
cerebrospinal fluid cytology.[<a href="#cit/section_5.1">1</a>] Most patients require treatment with corticosteroids, particularly if they are receiving radiation therapy.</p>
  <p id="_1115" tabindex="-1">Patients who have spinal axis tumors that 
are either infrequently curable or unresectable should be considered 
candidates for clinical trials. Information about ongoing clinical 
trials is available from the <a href="https://www.cancer.gov/about-cancer/treatment/clinical-trials" title="https://www.cancer.gov/about-cancer/treatment/clinical-trials">NCI website</a>.</p>
  <h6 do-not-show="toc">References</h6>
  <ol>
    <li id="section_5.1">Cloughesy T, Selch MT, Liau L: Brain. In: 
Haskell CM: Cancer Treatment. 5th ed. Philadelphia, Pa: WB Saunders Co, 
2001, pp 1106-42.</li>
    <li id="section_5.2">Mehta M, Vogelbaum  MA, Chang S, et al.: 
Neoplasms of the central nervous system. In: DeVita VT Jr, Lawrence TS, 
Rosenberg SA: Cancer: Principles and Practice of Oncology. 9th ed. 
Philadelphia, Pa: Lippincott Williams &amp; Wilkins, 2011, pp 1700-49.</li>
  </ol>
</div>
    			</section><section id="_1166">
    				<h2>Metastatic Brain Tumors</h2>
    				 <div id="_section_1166" class="pdq-sections"><nav class="onthispage in-this-section" role="navigation"><h6>In This Section</h6><ul><li><a href="#_1167_toc">General Information About Metastatic Brain Tumors</a></li><li><a href="#_1173_toc">Clinical Features</a></li><li><a href="#_1180_toc">Diagnostic Evaluation</a><ul><li><a href="#_1184_toc">Imaging tests</a></li><li><a href="#_1186_toc">Biopsy</a></li></ul></li><li><a href="#_1188_toc">Treatment of Metastatic Brain Tumors</a><ul><li><a href="#_1193_toc">Treatment for patients with one to four metastases</a></li></ul></li><li><a href="#_1215_toc">Leptomeningeal carcinomatosis (LC)</a></li></ul></nav>
  <section id="_1167">
    <h3 id="_1167_toc">General Information About Metastatic Brain Tumors</h3>
    <p id="_1168" tabindex="-1">Brain metastases outnumber primary 
neoplasms by at least 10 to 1, and they occur in 20% to 40% of cancer 
patients, with  subsequent median survival generally less than 6 
months.[<a href="#cit/section_6.1">1</a>] The exact incidence is unknown
 because no national cancer registry documents brain metastases, but it 
has been estimated that  98,000 to 170,000 new cases are diagnosed in 
the United States each year.[<a href="#cit/section_6.2">2</a>,<a href="#cit/section_6.3">3</a>]
 This number may be increasing because of  the capacity of magnetic 
resonance imaging (MRI) to detect small metastases and because of 
prolonged survival resulting from improved systemic therapy.[<a href="#cit/section_6.1">1</a>,<a href="#cit/section_6.2">2</a>]</p>
    <p id="_1169" tabindex="-1">The most common primary tumors with brain metastases and the percentage of patients effected are as follows:[<a href="#cit/section_6.1">1</a>,<a href="#cit/section_6.2">2</a>]</p>
    <div class="pdq-content-list">
      <ul id="_1170">
        <li>Lung (18%-64%).</li>
        <li>Breast (2%–21%).</li>
        <li>Cancer of unknown primary (1%–18%).</li>
        <li>Melanoma (4%-16%).</li>
        <li>Colorectal (2%-12%).</li>
        <li>Kidney (1%-8%).</li>
      </ul>
    </div>
    <p id="_1171" tabindex="-1">Eighty percent of brain metastases occur
 in the cerebral hemispheres, 15% occur in the cerebellum, and 5% occur 
in the brain stem.[<a href="#cit/section_6.2">2</a>] Metastases to the brain are multiple in more than 70% of cases, but solitary metastases also occur.[<a href="#cit/section_6.1">1</a>]</p>
    <p id="_1172" tabindex="-1">Brain involvement can occur with cancers
 of the nasopharyngeal region by direct extension along the cranial 
nerves or through the foramina at the base of the skull. Dural 
metastases may constitute as much as  9% of total brain metastases.</p>
  </section>
  <section id="_1173">
    <h3 id="_1173_toc">Clinical Features</h3>
    <p id="_1174" tabindex="-1">The diagnosis of brain metastases in cancer patients is based on the following:</p>
    <div class="pdq-content-list">
      <ul id="_1175">
        <li>Patient history.</li>
        <li>Neurological examination.</li>
        <li>Diagnostic procedures, including a contrast MRI of the brain.</li>
      </ul>
    </div>
    <p id="_1176" tabindex="-1">Patients may describe any of the following:</p>
    <div class="pdq-content-list">
      <ul id="_1177">
        <li>Headaches.</li>
        <li>Weakness.</li>
        <li>Seizures.</li>
        <li>Sensory defects.</li>
        <li>Gait problems.</li>
      </ul>
    </div>
    <p id="_1178" tabindex="-1">Often, family members or friends may notice the following:</p>
    <div class="pdq-content-list">
      <ul id="_1179">
        <li> Lethargy.</li>
        <li>Emotional lability.</li>
        <li>Personality change.</li>
      </ul>
    </div>
  </section>
  <section id="_1180">
    <h3 id="_1180_toc">Diagnostic Evaluation</h3>
    <p id="_1181" tabindex="-1">A physical examination may show 
objective neurological findings or only minor cognitive changes.  The 
presence of multiple lesions and a high predilection of primary tumor 
metastasis may be sufficient to make the diagnosis of brain metastasis. 
 </p>
    <p id="_1182" tabindex="-1">A lesion in the brain should not be assumed to be a metastasis just because a
patient has had a previous cancer; such an assumption could result in
overlooking appropriate treatment of a curable tumor.  </p>
    <section id="_1184">
      <h4 id="_1184_toc">Imaging tests</h4>
      <p id="_1185" tabindex="-1">Computed tomography scans with 
contrast or MRIs with gadolinium are quite sensitive in diagnosing the 
presence of metastases.   Positron emission tomography scanning and 
spectroscopic evaluation are new strategies to diagnose cerebral 
metastases and to differentiate the metastases from other intracranial 
lesions.[<a href="#cit/section_6.4">4</a>]</p>
    </section>
    <section id="_1186">
      <h4 id="_1186_toc">Biopsy</h4>
      <p id="_1187" tabindex="-1">In the case of a solitary lesion or a 
questionable relationship to the primary tumor, a brain biopsy (via 
resection or stereotactic biopsy) may be necessary.     </p>
    </section>
  </section>
  <section id="_1188">
    <h3 id="_1188_toc">Treatment of Metastatic Brain Tumors</h3>
    <p id="_1189" tabindex="-1">The optimal therapy for patients with brain metastases continues to evolve.[<a href="#cit/section_6.1">1</a>,<a href="#cit/section_6.2">2</a>,<a href="#cit/section_6.5">5</a>] The following treatments have been used in the management of metastatic brain tumors: </p>
    <div class="pdq-content-list">
      <ul id="_1190">
        <li>Radiation therapy.</li>
        <li>Radiosurgery.</li>
        <li>Surgical resection.</li>
        <li>Corticosteroids.</li>
        <li>Anticonvulsants.</li>
      </ul>
    </div>
    <p id="_1191" tabindex="-1">Because most cases of brain metastases 
involve multiple metastases, a mainstay of therapy has historically been
 whole-brain radiation therapy (WBRT); however, stereotactic 
radiosurgery  has come into increasingly common use. The role of 
radiosurgery continues to be defined.  Stereotactic radiosurgery in 
combination with WBRT has been assessed.</p>
    <p id="_1328" tabindex="-1">Surgery is indicated to obtain tissue 
from a metastasis with an unknown primary tumor or to decompress a 
symptomatic dominant lesion that is causing significant mass effect.</p>
    <p id="_1192" tabindex="-1">Chemotherapy is usually not the primary 
therapy for most patients; however, it may have a role in the treatment 
of patients with brain metastases from chemosensitive tumors and can 
even be curative when combined with radiation for metastatic testicular 
germ cell tumors.[<a href="#cit/section_6.1">1</a>,<a href="#cit/section_6.6">6</a>]  Intrathecal chemotherapy is also used for meningeal spread of metastatic tumors.</p>
    <section id="_1193">
      <h4 id="_1193_toc">Treatment for patients with one to four metastases</h4>
      <section id="_1194">
        <h5 id="_1194_toc">Standard treatment options for patients with one to four metastases</h5>
        <p id="_1230" tabindex="-1">About 10% to 15% of patients with 
cancer will have a single brain metastasis.  Radiation therapy is the 
mainstay of palliation for these patients. The extent of extracranial 
disease can influence treatment of the brain lesions. In the presence of
 extensive active systemic disease, surgery provides little benefit for 
overall survival (OS). In patients with stable minimal extracranial 
disease, combined modality treatment may be considered, using surgical 
resection followed by radiation therapy.  However, the published 
literature does not provide clear guidance.</p>
        <p id="_1195" tabindex="-1">Standard treatment options for patients with one to four metastases include the following:</p>
        <div class="pdq-content-list">
          <ol id="_1196">
            <li>WBRT with or without surgical resection.</li>
            <li>WBRT with or without stereotactic radiosurgery.</li>
            <li>Focal therapy alone (surgical resection or stereotactic radiosurgery).</li>
          </ol>
        </div>
        <p id="_1202" tabindex="-1">Evidence (treatment for one to four metastases):</p>
        <div class="pdq-content-list">
          <ol id="_1200">
            <li>Three randomized trials examined resection of solitary 
brain metastases followed by WBRT versus WBRT alone, totaling 195 
randomly assigned patients.[<a href="#cit/section_6.7">7</a>-<a href="#cit/section_6.9">9</a>]
 The process that necessarily goes into selecting appropriate patients 
for surgical resection may account for the small numbers in each trial. 
 In the first trial,[<a href="#cit/section_6.7">7</a>][<a href="https://www.cancer.gov/Common/PopUps/popDefinition.aspx?id=632558&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000632558&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence: 1iiD</a>]  performed at a single center, all patients were selected and operated upon by one surgeon.   <div class="pdq-content-list"><ol id="_1329" class="lower-alpha"><li>The first two trials showed an improvement in survival in the surgery group,[<a href="#cit/section_6.7">7</a>,<a href="#cit/section_6.8">8</a>] but the third trial showed a trend in favor of the WBRT–only group.[<a href="#cit/section_6.9">9</a>]</li><li>The three trials were combined in a trial-level meta-analysis.[<a href="#cit/section_6.10">10</a>] The combined analysis showed the following:  <div class="pdq-content-list"><ul id="_1330"><li>
 The combined analysis did not show a statistically significant 
difference in OS (hazard ratio [HR] = 0.72; 95% confidence interval 
[CI], 0.34–1.53; <em>P</em> = .4); or in death from neurologic causes (relative risk<sub>death</sub> = 0.68; 95% CI, 0.43–1.09; <em>P</em> = .11).[<a href="#cit/section_6.10">10</a>]</li><li>One of the trials reported that combined therapy increased the duration of functionally independent survival.[<a href="#cit/section_6.7">7</a>][<a href="https://www.cancer.gov/Common/PopUps/popDefinition.aspx?id=632558&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000632558&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence: 1iiD</a>] </li><li>None of the trials assessed or reported quality of life.  </li></ul></div></li></ol></div></li>
            <li>The need for WBRT after resection of solitary brain metastases has been studied.[<a href="#cit/section_6.11">11</a>] Patients were randomly assigned to either undergo postoperative WBRT or receive no further treatment after resection.<div class="pdq-content-list"><ul id="_1204"><li>Patients
 in the WBRT group were less likely to have tumor progression in the 
brain and were significantly less likely to die of neurological causes.</li><li>OS was the same in each group, and there was no difference in duration of functional independence.</li></ul></div></li>
            <li>One additional randomized study of observation versus 
WBRT after either surgery or stereotactic radiosurgery for solitary 
brain metastases was closed  after 19 patients had been entered because 
of slow accrual; therefore, little can be deduced from the trial.[<a href="#cit/section_6.12">12</a>]</li>
            <li>A Radiation Therapy Oncology Group (RTOG) study (<a href="https://www.cancer.gov/clinicaltrials/NCT00002708">RTOG-9508</a>)
 randomly assigned 333 patients with one to three metastases with a 
maximum diameter of 4 cm to WBRT (37.5 Gy over 3 weeks) with or without a
 stereotactic boost.[<a href="#cit/section_6.13">13</a>] Patients with 
active systemic disease requiring therapy were excluded.  The primary 
endpoint was OS with predefined hypotheses in both the full study 
population and the 186 patients with a solitary metastasis (and no 
statistical adjustment of <em>P</em> values for the two separate hypotheses).[<a href="#cit/section_6.13">13</a>][Levels of evidence: <a href="https://www.cancer.gov/Common/PopUps/popDefinition.aspx?id=335129&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000335129&amp;version=HealthProfessional&amp;language=English'); return(false);">1iiDii</a> for the full study population and  <a href="https://www.cancer.gov/Common/PopUps/popDefinition.aspx?id=335125&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000335125&amp;version=HealthProfessional&amp;language=English'); return(false);">1iiA</a> for patients with solitary metastases]<div class="pdq-content-list"><ol id="_1337" class="lower-alpha"><li>  Mean OS in the combined-therapy group was 5.7 months, and mean OS in the WBRT–alone group was 6.5 months (<em>P</em> = .14).<div class="pdq-content-list"><ul id="_1338"><li>In the subgroup with solitary metastases, OS was better in the combined-therapy group (6.5 months vs. 4.9 months; <em>P</em> = .039 in univariate analysis; <em>P</em> = .053 in a multivariable analysis adjusting for baseline prognostic factors). </li><li>In
 patients with multiple metastases, survival was 5.8 months in the 
combined-therapy group versus 6.7 months in the WBRT–only group (<em>P</em> =  .98). </li><li>The
 combined-treatment group had a survival advantage of 2.5 months in 
patients with a single metastasis but not in patients with multiple 
lesions. </li></ul></div></li><li>Local control was better in the full population with combined therapy.</li><li>At
 the 6-month follow-up, Karnofsky Performance status (considered a soft 
endpoint because of its imprecision and subjectivity) was better in the 
combined-therapy group, but there was no difference in mental status 
between the treatment groups.  Acute and late toxicities were similar in
 both treatment arms.  Quality of life was not assessed.</li></ol></div></li>
            <li>A phase III randomized trial compared adjuvant WBRT with
 observation after surgery or radiosurgery for a limited number of brain
 metastases in patients with stable solid tumors.[<a href="#cit/section_6.14">14</a>][<a href="https://www.cancer.gov/Common/PopUps/popDefinition.aspx?id=335127&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000335127&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence: 1iiC</a>]<div class="pdq-content-list"><ul id="_1234"><li>Health-related quality of life was improved in the observation-only arm, compared with  WBRT. </li><li>Patients in the observation arm had better mean scores in physical, role, and cognitive functioning at 9 months. </li><li>In
 an exploratory analysis, statistically significant worse scores for 
bladder control, communication deficit, drowsiness, hair loss, motor 
dysfunction, leg weakness, appetite loss, constipation, nausea/vomiting,
 pain, and social functioning were observed in patients who underwent 
WBRT, compared with those who underwent observation only.</li></ul></div></li>
            <li>A meta-analysis of two trials with a total of 358 
participants found no statistically significant difference in OS between
 the WBRT plus stereotactic radiosurgery group and  the WBRT–alone group
 (HR, 0.82; 95% CI,  0.65–1.02).[<a href="#cit/section_6.15">15</a>][<a href="https://www.cancer.gov/Common/PopUps/popDefinition.aspx?id=335131&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000335131&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence: 1iiDiii</a>]<div class="pdq-content-list"><ul id="_1235"><li>Patients
 in the WBRT plus stereotactic radiosurgery group had decreased local 
failure, compared with patients who received WBRT alone (HR, 0.27; 95% 
CI, 0.14–0.52).</li><li>Unchanged or improved Karnofsky Performance 
status at 6 months was seen in 43% of patients in the combined-therapy 
group versus only 28% in the WBRT-alone group (<em>P</em> = .03).</li></ul></div>   </li>
          </ol>
        </div>
        <p id="_1212" tabindex="-1">A study that had a primary endpoint 
of learning and neurocognition, using a standardized test for total 
recall, was stopped by the Data and Safety Monitoring Board because of 
worse outcomes in the WBRT group.[<a href="#cit/section_6.16">16</a>][<a href="https://www.cancer.gov/Common/PopUps/popDefinition.aspx?id=632558&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000632558&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence: 1iiD</a>] </p>
        <p id="_1331" tabindex="-1">Given this body of information, 
focal therapy plus WBRT or focal therapy alone, with close follow-up 
with serial MRIs and initiation of salvage therapy when clinically 
indicated, appear to be reasonable treatment options.  The pros and cons
 of each approach should be discussed with the patient.</p>
        <p id="_1213" tabindex="-1">Several randomized trials  have been
 performed that were designed with varying primary endpoints to address 
whether WBRT is necessary after focal treatment. The results can be 
summarized as follows:[<a href="#cit/section_6.16">16</a>-<a href="#cit/section_6.18">18</a>]</p>
        <div class="pdq-content-list">
          <ol id="_1214">
            <li>Studies consistently show that the addition of WBRT to 
focal therapy decreases the risk of progression and new metastases in 
the brain.</li>
            <li>The addition of WBRT does not improve OS.</li>
            <li>The decrease in risk of intracranial disease progression
 does not translate into improved functional or neurologic status, nor 
does it appear to decrease the risk of death from neurologic 
deterioration.</li>
            <li>About half or more of the patients who receive focal 
therapy alone ultimately require salvage therapy, such as WBRT or 
radiosurgery, compared with about a quarter of the patients who are 
given up-front WBRT.</li>
            <li>The impact of better local control associated with WBRT on quality of life has not been reported and remains an open question.</li>
          </ol>
        </div>
      </section>
    </section>
  </section>
  <section id="_1215">
    <h3 id="_1215_toc">Leptomeningeal carcinomatosis (LC)</h3>
    <p id="_1216" tabindex="-1">LC occurs in about 5% of all cancer patients.  The most common types of cancer to spread to the leptomeninges are:</p>
    <div class="pdq-content-list">
      <ul id="_1217">
        <li>Breast  tumors (35%).</li>
        <li>Lung tumors (24%).</li>
        <li>Hematologic malignancies (16%).</li>
      </ul>
    </div>
    <p id="_1218" tabindex="-1">Diagnosis includes a combination of 
neurospinal axis imaging and cerebrospinal fluid (CSF) cytology.  Median
 OS is in the range of 10 to  12 weeks.</p>
    <p id="_1219" tabindex="-1">The management of LC includes the following:</p>
    <div class="pdq-content-list">
      <ul id="_1220">
        <li>Intrathecal chemotherapy.</li>
        <li>Intrathecal chemotherapy and systemic chemotherapy. </li>
        <li>Intrathecal chemotherapy and radiation therapy. </li>
        <li>Supportive care.</li>
      </ul>
    </div>
    <p id="_1221" tabindex="-1">In a series of 149 patients with 
metastatic non-small cell lung carcinoma, cytologically proven LC, poor 
performance status, high protein level in the CSF, and a high initial 
CSF white blood cell count were significant poor prognostic factors for 
survival.[<a href="#cit/section_6.19">19</a>] Patients received active 
treatment, including intrathecal chemotherapy, WBRT, or epidermal growth
 factor receptor-thymidine kinase-1, or underwent a ventriculoperitoneal
 shunt procedure. </p>
    <p id="_1222" tabindex="-1">In a retrospective series of 38 patients
 with metastatic breast cancer and LC, the proportion of LC cases varied
 by breast cancer subtype:[<a href="#cit/section_6.20">20</a>]</p>
    <div class="pdq-content-list">
      <ul id="_1332">
        <li>Luminal A (18.4%).</li>
        <li> Luminal B (31.6%). </li>
        <li>Human epidermal growth factor receptor 2 (HER2)-positive (26.3%). </li>
        <li>Triple-negative breast cancer subtype (23.7%).</li>
      </ul>
    </div>
    <p id="_1333" tabindex="-1">Patients with triple-negative breast 
cancer had a shorter interval between metastatic breast cancer diagnosis
 and the development  of LC. Median survival did not differ across 
breast cancer subtypes.  Consideration of intrathecal administration of 
trastuzumab in patients with HER2-positive LC has also been described in
 case reports.[<a href="#cit/section_6.21">21</a>]</p>
  </section>
  <h6 do-not-show="toc">References</h6>
  <ol>
    <li id="section_6.1">Patchell RA: The management of brain metastases. Cancer Treat Rev 29 (6): 533-40, 2003.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14585263&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14585263&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_6.2">Mehta M, Vogelbaum  MA, Chang S, et al.: 
Neoplasms of the central nervous system. In: DeVita VT Jr, Lawrence TS, 
Rosenberg SA: Cancer: Principles and Practice of Oncology. 9th ed. 
Philadelphia, Pa: Lippincott Williams &amp; Wilkins, 2011, pp 1700-49.</li>
    <li id="section_6.3">Hutter A, Schwetye KE, Bierhals AJ, et al.: 
Brain neoplasms: epidemiology, diagnosis, and prospects for 
cost-effective imaging. Neuroimaging Clin N Am 13 (2): 237-50, x-xi, 
2003.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=13677804&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=13677804&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_6.4">Schaefer PW, Budzik RF Jr, Gonzalez RG: Imaging of cerebral metastases. Neurosurg Clin N Am 7 (3): 393-423, 1996.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8823771&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8823771&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_6.5">Soffietti R, Cornu P, Delattre JY, et al.: EFNS
 Guidelines on diagnosis and treatment of brain metastases: report of an
 EFNS Task Force. Eur J Neurol 13 (7): 674-81, 2006.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16834697&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16834697&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_6.6">Ogawa K, Yoshii Y, Nishimaki T, et al.: 
Treatment and prognosis of brain metastases from breast cancer. J 
Neurooncol 86 (2): 231-8, 2008.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17849084&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17849084&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_6.7">Patchell RA, Tibbs PA, Walsh JW, et al.: A 
randomized trial of surgery in the treatment of single metastases to the
 brain. N Engl J Med 322 (8): 494-500, 1990.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2405271&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2405271&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_6.8">Vecht CJ, Haaxma-Reiche H, Noordijk EM, et al.:
 Treatment of single brain metastasis: radiotherapy alone or combined 
with neurosurgery? Ann Neurol 33 (6): 583-90, 1993.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8498838&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8498838&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_6.9">Mintz AH, Kestle J, Rathbone MP, et al.: A 
randomized trial to assess the efficacy of surgery in addition to 
radiotherapy in patients with a single cerebral metastasis. Cancer 78 
(7): 1470-6, 1996.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8839553&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8839553&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_6.10">Hart MG, Grant R, Garside R, et al.: 
Chemotherapeutic wafers for high grade glioma. Cochrane Database Syst 
Rev  (3): CD007294, 2008.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18646178&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18646178&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_6.11">Patchell RA, Tibbs PA, Regine WF, et al.: 
Postoperative radiotherapy in the treatment of single metastases to the 
brain: a randomized trial. JAMA 280 (17): 1485-9, 1998.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9809728&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9809728&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_6.12">Roos DE, Wirth A, Burmeister BH, et al.: Whole
 brain irradiation following surgery or radiosurgery for solitary brain 
metastases: mature results of a prematurely closed randomized 
Trans-Tasman Radiation Oncology Group trial (TROG 98.05). Radiother 
Oncol 80 (3): 318-22, 2006.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16956684&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16956684&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_6.13">Andrews DW, Scott CB, Sperduto PW, et al.: 
Whole brain radiation therapy with or without stereotactic radiosurgery 
boost for patients with one to three brain metastases: phase III results
 of the RTOG 9508 randomised trial. Lancet 363 (9422): 1665-72, 
2004.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15158627&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15158627&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_6.14">Soffietti R, Kocher M, Abacioglu UM, et al.: A
 European Organisation for Research and Treatment of Cancer phase III 
trial of adjuvant whole-brain radiotherapy versus observation in 
patients with one to three brain metastases from solid tumors after 
surgical resection or radiosurgery: quality-of-life results. J Clin 
Oncol 31 (1): 65-72, 2013.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23213105&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23213105&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_6.15">Patil CG, Pricola K, Sarmiento JM, et al.: 
Whole brain radiation therapy (WBRT) alone versus WBRT and radiosurgery 
for the treatment of brain metastases. Cochrane Database Syst Rev 9: 
CD006121, 2012.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22972090&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22972090&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_6.16">Chang EL, Wefel JS, Hess KR, et al.: 
Neurocognition in patients with brain metastases treated with 
radiosurgery or radiosurgery plus whole-brain irradiation: a randomised 
controlled trial. Lancet Oncol 10 (11): 1037-44, 2009.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19801201&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19801201&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_6.17">Aoyama H, Shirato H, Tago M, et al.: 
Stereotactic radiosurgery plus whole-brain radiation therapy vs 
stereotactic radiosurgery alone for treatment of brain metastases: a 
randomized controlled trial. JAMA 295 (21): 2483-91, 2006.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16757720&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16757720&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_6.18">Kocher M, Soffietti R, Abacioglu U, et al.: 
Adjuvant whole-brain radiotherapy versus observation after radiosurgery 
or surgical resection of one to three cerebral metastases: results of 
the EORTC 22952-26001 study. J Clin Oncol 29 (2): 134-41, 2011.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21041710&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21041710&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_6.19">Lee SJ, Lee JI, Nam DH, et al.: Leptomeningeal
 carcinomatosis in non-small-cell lung cancer patients: impact on 
survival and correlated prognostic factors. J Thorac Oncol 8 (2): 
185-91, 2013.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23328548&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23328548&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_6.20">Torrejón D, Oliveira M, Cortes J, et al.: 
Implication of breast cancer phenotype for patients with leptomeningeal 
carcinomatosis. Breast 22 (1): 19-23, 2013.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23137566&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23137566&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_6.21">Bartsch R, Berghoff AS, Preusser M: Optimal 
management of brain metastases from breast cancer. Issues and 
considerations. CNS Drugs 27 (2): 121-34, 2013.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23239265&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23239265&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
  </ol>
</div>
    			</section><section id="_687">
    				<h2>Recurrent Adult CNS Tumors Treatment</h2>
    				 <div id="_section_687" class="pdq-sections"><nav class="onthispage in-this-section" role="navigation"><h6>In This Section</h6><ul><li><a href="#_961_toc">Chemotherapy</a><ul><li><a href="#_977_toc">Localized chemotherapy (carmustine wafer)</a></li><li><a href="#_692_toc">Systemic chemotherapy</a></li></ul></li><li><a href="#_976_toc">Antiangiogenesis Therapy</a></li><li><a href="#_694_toc">Radiation Therapy</a></li><li><a href="#_1228_toc">Surgery</a></li><li><a href="#_TrialSearch_687_sid_7_toc">Current Clinical Trials</a></li></ul></nav>
  <p id="_1223" tabindex="-1">Patients who have recurrent CNS tumors are
 rarely curable and should be considered candidates for clinical trials.
 Information about ongoing clinical trials is available from the <a href="https://www.cancer.gov/about-cancer/treatment/clinical-trials" title="https://www.cancer.gov/about-cancer/treatment/clinical-trials">NCI website</a>.</p>
  <p id="_990" tabindex="-1">Standard treatment options for recurrent CNS tumors include the following:</p>
  <div class="pdq-content-list">
    <ol id="_991">
      <li>
        <a href="https://www.cancer.gov/types/brain/hp/adult-brain-treatment-pdq#link/_961">Chemotherapy</a>.</li>
      <li>
        <a href="https://www.cancer.gov/types/brain/hp/adult-brain-treatment-pdq#link/_976">Antiangiogenesis therapy</a>.</li>
      <li>
        <a href="https://www.cancer.gov/types/brain/hp/adult-brain-treatment-pdq#link/_694">Radiation therapy</a>.</li>
      <li>
        <a href="https://www.cancer.gov/types/brain/hp/adult-brain-treatment-pdq#link/_1228">Surgery</a>.</li>
    </ol>
  </div>
  <section id="_961">
    <h3 id="_961_toc">Chemotherapy</h3>
    <section id="_977">
      <h4 id="_977_toc">Localized chemotherapy (carmustine wafer)</h4>
      <p id="_691" tabindex="-1">Carmustine wafers have been 
investigated for the treatment of recurrent malignant gliomas, but the 
impact on survival is less clear than at the time of initial diagnosis 
and resection.    </p>
      <p id="_1020" tabindex="-1">Evidence (localized chemotherapy):</p>
      <div class="pdq-content-list">
        <ol id="_1021">
          <li>In a multicenter randomized, placebo-controlled trial, 222
 patients with recurrent malignant primary brain tumors requiring 
reoperation were randomly assigned to receive implanted carmustine 
wafers or placebo biodegradable wafers.[<a href="#cit/section_7.1">1</a>][<a href="https://www.cancer.gov/Common/PopUps/popDefinition.aspx?id=335106&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000335106&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence: 1iA</a>]
 Approximately half of the patients had received prior systemic 
chemotherapy. The two treatment groups were well balanced at baseline. <div class="pdq-content-list"><ul id="_1224"><li>Median
 survival was 31 weeks  in the group receiving carmustine wafers versus 
23 weeks in the group receiving placebo wafers.  The statistical 
significance between the two overall survival curves depended on the 
method of analysis. </li><li>The hazard ratio (HR) for risk of dying in 
the direct intention-to-treat comparison between the two groups was 0.83
 (95% confidence interval [CI], 0.63–1.10; <em>P </em> = .19). The 
baseline characteristics were similar in the two groups, but the 
investigators performed an additional analysis, adjusting for prognostic
 factors, because they felt that even small differences in baseline 
characteristics could have a powerful influence on outcomes. In the 
adjusted proportional hazards model, the HR for risk of death was 0.67 
(95% CI, 0.51–0.90, <em>P</em> = .006). The investigators emphasized this latter analysis and reported this as a positive trial.[<a href="#cit/section_7.1">1</a>][<a href="https://www.cancer.gov/Common/PopUps/popDefinition.aspx?id=335106&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000335106&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence: 1iA</a>]</li></ul></div></li>
          <li>A Cochrane Collaboration systematic review of 
chemotherapeutic wafers for high-grade glioma focused on the unadjusted 
analysis and reported the same trial as negative.[<a href="#cit/section_7.2">2</a>]</li>
        </ol>
      </div>
    </section>
    <section id="_692">
      <h4 id="_692_toc">Systemic chemotherapy</h4>
      <p id="_920" tabindex="-1">Systemic therapy (e.g., temozolomide, 
lomustine,     or the combination of procarbazine, a nitrosourea, and 
PCV in patients who have not previously received the drugs) has been 
used at the time of recurrence of primary malignant brain tumors. 
However, this approach has not been tested in controlled studies. 
Patient-selection factors likely play a strong role in determining 
outcomes, so the impact of therapy on survival is not clear.</p>
    </section>
  </section>
  <section id="_976">
    <h3 id="_976_toc">Antiangiogenesis Therapy</h3>
    <p id="_916" tabindex="-1">In 2009, the U.S. Food and Drug 
Administration (FDA) granted accelerated approval of bevacizumab 
monotherapy for patients with progressive glioblastoma. The indication 
was granted under the FDA’s accelerated approval program that permits 
the use of certain surrogate endpoints or an effect on a clinical 
endpoint other than survival or irreversible morbidity as bases for 
approvals of products intended for serious or life-threatening illnesses
 or conditions. </p>
    <p id="_1225" tabindex="-1">The approval was based on the 
demonstration of improved objective response rates observed in two 
historically controlled, single-arm, or noncomparative phase II trials.[<a href="#cit/section_7.3">3</a>,<a href="#cit/section_7.4">4</a>][<a href="https://www.cancer.gov/Common/PopUps/popDefinition.aspx?id=587991&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000587991&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence: 3iiiDiv</a>] On the basis of these data and FDA approval, bevacizumab monotherapy has become standard therapy for recurrent glioblastoma.</p>
    <p id="_1022" tabindex="-1">Evidence (antiangiogenesis therapy):</p>
    <div class="pdq-content-list">
      <ol id="_1023">
        <li>The FDA independently reviewed an open-label, multicenter, 
noncomparative phase II study that randomly assigned 167 recurrent 
glioblastoma multiforme (GBM) patients to receive bevacizumab alone or 
bevacizumab in combination with irinotecan,[<a href="#cit/section_7.3">3</a>] although only efficacy data from the bevacizumab monotherapy arm (n = 85) were used to support drug approval. <div class="pdq-content-list"><ul id="_1226"><li>Tumor
 responses were observed in 26% of  patients treated with bevacizumab 
alone, and the median duration of response in these patients was 4.2 
months. </li><li>On the basis of this externally controlled trial, the 
incidence of adverse events associated with bevacizumab did not appear 
to be significantly increased in GBM patients. </li></ul></div></li>
        <li>The FDA independently assessed another single-arm, 
single-institution trial in which 56 recurrent glioblastoma patients 
were treated with bevacizumab alone.[<a href="#cit/section_7.4">4</a>] <div class="pdq-content-list"><ul id="_1227"><li>Responses were observed in 20% of patients, and the median duration of response was 3.9 months.</li></ul></div></li>
      </ol>
    </div>
    <p id="_918" tabindex="-1">Currently, however, no data are available
 from prospective, randomized controlled trials demonstrating 
improvement in health outcomes, such as disease-related symptoms or 
increased survival with the use of bevacizumab to treat  glioblastoma. </p>
  </section>
  <section id="_694">
    <h3 id="_694_toc">Radiation Therapy</h3>
    <p id="_695" tabindex="-1">Because there are no randomized trials, 
the role of repeat radiation after disease progression or the 
development of radiation-induced cancers is also ill defined. 
Interpretation is difficult because the literature is limited to small 
retrospective case series.[<a href="#cit/section_7.5">5</a>] The decision must be made carefully because of the risk of neurocognitive deficits and radiation necrosis.</p>
  </section>
  <section id="_1228">
    <h3 id="_1228_toc">Surgery</h3>
    <p id="_1229" tabindex="-1">Re-resection of recurrent CNS tumors is 
used for some patients. However, most patients do not qualify because of
  a deteriorating condition or technically inoperable tumors. The 
evidence is limited to noncontrolled studies and case series of patients
 who are healthy enough and have tumors that are small enough  to 
technically debulk. The impact on survival  of reoperation versus 
patient selection is not known.</p>
  </section>
  <section id="_TrialSearch_687_sid_7">
    <h3 id="_TrialSearch_687_sid_7_toc">Current Clinical Trials</h3>
    <p id="_TrialSearch_687_22" tabindex="-1">Use our <a href="https://www.cancer.gov/about-cancer/treatment/clinical-trials/advanced-search" title="https://www.cancer.gov/about-cancer/treatment/clinical-trials/advanced-search">advanced clinical trial search</a>
 to find NCI-supported cancer clinical trials that are now enrolling 
patients. The search can be narrowed by location of the trial, type of 
treatment, name of the drug, and other criteria. <a href="https://www.cancer.gov/about-cancer/treatment/clinical-trials/" title="https://www.cancer.gov/about-cancer/treatment/clinical-trials/">General information</a> about clinical trials is also available.</p>
  </section>
  <h6 do-not-show="toc">References</h6>
  <ol>
    <li id="section_7.1">Brem H, Piantadosi S, Burger PC, et al.: 
Placebo-controlled trial of safety and efficacy of intraoperative 
controlled delivery by biodegradable polymers of chemotherapy for 
recurrent gliomas. The Polymer-brain Tumor Treatment Group. Lancet 345 
(8956): 1008-12, 1995.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7723496&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7723496&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_7.2">Hart MG, Grant R, Garside R, et al.: 
Chemotherapeutic wafers for high grade glioma. Cochrane Database Syst 
Rev  (3): CD007294, 2008.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18646178&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18646178&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_7.3">Friedman HS, Prados MD, Wen PY, et al.: 
Bevacizumab alone and in combination with irinotecan in recurrent 
glioblastoma. J Clin Oncol 27 (28): 4733-40, 2009.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19720927&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19720927&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_7.4">Kreisl TN, Kim L, Moore K, et al.: Phase II 
trial of single-agent bevacizumab followed by bevacizumab plus 
irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 
27 (5): 740-5, 2009.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19114704&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19114704&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_7.5">Paulino AC, Mai WY, Chintagumpala M, et al.: 
Radiation-induced malignant gliomas: is there a role for reirradiation? 
Int J Radiat Oncol Biol Phys 71 (5): 1381-7, 2008.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18262733&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18262733&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
  </ol>
</div>
    			</section><section id="_233">
    				<h2>Changes to This Summary (05/03/2019)</h2>
    				 <div id="_section_233" class="pdq-sections">
  <p id="_1359" tabindex="-1">The PDQ cancer information summaries are reviewed regularly and updated as
new information becomes available.  This section describes the latest
changes made to this summary as of the date above.</p>
  <p id="_1378" tabindex="-1">
    <strong>
      <a href="https://www.cancer.gov/types/brain/hp/adult-brain-treatment-pdq#link/_1">General Information About Adult  Central Nervous System (CNS) Tumors</a>
    </strong>
  </p>
  <p id="_1391" tabindex="-1">The <a href="https://www.cancer.gov/types/brain/hp/adult-brain-treatment-pdq#link/_972">Prognostic Factors</a> subsection was extensively revised.</p>
  <p id="_1392" tabindex="-1">
    <strong>
      <a href="https://www.cancer.gov/types/brain/hp/adult-brain-treatment-pdq#link/_5">World Health Organization (WHO) Classification of Adult Primary CNS Tumors</a>
    </strong>
  </p>
  <p id="_1393" tabindex="-1">Added American Joint Committee on Cancer as <a href="https://www.cancer.gov/types/brain/hp/adult-brain-treatment-pdq#link/_257">reference 2</a>. </p>
  <p id="_1394" tabindex="-1">
    <strong>
      <a href="https://www.cancer.gov/types/brain/hp/adult-brain-treatment-pdq#link/_69">Treatment Option Overview for Adult Primary CNS Tumors</a>
    </strong>
  </p>
  <p id="_1395" tabindex="-1">Revised <a href="https://www.cancer.gov/types/brain/hp/adult-brain-treatment-pdq#link/_737">text</a>
 to state that treatment options for patients with low-grade gliomas are
 not as clear as in the case of high-grade tumors and include 
observation, postoperative radiation therapy, and chemotherapy with 
temozolomide.</p>
  <p id="_1396" tabindex="-1">Added <a href="https://www.cancer.gov/types/brain/hp/adult-brain-treatment-pdq#link/_1381">text</a>
 about the EORTC 22033-26033 [NCT00182819] trial, which randomly 
assigned 707 patients with low-grade glioma and at least one high-risk 
feature to receive either radiation therapy or temozolomide 
chemotherapy. Radiation therapy consisted of conformal treatment; 
chemotherapy was dose-dense oral temozolomide. There was no significant 
difference in progression-free survival or health-related quality of 
life (cited Baumert et al. as reference 16 and Reijneveld et al. as 
reference 17).</p>
  <p id="_disclaimerHP_3" tabindex="-1">This summary is written and maintained by the <a href="https://www.cancer.gov/publications/pdq/editorial-boards/adult-treatment" title="https://www.cancer.gov/publications/pdq/editorial-boards/adult-treatment">PDQ Adult Treatment Editorial Board</a>, which is
editorially independent of NCI.  The summary reflects an independent review of
the literature and does not represent a policy statement of NCI or NIH.  More
information about summary policies and the role of the PDQ Editorial Boards  in
maintaining the PDQ summaries can be found on the <a href="https://www.cancer.gov/types/brain/hp/adult-brain-treatment-pdq#link/_AboutThis_1">About This PDQ Summary</a> and <a href="https://www.cancer.gov/publications/pdq" title="https://www.cancer.gov/publications/pdq">PDQ® - NCI's Comprehensive Cancer Database</a> pages.
</p>
</div>
    			</section><section id="_AboutThis_1">
    				<h2>About This PDQ Summary</h2>
    				 <div id="_section_AboutThis_1" class="pdq-sections">
  <section id="_AboutThis_2">
    <h3 id="_AboutThis_2_toc">Purpose of This Summary</h3>
    <p id="_AboutThis_3" tabindex="-1">This PDQ cancer information 
summary for health professionals provides comprehensive, peer-reviewed, 
evidence-based information about the treatment of adult central nervous 
system tumors. It is intended as a resource to inform and assist 
clinicians who care for cancer patients.  It does not provide formal 
guidelines or recommendations for making health care decisions.</p>
  </section>
  <section id="_AboutThis_4">
    <h3 id="_AboutThis_4_toc">Reviewers and Updates</h3>
    <p id="_AboutThis_5" tabindex="-1">This summary is reviewed regularly and updated as necessary by the <a href="https://www.cancer.gov/publications/pdq/editorial-boards/adult-treatment" title="https://www.cancer.gov/publications/pdq/editorial-boards/adult-treatment">PDQ Adult Treatment Editorial Board</a>,
 which is editorially independent of the National Cancer Institute 
(NCI).  The summary reflects an independent review of the literature and
 does not represent a policy statement of NCI or the National Institutes
 of Health (NIH).</p>
    <p id="_AboutThis_22" tabindex="-1"> Board members review recently published articles each month to determine whether an article should:</p>
    <div class="pdq-content-list">
      <ul id="_AboutThis_6">
        <li>be discussed at a meeting,</li>
        <li>be cited with text, or</li>
        <li>replace or update an existing article that is already cited.</li>
      </ul>
    </div>
    <p id="_AboutThis_7" tabindex="-1">Changes to the summaries are made
 through a consensus process in which Board members evaluate the 
strength of the evidence in  the published articles and determine how 
the article should be included in the summary.</p>
    <p id="" tabindex="-1">The lead reviewers for Adult Central Nervous System Tumors Treatment are:</p>
    <div class="pdq-content-list">
      <ul id="">
        <li>Andrew S. Chi, MD, PhD (New York University Medical Center)</li>
        <li>Minh Tam Truong, MD (Boston University Medical Center)</li>
      </ul>
    </div>
    <p id="_AboutThis_9" tabindex="-1">Any comments or questions about the summary content should be submitted to Cancer.gov through the NCI website's <a href="https://www.cancer.gov/contact/email-us" title="https://www.cancer.gov/contact/email-us">Email Us</a>.
 Do not contact the individual Board Members with questions or comments 
about the summaries. Board members will not respond to individual 
inquiries.</p>
  </section>
  <section id="_AboutThis_10">
    <h3 id="_AboutThis_10_toc">Levels of Evidence</h3>
    <p id="_AboutThis_11" tabindex="-1">Some of the reference citations 
in this summary are accompanied by a level-of-evidence designation. 
These designations are intended to help readers assess the strength of 
the evidence supporting the use of specific interventions or approaches.
 The PDQ Adult Treatment Editorial Board uses a <a href="https://www.cancer.gov/publications/pdq/levels-evidence/treatment">formal evidence ranking system</a> in developing its level-of-evidence designations.</p>
  </section>
  <section id="_AboutThis_12">
    <h3 id="_AboutThis_12_toc">Permission to Use This Summary</h3>
    <p id="_AboutThis_13" tabindex="-1">PDQ is a registered trademark. 
Although the content of PDQ documents can be used freely as text, it 
cannot be identified as an NCI PDQ cancer information summary unless it 
is presented in its entirety and is regularly updated. However, an 
author would be permitted to write a sentence such as “NCI’s PDQ cancer 
information summary about breast cancer prevention states the risks 
succinctly: [include excerpt from the summary].”</p>
    <p id="_AboutThis_14" tabindex="-1">The preferred citation for this PDQ summary is:</p>
    <p id="_AboutThis_15" tabindex="-1">PDQ® Adult Treatment Editorial 
Board. PDQ Adult Central Nervous System Tumors Treatment. Bethesda, MD: 
National Cancer Institute. Updated  &lt;MM/DD/YYYY&gt;. Available at: <a href="https://www.cancer.gov/types/brain/hp/adult-brain-treatment-pdq" title="https://www.cancer.gov/types/brain/hp/adult-brain-treatment-pdq">https://www.cancer.gov/types/brain/hp/adult-brain-treatment-pdq</a>.  Accessed &lt;MM/DD/YYYY&gt;. [PMID: 26389419]</p>
    <p id="_AboutThis_16" tabindex="-1">Images in this summary are used 
with permission of the author(s), artist, and/or publisher for use 
within the PDQ summaries only. Permission to use images outside the 
context of PDQ information must be obtained from the owner(s) and cannot
 be granted by  the National Cancer Institute. Information about using 
the illustrations in this summary, along with many other cancer-related 
images, is available in <a href="https://visualsonline.cancer.gov/" title="https://visualsonline.cancer.gov/">Visuals Online</a>, a collection of over 2,000 scientific images.

</p>
  </section>
  <section id="_AboutThis_17">
    <h3 id="_AboutThis_17_toc">Disclaimer</h3>
    <p id="_AboutThis_18" tabindex="-1">Based on the strength of the 
available evidence, treatment options may be described as either 
“standard” or “under clinical evaluation.” These classifications should 
not be used as a basis for insurance reimbursement determinations. More 
information on insurance coverage is available on Cancer.gov on the <a href="https://www.cancer.gov/about-cancer/managing-care" title="https://www.cancer.gov/about-cancer/managing-care">Managing Cancer Care</a> page.</p>
  </section>
  <section id="_AboutThis_20">
    <h3 id="_AboutThis_20_toc">Contact Us</h3>
    <p id="_AboutThis_21" tabindex="-1">More information about contacting us or receiving help with the Cancer.gov website can be found on our <a href="https://www.cancer.gov/contact" title="https://www.cancer.gov/contact">Contact Us for Help</a> page. Questions can also be submitted to Cancer.gov through the website’s <a href="https://www.cancer.gov/contact/email-us" title="https://www.cancer.gov/contact/email-us">Email Us</a>.</p>
  </section>
</div>
    			</section></div>
						
								
			    			
						
								
			    			
						
								
			    			
						
								
			    			
						
								
			    			
						
								
			    			
						
								
			    			
						
								
			    			
						
			</div>

	</div>
</div>

								<footer class="article-footer">


								    <div id="cgvDate">
	<div class="contentid-3240 slot-item only-SI">
												
				
					
		
	    
        	
				
                			<div class="document-dates horizontal">
			<ul class="clearfix">
									    	    		<li><strong>Updated:</strong> May
 3, 2019</li>    	    
							</ul>
		</div>
	
	</div>
</div>

								    


								    <div id="nvcgSlPublicUse">
	<div class="contentid-911758 slot-item only-SI">
		<div class="public-use">
	<p id="public-use"><i>If you would like to reproduce some or all of this content, see <a href="https://www.cancer.gov/policies/copyright-reuse">Reuse of NCI Information</a>
 for guidance about copyright and permissions. In the case of permitted 
digital reproduction, please credit the National Cancer Institute as the
 source and link to the original NCI product using the original 
product's title; e.g., “Adult Central Nervous System Tumors Treatment 
(PDQ®)–Health Professional Version was originally published by the 
National Cancer Institute.”</i></p>

<p id="comment-policy" class="blog-comment-policy">We welcome your comments on this post. All comments must follow our <a href="https://www.cancer.gov/policies/comments">comment policy</a>.</p></div>

	</div>
</div>
								    <div id="nvcgSlSyndication">
	<div class="contentid-911760 slot-item only-SI">
		<div class="syndication">
	<div class="row collapse-edges">
  <div class="large-1 small-2 columns"> <img alt="" src="Adult%20Central%20Nervous%20System%20Tumors%20Treatment%20(PDQ%C2%AE)%E2%80%94Health%20Professional%20Version%20-%20National%20Cancer%20Institute_files/syndication.png"></div>
  <div class="large-11 small-10 columns">
    <p style="margin-top: 0;">Want to use this content on your website or other digital platform? Our <a href="https://www.cancer.gov/syndication">syndication services page</a> shows you how.</p>
  </div>
</div></div>

	</div>
</div>

								</footer>
							</div> <!-- End resizeable area -->
                        </article>
                        <!-- ********************************* END Page Content ********************************** -->
                    </div> <!-- END Main -->
                </div> <!-- END "row" -->
            </div> <!-- END "row general-page-body-container collapse" -->
		<div id="overlay" style="display:none"></div></div> <!-- End MAIN CONTENT AREA -->

        </div> <!-- END Page -->

        <!-- FOOTER -->
        <footer class="site-footer">
            <div id="nvcgSlFooter">
	<div class="contentid-911586 slot-item only-SI">
		

<div class="site-footer__container">
<div class="site-footer__header">
<h1>National Cancer Institute <span>at the National Institutes of Health</span></h1>
</div>
<div class="site-footer__nav">
<div class="site-footer__icons">
<h2>FOLLOW US</h2>
<ul>
<li><a class="facebook icon" onclick="NCIAnalytics.FooterLink(this, 'Facebook');" href="https://www.cancer.gov/social-media#facebook"> <span class="hidden">Facebook</span> </a></li>
<li><a class="twitter icon" onclick="NCIAnalytics.FooterLink(this, 'Twitter');" href="https://www.cancer.gov/social-media#twitter"> <span class="hidden">Twitter</span> </a></li>
<li><a class="instagram icon no-exit-notification" onclick="NCIAnalytics.FooterLink(this, 'Instagram');" href="http://instagram.com/nationalcancerinstitute"> <span class="hidden">Instagram</span> </a></li>
<li><a class="youtube icon" onclick="NCIAnalytics.FooterLink(this, 'YouTube');" href="https://www.cancer.gov/social-media#youTube"> <span class="hidden">YouTube</span></a></li>
<li><a class="linkedin icon" onclick="NCIAnalytics.FooterLink(this, 'LinkedIn');" href="https://www.cancer.gov/social-media#linkedIn"> <span class="hidden">LinkedIn</span> </a></li>
<li><a class="govdelivery icon" onclick="NCIAnalytics.FooterLink(this, 'GovDelivery');" href="https://public.govdelivery.com/accounts/USNIHNCI/subscriber/new"> <span class="hidden">GovDelivery</span> </a></li>
<li><a class="rss icon" onclick="NCIAnalytics.FooterLink(this, 'RSS');" href="https://www.cancer.gov/syndication/rss" title=""> <span class="hidden">RSS</span> </a></li>
</ul>
</div>
<div class="site-footer__contact">
<h2>CONTACT INFORMATION</h2>
<ul>
<li><a onclick="NCIAnalytics.FooterLink(this, 'Contact Us');" href="https://www.cancer.gov/contact" title="">Contact Us</a></li>
<li><a onclick="NCIAnalytics.FooterLink(this, 'LiveHelp Chat'); window.open('https://livehelp.cancer.gov', 'LiveHelp','scrollbars=yes,resizable=yes,menubar=yes,toolbar=yes,location=yes,width=650,height=600'); return false;" href="https://livehelp.cancer.gov/">LiveHelp Online Chat</a></li>
</ul>
</div>
<div class="site-footer__info">
<h2>MORE INFORMATION</h2>
<ul>
<li><a onclick="NCIAnalytics.FooterLink(this, 'About Website');" href="https://www.cancer.gov/about-website" title="">About This Website</a></li>
<li><a onclick="NCIAnalytics.FooterLink(this, 'Cancer.gov en Espanol');" href="https://www.cancer.gov/espanol" title="">Cancer.gov en español</a></li>
<li><a onclick="NCIAnalytics.FooterLink(this, 'Multimedia');" href="https://www.cancer.gov/multimedia" title="">Multimedia</a></li>
<li><a onclick="NCIAnalytics.FooterLink(this, 'Publications');" href="https://www.cancer.gov/publications" title="">Publications</a></li>
<li><a onclick="NCIAnalytics.FooterLink(this, 'Site Map');" href="https://www.cancer.gov/about-website/sitemap" title="">Site Map</a></li>
<li><a onclick="NCIAnalytics.FooterLink(this, 'Digital Standards');" href="https://www.cancer.gov/digital-standards" title="">Digital Standards for NCI Websites</a></li>
</ul>
</div>
<div class="site-footer__policies">
<h2>POLICIES</h2>
<ul>
<li><a onclick="NCIAnalytics.FooterLink(this, 'Accessibility');" href="https://www.cancer.gov/policies/accessibility" title="">Accessibility</a></li>
<li><a onclick="NCIAnalytics.FooterLink(this, 'Comments');" href="https://www.cancer.gov/policies/comments" title="">Comment Policy</a></li>
<li><a onclick="NCIAnalytics.FooterLink(this, 'Disclaimer');" href="https://www.cancer.gov/policies/disclaimer" title="">Disclaimer</a></li>
<li><a onclick="NCIAnalytics.FooterLink(this, 'FOIA');" href="https://www.cancer.gov/policies/foia" title="">FOIA</a></li>
<li><a onclick="NCIAnalytics.FooterLink(this, 'Privacy and Security');" href="https://www.cancer.gov/policies/privacy-security" title="">Privacy &amp; Security</a></li>
<li><a onclick="NCIAnalytics.FooterLink(this, 'Reuse');" href="https://www.cancer.gov/policies/copyright-reuse" title="">Reuse &amp; Copyright</a></li>
<li><a onclick="NCIAnalytics.FooterLink(this, 'Syndication');" href="https://www.cancer.gov/syndication" title="">Syndication Services</a></li>
<li><a onclick="NCIAnalytics.FooterLink(this, 'Linking');" href="https://www.cancer.gov/policies/linking" title="">Website Linking</a></li>
</ul>
</div>
</div>
<div class="site-footer__agencies">
<ul>
<li><a onclick="NCIAnalytics.FooterLink(this, 'HHS');" href="http://www.hhs.gov/">U.S. Department of Health and Human Services</a></li>
<li><a onclick="NCIAnalytics.FooterLink(this, 'NIH');" href="http://www.nih.gov/">National Institutes of Health</a></li>
<li><a onclick="NCIAnalytics.FooterLink(this, 'NCI');" href="https://www.cancer.gov/">National Cancer Institute</a></li>
<li><a onclick="NCIAnalytics.FooterLink(this, 'USA.gov');" href="http://usa.gov/">USA.gov</a></li>
</ul>
</div>
<div class="site-footer__tagline">
<h4>NIH ... Turning Discovery Into Health <sup>®</sup></h4>
</div>
<a class="back-to-top" href="#top">TOP</a></div>

	</div>
</div>
        </footer>
        <!-- END FOOTER -->
        
        <!-- UNIVERSAL ANALYTICS AND DTM PAGEBOTTOM TAGS - DO NOT MODIFY -->
        <script id="_fed_an_ua_tag" src="Adult%20Central%20Nervous%20System%20Tumors%20Treatment%20(PDQ%C2%AE)%E2%80%94Health%20Professional%20Version%20-%20National%20Cancer%20Institute_files/Universal-Federated-Analytics-Min.js" defer="defer"></script>
        <script type="text/javascript">_satellite.pageBottom();</script><script>
var live_or_other=-1<document.URL.indexOf("www.cancer.gov")?"live":"other",wa_hier1="",wa_hier2="",wa_lang="",AllSuites={nciglobal:{live:"nciglobal",other:"ncidevelopment"},ncienterprise:{live:"ncienterprise",other:"ncienterprise-dev"},"ncienglish-all":{live:"ncienglish-all",other:"ncienglish-all-dev"},"ncispanish-all":{live:"ncispanish-all",other:"ncispanish-all-dev"},ncincidictionary:{live:"ncincidictionary",other:"ncincidictionary-dev"},ncidrugdictionary:{live:"ncidrugdictionary",other:"ncidrugdictionary-dev"},ncinews:{live:"ncinews",other:"ncinews-dev"},nciresearch:{live:"nciresearch",other:"nciresearch-dev"},nciabout:{live:"nciabout",other:"nciabout-dev"},nciclinicaltrials:{live:"nciclinicaltrials",other:"nciclinicaltrials-dev"},ncicancertopics:{live:"ncicancertopics",other:"ncicancertopics-dev"},ncitiposdecancer:{live:"ncitiposdecancer",other:"ncitiposdecancer-dev"},ncinoticias:{live:"ncinoticias",other:"ncinoticias-dev"},ncinuestroinstituto:{live:"ncinuestroinstituto",other:"ncinuestroinstituto-dev"},ncielcancer:{live:"ncielcancer",other:"ncielcancer-dev"},"nciogcr-governmentcongressionalrelations":{live:"nciogcr-governmentcongressionalrelations",other:"nciogcr-govcongressionalrelations-dev"}},AnalyticsMapping={GetSuites:function(e){var n=e.split(","),c="";for(i=0;i<n.length;i++)try{var t=n[i].replace(" ","");c+=AllSuites[t][live_or_other],i<n.length-1&&(c+=",")}catch(i){c+=""}return c}},suiteMeta=document.head.querySelector('[name="dcterms.coverage"]'),suites=suiteMeta?suiteMeta.content:"nciglobal,ncienterprise",s_account=AnalyticsMapping.GetSuites(suites);</script><script>
var oga_pattern=/grants\-training\/grants/gi,cct_pattern=/grants\-training\/training/gi,pdq_pattern=/pdq/gi,trimmedPathname=document.location.pathname.replace(/\/$/,""),NCIAnalytics={displayAlerts:!1,stringDelimiter:"|",fieldDelimiter:"~",siteSection:function(a){var i=document.location.pathname;return oga_pattern.test(i)?"oga":cct_pattern.test(i)?"cct":pdq_pattern.test(i)?"pdq":""}(),SelectedOptionList:function(a,i){var e=document.getElementById(a).selectedOptions;if(0<e.length){var c=[].slice.call(e);return c.map(function(a){return a.textContent}).join(i)}return""},ClickParams:function(m,a,i,e){this.sender=m,this.ReportSuites=s_account,this.LinkType=i,this.LinkName=e,this.Props={},this.Evars={},this.Events={},this.EventsWithIncrementors={},this.LogToOmniture=function(){var a;if("function"==typeof s_gi&&this.ReportSuites){for(var i in a=s_gi(this.ReportSuites),a.linkTrackVars="",a.prop8=s.prop8,a.linkTrackVars+="channel,",a.linkTrackVars+="prop8",this.Props)a["prop"+i]=this.Props[i],0<a.linkTrackVars.length&&(a.linkTrackVars+=","),a.linkTrackVars+="prop"+i;if(this.Props[67]||(a.prop67="D=pageName",0<a.linkTrackVars.length&&(a.linkTrackVars+=","),a.linkTrackVars+="prop67"),0<=s.mainCGovIndex)try{var e="",c="NCIEngagement";e=window[c].getAndResetEngagementCookie()||0,e&&0<parseInt(e)&&(this.EventsWithIncrementors&&this.EventsWithIncrementors.hasOwnProperty("push")?this.EventsWithIncrementors.push("92="+e):this.EventsWithIncrementors=["92="+e])}catch(a){}for(var i in this.Props[4]||(a.prop4="D=pev1",0<a.linkTrackVars.length&&(a.linkTrackVars+=","),a.linkTrackVars+="prop4"),a.eVar2=s.eVar2,0<a.linkTrackVars.length&&(a.linkTrackVars+=","),a.linkTrackVars+="eVar2",this.Evars)a["eVar"+i]=this.Evars[i],0<a.linkTrackVars.length&&(a.linkTrackVars+=","),a.linkTrackVars+="eVar"+i;if(0<this.Events.length){var n="";0<a.linkTrackVars.length&&(a.linkTrackVars+=","),a.linkTrackVars+="events";for(var i=0;i<this.Events.length;i++)0<n.length&&(n+=","),n+="event"+this.Events[i];a.linkTrackEvents=n,a.events=n}if(0<this.EventsWithIncrementors.length){var t="",n="",r="";0<a.linkTrackVars.length&&a.linkTrackVars.indexOf("events")<0&&(a.linkTrackVars+=","),a.linkTrackVars+="events";for(var i=0;i<this.EventsWithIncrementors.length;i++)0<n.length&&(n+=","),t="event"+this.EventsWithIncrementors[i],n+=t,r=t.split(":"),r=r[0].split("="),r=r[0];a.linkTrackEvents=a.linkTrackEvents?a.linkTrackEvents+","+r:r,a.events=a.events?a.events+","+n:n}for(var i in a.tl(m,this.LinkType,this.LinkName),a.events="",this.Props)a["prop"+i]="";for(var i in this.Evars)a["eVar"+i]="";if(NCIAnalytics.displayAlerts){var l="ScriptBuilder:\nlocal_s.linkTrackVars="+a.linkTrackVars;if("None"!=a.linkTrackEvents&&(l+="\nlocal_s.linkTrackEvents="+a.linkTrackEvents),0<a.linkTrackVars.length)for(var o=a.linkTrackVars.split(","),i=0;i<o.length;i++)"events"!=o[i]&&(l+="\nlocal_s."+o[i],l+="="+a[o[i]]);l+="\nReport Suites="+this.ReportSuites,l+="\nLink Type="+this.LinkType,l+="\nLink Name="+this.LinkName,alert(l)}}}},SiteWideSearch:function(a){var i="sitewide",e=" ";document.getElementById("swKeyword")&&document.getElementById("swKeyword").value&&(e=document.getElementById("swKeyword").value),document.getElementById("swKeywordQuery")&&document.getElementById("swKeywordQuery").value&&(e=document.getElementById("swKeywordQuery").value),"spanish"==s.prop8.toLowerCase()&&(i+="_spanish"),clickParams=new NCIAnalytics.ClickParams(a,"nciglobal","o","SiteWideSearch"),clickParams.Props={11:i,14:e},clickParams.Evars={11:i,13:"+1",14:e},clickParams.Events=[2],clickParams.LogToOmniture()},PageNotFound:function(a){var i=a.dataset.language,e="pagenotfoundsearch",c=document.getElementById("nfKeyword").value;"es"===i&&(e+="_spanish"),clickParams=new NCIAnalytics.ClickParams(a,"nciglobal","o","PageNotFound"),clickParams.Props={11:e,14:c},clickParams.Evars={11:e,13:"+1",14:c},clickParams.Events=[2],clickParams.LogToOmniture()},SiteWideSearchResultsSearch:function(a,i,e){for(var c=document.getElementById(i).value,n=document.getElementsByName(e),t=0;t<n.length;t++)if(n[t].checked){if(2==n[t].value){var r="sitewide_bottom_withinresults";break}var r="sitewide_bottom_new";break}"spanish"==s.prop8.toLowerCase()&&(r+="_spanish"),clickParams=new NCIAnalytics.ClickParams(this,"nciglobal","o","SiteWideSearchResultsSearch"),clickParams.Props={11:r,14:c},clickParams.Evars={11:r,13:"+1",14:c},clickParams.Events=[2],clickParams.LogToOmniture()},SiteWideSearchResults:function(a,i,e){var c=i?"best_bets":"generic";clickParams=new NCIAnalytics.ClickParams(a,"nciglobal","o","SiteWideSearchResults"),clickParams.Props={12:c,13:e},clickParams.Evars={12:c},clickParams.LogToOmniture()},CTSearchResults:function(a,i){clickParams=new NCIAnalytics.ClickParams(a,"nciglobal,nciclinicaltrials","o","CTSearchResults"),clickParams.Props={13:i},clickParams.LogToOmniture()},TermsDictionarySearch:function(a,i){var e=document.getElementById("radioStarts").checked?"starts with":"contains";NCIAnalytics.TermsDictionarySearchCore(a,document.getElementById("AutoComplete1").value,e,"TermsDictionarySearch",i)},GeneticsDictionarySearch:function(a,i,e){var c=e?"starts with":"contains";clickParams=new NCIAnalytics.ClickParams(a,"","o","GeneticsDictionarySearch"),clickParams.Props={11:"dictionary_genetics",22:i,24:c},clickParams.Evars={11:"dictionary_genetics",13:"+1",26:c},clickParams.Events=[2],clickParams.LogToOmniture()},GeneticsDictionarySearchNew:function(a){var i=document.getElementById("radioStarts").checked?"starts with":"contains";clickParams=new NCIAnalytics.ClickParams(a,"","o","GeneticsDictionarySearch"),clickParams.Props={11:"dictionary_genetics",22:document.getElementById("AutoComplete1").value,24:i},clickParams.Evars={11:"dictionary_genetics",13:"+1",26:i},clickParams.Events=[2],clickParams.LogToOmniture()},GeneticsDictionarySearchAlphaList:function(a,i){clickParams=new NCIAnalytics.ClickParams(a,"","o","GeneticsDictionarySearchAlphaList"),clickParams.Props={11:"dictionary_genetics",22:i,24:"starts with"},clickParams.Evars={11:"dictionary_genetics",13:"+1",26:"starts with"},clickParams.Events=[2],clickParams.LogToOmniture()},GeneticsDictionaryResults:function(a,i){clickParams=new NCIAnalytics.ClickParams(a,"","o","GeneticsDictionaryResults"),clickParams.Props={13:i},clickParams.LogToOmniture()},TermsDictionarySearchAlphaList:function(a,i){NCIAnalytics.TermsDictionarySearchCore(a,i,"starts with","TermsDictionarySearchAlphaList",!1)},TermsDictionarySearchAlphaListSpanish:function(a,i){NCIAnalytics.TermsDictionarySearchCore(a,i,"starts with","TermsDictionarySearchAlphaList",!0)},TermsDictionarySearchCore:function(a,i,e,c,n){if(n)var t="diccionario";else var t="dictionary_terms";clickParams=new NCIAnalytics.ClickParams(a,"nciglobal","o",c),clickParams.Props={11:t,22:i,24:e},clickParams.Evars={11:t,13:"+1",26:e},clickParams.Events=[2],clickParams.LogToOmniture()},TermsDictionaryResults:function(a,i){clickParams=new NCIAnalytics.ClickParams(a,"nciglobal","o","TermsDictionaryResults"),clickParams.Props={13:i},clickParams.LogToOmniture()},DrugDictionarySearch:function(a){var i=document.getElementById("radioStarts").checked?"starts with":"contains";NCIAnalytics.DrugDictionarySearchCore(a,document.getElementById("AutoComplete1").value,i,"DrugDictionarySearch")},DrugDictionarySearchAlphaList:function(a,i){NCIAnalytics.DrugDictionarySearchCore(a,i,"starts with","DrugDictionarySearchAlphaList")},DrugDictionarySearchCore:function(a,i,e,c){var n="dictionary_drugs";clickParams=new NCIAnalytics.ClickParams(a,"nciglobal,ncidrugdictionary","o",c),clickParams.Props={11:n,22:i,24:e},clickParams.Evars={11:n,13:"+1",26:e},clickParams.Events=[2],clickParams.LogToOmniture()},DrugDictionaryResults:function(a,i){clickParams=new NCIAnalytics.ClickParams(a,"nciglobal,ncidrugdictionary","o","DrugDictionaryResults"),clickParams.Props={13:i},clickParams.LogToOmniture()},FeaturedClinicalTrialSearch:function(a){var i="clinicaltrials_featured",e=document.getElementById("keyword").value;clickParams=new NCIAnalytics.ClickParams(a,"nciglobal","o","FeaturedClinicalTrialSearch"),clickParams.Props={11:i,22:e},clickParams.Evars={11:i,13:"+1"},clickParams.Events=[2],clickParams.LogToOmniture()},NewsSearch:function(a,i){var e=document.getElementById("keyword").value,c=document.getElementById("startMonth").options[document.getElementById("startMonth").selectedIndex].text.replace(/^\s+|\s+$/g,"")+" "+document.getElementById("startYear").value,n=document.getElementById("endMonth").options[document.getElementById("endMonth").selectedIndex].text+" "+document.getElementById("endYear").value;NCIAnalytics.KeywordDateRangeSearch(a,i,e,c,n)},GeneticServicesDirectorySearch:function(a){var i="genetics",e="",c="",n=document.getElementById(ids.txtCity).value,t="",r="",l=document.getElementById(ids.txtLastName).value,s="",o="",m="",k;e=NCIAnalytics.SelectedOptionList(ids.selCancerType,NCIAnalytics.stringDelimiter),c=NCIAnalytics.SelectedOptionList(ids.selCancerFamily,NCIAnalytics.stringDelimiter),t=NCIAnalytics.SelectedOptionList(ids.selState,NCIAnalytics.stringDelimiter),r=NCIAnalytics.SelectedOptionList(ids.selCountry,NCIAnalytics.stringDelimiter),s=[e,c,n,t,r,l].join(NCIAnalytics.fieldDelimiter),o=[e,c].join(NCIAnalytics.fieldDelimiter),clickParams=new NCIAnalytics.ClickParams(a,"nciglobal","o","GeneticServicesDirectorySearch"),clickParams.Props={11:i,22:s,23:o},clickParams.Evars={11:i,13:"+1",25:o},clickParams.Events=[2],clickParams.LogToOmniture()},KeywordDateRangeSearch:function(a,i,e,c,n){clickParams=new NCIAnalytics.ClickParams(a,"nciglobal","o","KeywordDateRangeSearch"),clickParams.Props={11:i,22:e},clickParams.Evars={11:i,23:c,24:n,13:"+1"},clickParams.Events=[2],clickParams.LogToOmniture()},KeywordSearch:function(a,i){var e=document.getElementById("keyword").value;clickParams=new NCIAnalytics.ClickParams(a,"nciglobal","o","KeywordSearch"),clickParams.Props={11:i,22:e},clickParams.Evars={11:i,13:"+1"},clickParams.Events=[2],clickParams.LogToOmniture()},SearchResults:function(a,i){clickParams=new NCIAnalytics.ClickParams(a,"nciglobal","o","SearchResults"),clickParams.Props={13:i},clickParams.LogToOmniture()},PDFLink:function(a){clickParams=new NCIAnalytics.ClickParams(a,"nciglobal","d","PDFLink"),clickParams.Evars={30:"+1"},clickParams.Events=[6],clickParams.LogToOmniture()},DownloadKindleClick:function(a){clickParams=new NCIAnalytics.ClickParams(a,"nciglobal","d","DownloadKindleClick"),clickParams.Evars={30:"+1"},clickParams.Events=[22],clickParams.LogToOmniture()},DownloadOtherEReaderClick:function(a){clickParams=new NCIAnalytics.ClickParams(a,"nciglobal","d","DownloadOtherEReaderClick"),clickParams.Evars={30:"+1"},clickParams.Events=[23],clickParams.LogToOmniture()},eMailLink:function(a){clickParams=new NCIAnalytics.ClickParams(a,"nciglobal","o","eMailLink"),clickParams.Props={43:"Email",66:(NCIAnalytics.siteSection?NCIAnalytics.siteSection+"_":"")+"email"},clickParams.Events=[17],clickParams.LogToOmniture()},HelpLink:function(a){clickParams=new NCIAnalytics.ClickParams(a,"nciglobal","o","HelpLink"),clickParams.Events=[5],clickParams.LogToOmniture()},PrintLink:function(a){clickParams=new NCIAnalytics.ClickParams(a,"nciglobal","o","PrintLink"),clickParams.Props={43:"Print",66:(NCIAnalytics.siteSection?NCIAnalytics.siteSection+"_":"")+"print"},clickParams.Events=[17],clickParams.LogToOmniture()},CTSPrintResults_TopLinkClick:function(a,i,e){clickParams=new NCIAnalytics.ClickParams(a,"nciglobal","o","CTSPrintResults_TopLinkClick"),clickParams.Props={21:"CTSPrintPage_"+i,62:"Clinical Trials: Print Results Page",67:s.pageName+"_"+e},clickParams.Evars={62:"Clinical Trials: Print Results Page"},"Email"!=i&&"Print Page"!=i||(clickParams.Events=[17]),clickParams.LogToOmniture()},CTSPrintResults_VewUpdatesLinkClick:function(a,i){clickParams=new NCIAnalytics.ClickParams(a,"nciglobal","o"," CTSPrintResults_VewUpdatesLinkClick");var e=a.href;clickParams.Props={21:"CTSPrintPage_CheckUpdates_"+a.attr("id"),62:"Clinical Trials: Print Results Page",67:s.pageName+"_"+i},clickParams.Evars={62:"Clinical Trials: Print Results Page"},clickParams.LogToOmniture()},CTSResultsPrintSelectedClick:function(a,i,e,c,n){NCIAnalytics.CTSResultsPrintSelectedWithFormClick(a,i,e,c,n,"clinicaltrials_basic")},CTSResultsPrintSelectedWithFormClick:function(a,i,e,c,n,t){clickParams=new NCIAnalytics.ClickParams(a,"nciglobal","o","CTSResultsPrintSelectedClick"),clickParams.Events=[48],clickParams.Props={21:"CTSPrintSelected_"+i+"_"+e+"_"+c+"_"+n,67:"D=pageName",74:t+"|print selected"},clickParams.LogToOmniture()},CTSResultsMaxSelectedClick:function(a){NCIAnalytics.CTSResultsSelectedErrorClick(a,"clinicaltrials_basic","maxselectionreached")},CTSResultsSelectedErrorClick:function(a,i,e){clickParams=new NCIAnalytics.ClickParams(a,"nciglobal","o","CTSResultsSelectedErrorClick"),clickParams.Events=[41],clickParams.Props={74:i+"|error",75:"printselected|"+e},clickParams.LogToOmniture()},CTStartOverClick:function(a){NCIAnalytics.CTStartOverWithFormClick(a,"clinicaltrials_basic","start over")},CTStartOverWithFormClick:function(a,i,e){clickParams=new NCIAnalytics.ClickParams(a,"nciglobal","o","CTStartOverClick"),clickParams.Events=[49],clickParams.Props={67:"D=pageName",74:i+"|"+e},clickParams.LogToOmniture()},SendToPrinterLink:function(a){clickParams=new NCIAnalytics.ClickParams(a,"nciglobal","o","SendToPrinterLink"),clickParams.Events=[14],clickParams.LogToOmniture()},HeaderLink:function(a,i){clickParams=new NCIAnalytics.ClickParams(a,"nciglobal","o","HeaderLink-"+i),clickParams.Props={36:i},clickParams.Evars={36:i},clickParams.Events=[16],clickParams.LogToOmniture()},FooterLink:function(a,i){clickParams=new NCIAnalytics.ClickParams(a,"nciglobal","o","FooterLink-"+i),clickParams.Props={36:i},clickParams.Evars={36:i},clickParams.Events=[16],clickParams.LogToOmniture()},RightNavLink:function(a,i){clickParams=new NCIAnalytics.ClickParams(a,"nciglobal","o","RightNavLink-"),clickParams.Props={27:a.innerHTML,66:(NCIAnalytics.siteSection?NCIAnalytics.siteSection+"_":"")+a.innerHTML.toLowerCase()},clickParams.Evars={49:a.innerHTML},clickParams.Events=[8],clickParams.LogToOmniture()},BulletinSubscription:function(a){clickParams=new NCIAnalytics.ClickParams(a,"nciglobal","o","BulletinSubscription"),clickParams.Events=[9],clickParams.LogToOmniture()},GenericLinkTrack:function(a,i){clickParams=new NCIAnalytics.ClickParams(a,"nciglobal","o","GenericLinkTrack"),clickParams.Props={4:a.href,5:a.innerHTML,28:i},clickParams.LogToOmniture()},LinkTracking:function(a,i,e){clickParams=new NCIAnalytics.ClickParams(this,"nciglobal","o","LinkTracking"),clickParams.Props={4:a,5:i+NCIAnalytics.stringDelimiter+a},clickParams.LogToOmniture()},CustomLink:function(a,i){clickParams=new NCIAnalytics.ClickParams(a,"nciglobal","o",i),clickParams.LogToOmniture()},GlobalLinkTrack:function(a){var i="",e="",c=a.sender||!0,n=a.label||"",t=this.siteSection||"",r=document.location.hash,l=!0;if(a.eventList)switch(a.eventList.toLowerCase()){case"ogapreaward":i=[101];break;case"ogareceiving":i=[102];break;case"ogacloseout":i=[103];break;case"cctappdownload":i=[104];break;case"ccthowtoapply":i=[105];break;case"timetoclick":e=a.timeToClickLink?["106="+a.timeToClickLink]:""}var o=new NCIAnalytics.ClickParams(c,"nciglobal","o","GlobalLinkTrack"),m=NCIAnalytics.buildPageDetail()||"";o.Props={28:s.pageName+m,48:a.previousPageMaxVerticalTrackingString||""},o.Props[48]||(o.Props[66]=(t?t+"_":"")+n.toLowerCase()),o.Events=i,o.EventsWithIncrementors=e,o.LogToOmniture()},BookmarkShareClick:function(a){clickParams=new NCIAnalytics.ClickParams(a,"nciglobal","o","BookmarkShareClick");var i=a.title?a.title:a[0].title;clickParams.Props={43:a.title,66:(NCIAnalytics.siteSection?NCIAnalytics.siteSection+"_":"")+"social-share_"+i.toLowerCase()},clickParams.Events=[17],clickParams.LogToOmniture()},CustomTweetClick:function(a,i){clickParams=new NCIAnalytics.ClickParams(a,"nciglobal","o",i),clickParams.LogToOmniture()},MegaMenuClick:function(a,i){clickParams=new NCIAnalytics.ClickParams(a,"nciglobal","o","MegaMenuClick");var e=a.ownerDocument.location.hostname+a.ownerDocument.location.pathname;"undefined"!=typeof pageNameOverride&&(localPageName=pageNameOverride),void 0===i[1]&&(clickParams.Props={53:i[0].text,54:i[0].text,55:i[0].text,56:e},clickParams.Evars={53:i[0].text}),void 0!==i[1]&&(clickParams.Props={53:i[1].text,54:i[0].text,55:i[0].text,56:e},clickParams.Evars={53:i[1].text}),void 0!==i[2]&&(clickParams.Props={53:i[2].text,54:i[1].text,55:i[0].text,56:e},clickParams.Evars={53:i[2].text}),clickParams.Events=[26],clickParams.LogToOmniture()},MegaMenuDesktopReveal:function(a,i){clickParams=new NCIAnalytics.ClickParams(a,"nciglobal","o","MegaMenuDesktopReveal"),clickParams.Events=[28],clickParams.Evars={52:i,43:"Mega Menu"},clickParams.Props={52:i},clickParams.LogToOmniture()},MegaMenuMobileReveal:function(a){clickParams=new NCIAnalytics.ClickParams(a,"nciglobal","o","MegaMenuMobileReveal"),clickParams.Events=[28],clickParams.Evars={43:"Hamburger Menu"},clickParams.LogToOmniture()},MegaMenuMobileAccordionClick:function(a,i,e){var c=i?"Expand":"Collapse";clickParams=new NCIAnalytics.ClickParams(a,"nciglobal","o","MegaMenuMobileAccordionClick"),clickParams.Events=i?[34]:[35],clickParams.Props={73:c+"|"+e},clickParams.LogToOmniture()},MegaMenuMobileLinkClick:function(a,i,e,c,n,t){clickParams=new NCIAnalytics.ClickParams(a,"nciglobal","o","MegaMenuMobileLinkClick"),clickParams.Events=[26],clickParams.Evars={53:n},clickParams.Props={53:n,54:t,55:e,56:i},clickParams.LogToOmniture()},LogoClick:function(a){clickParams=new NCIAnalytics.ClickParams(a,"nciglobal","o","Logolick");var i=a.ownerDocument.location.hostname+a.ownerDocument.location.pathname;"undefined"!=typeof pageNameOverride&&(localPageName=pageNameOverride),clickParams.Props={53:"NCI Logo",56:i},clickParams.Evars={53:"NCI Logo"},clickParams.Events=[26],clickParams.LogToOmniture()},UtilityBarClick:function(a,i){clickParams=new NCIAnalytics.ClickParams(a,"nciglobal","o","UtilityBarDictionaryClick");var e=a.ownerDocument.location.hostname+a.ownerDocument.location.pathname;"undefined"!=typeof pageNameOverride&&(localPageName=pageNameOverride),clickParams.Props={36:i,53:i,56:e},clickParams.Evars={36:i,53:i},clickParams.Events=[16],clickParams.LogToOmniture()},CardClick:function(a,i,e,c,n){clickParams=new NCIAnalytics.ClickParams(a,"nciglobal","o","FeatureCardClick");var t=a.ownerDocument.location.hostname+a.ownerDocument.location.pathname;"undefined"!=typeof pageNameOverride&&(localPageName=pageNameOverride);var r=c+":"+n;clickParams.Props={57:i,58:e,59:r,60:t},clickParams.Events=[27],clickParams.LogToOmniture()},TimelyContentZoneTab:function(a,i){clickParams=new NCIAnalytics.ClickParams(a,"nciglobal","o","TimelyContentZoneTab"),clickParams.Props={37:i},clickParams.Evars={37:i},clickParams.LogToOmniture()},TimelyContentZoneLink:function(a,e){var c;if(!a)var a=window.event;if(a.target?c=a.target:a.srcElement&&(c=a.srcElement),3==c.nodeType&&(c=c.parentNode),"IMG"==c.nodeName&&(c=c.parentNode),"EM"==c.nodeName&&(c=c.parentNode),"A"==c.nodeName){var n="",t=!1;for(clickParams=new NCIAnalytics.ClickParams(this,"nciglobal","o","TimelyContentZoneLink"),i=0;i<c.innerHTML.length;i++)"<"==c.innerHTML.charAt(i)&&(t=!0),t||(n+=c.innerHTML.charAt(i)),">"==c.innerHTML.charAt(i)&&(t=!1);var r=c.innerHTML.toLowerCase();-1<r.search("video_icon.jpg")?n="Video: "+n:-1<r.search("audio_icon.jpg")&&(n="Audio: "+n),clickParams.Props={38:n,39:c.href,40:e},clickParams.Evars={38:n,39:c.href,40:e},clickParams.LogToOmniture()}},QuestionsAboutCancerFooter:function(a){clickParams=new NCIAnalytics.ClickParams(a,"nciglobal","o","QuestionsAboutCancerFooter"),clickParams.Events=[5],clickParams.LogToOmniture()},QuestionsAboutCancerHeader:function(a){clickParams=new NCIAnalytics.ClickParams(a,"nciglobal","o","QuestionsAboutCancerHeader"),clickParams.Events=[18],clickParams.LogToOmniture()},FindCancerTypeBox:function(a){clickParams=new NCIAnalytics.ClickParams(a,"nciglobal","o","FindCancerTypeBox"),clickParams.Events=[19],clickParams.LogToOmniture()},TileCarousel:function(a,i,e){clickParams=new NCIAnalytics.ClickParams(a,"nciglobal","o","TileCarousel"),clickParams.Props={41:i,42:e},clickParams.Evars={41:i,42:e},clickParams.Events=[20],clickParams.LogToOmniture()},VideoCarouselClickSwipe:function(a,i){clickParams=new NCIAnalytics.ClickParams(a,"nciglobal","o","VideoCarouselClickSwipe"),clickParams.Props={66:i,67:"D=pageName"},clickParams.Events=[63],clickParams.LogToOmniture()},VideoCarouselComplete:function(a,i){clickParams=new NCIAnalytics.ClickParams(a,"nciglobal","o","VideoCarouselComplete"),clickParams.Props={66:i,67:"D=pageName"},clickParams.Events=[64],clickParams.LogToOmniture()},ImageCarouselClickSwipe:function(a,i,e,c,n,t){clickParams=new NCIAnalytics.ClickParams(a,"nciglobal","o","ImageCarouselClick"),clickParams.Props={66:"imgcar_"+i+"_"+e+"_"+c+"_"+n,67:t},clickParams.Events=[62],clickParams.LogToOmniture()},LinkTrackTagBuilder:function(a){if(0==a.button){var i=NCIAnalytics.GetElement(NCIAnalytics.GetEventTarget(a),"A");null==i||null==i.href||""==i.href||null!=i.onclick&&-1!=i.onclick.toString().indexOf("NCIAnalytics")||NCIAnalytics.LinkTracking(NCIAnalytics.DissectLink(i.href),location.pathname)}},DissectLink:function(a){if(-1==a.indexOf("clickpassthrough")){var i=a.split("//");return 1<i.length?i[1]:a}for(var i=a.split("&"),e=0;e<i.length;e++)if(-1!=i[e].indexOf("redirectUrl"))return unescape(i[e].substring(12))},GetElement:function(a,i){try{for(var e=a;null!=e&&"BODY"!=e.tagName;){if(e.tagName==i)return e;e=e.parentNode}}catch(a){}},GetEventTarget:function(a){var i=a.target?a.target:a.srcElement;return null!=i&&3==i.nodeType&&(i=i.parentNode),i},Resize:function(a,i){var e="ResizedTo"+i;clickParams=new NCIAnalytics.ClickParams(a,"nciglobal","o",e),clickParams.Evars={5:i},clickParams.Events=[7],clickParams.LogToOmniture()},OnThisPageClick:function(a,i,e){clickParams=new NCIAnalytics.ClickParams(a,"nciglobal","o","OnThisPageClick"),i="OnThisPage_"+i,href=a.getAttribute?a.getAttribute("href"):a[0].getAttribute("href"),clickParams.Props={4:href,66:i,67:"D=pageName"},clickParams.Events=[29],-1<i.search(/^OnThisPage_how\sto\sapply/gi)&&clickParams.Events.push(105),clickParams.LogToOmniture()},InThisSectionClick:function(a,i,e){clickParams=new NCIAnalytics.ClickParams(a,"nciglobal","o","InThisSectionClick"),clickParams.Props={66:"InThisSection_"+i,67:"D=pageName"},clickParams.Events=[69],clickParams.LogToOmniture()},PDQMobileClick:function(a,i,e,c){var n=e?"AccordionSectionExpand_":"AccordionSectionCollapse_";clickParams=new NCIAnalytics.ClickParams(a,"nciglobal","o","PDQMobileClick"),clickParams.Events=e?[31]:[32],clickParams.Props={66:n+i,67:"D=pageName"},clickParams.LogToOmniture()},BackToTopReveal:function(a,i){clickParams=new NCIAnalytics.ClickParams(a,"nciglobal","o","BackToTopReveal"),clickParams.Events=[20],clickParams.LogToOmniture()},BackToTopClick:function(a,i){clickParams=new NCIAnalytics.ClickParams(a,"nciglobal","o","BackToTopClick"),clickParams.Events=[21],clickParams.Props={50:i?"UtilityBarShowing":"UtilityBarHidden"},clickParams.LogToOmniture()},SectionMenuButtonClick:function(a,i){clickParams=new NCIAnalytics.ClickParams(a,"nciglobal","o","SectionMenuButtonClick"),clickParams.Events=[30],clickParams.Evars={43:"Section Menu",45:i},clickParams.LogToOmniture()},SectionAccordionClick:function(a,i,e,c,n){var t=e?"Expand":"Collapse";clickParams=new NCIAnalytics.ClickParams(a,"nciglobal","o","SectionAccordionClick"),clickParams.Events=e?[31]:[32],clickParams.Evars={43:"Section Menu",45:c},clickParams.Props={68:t+"|"+n,66:(NCIAnalytics.siteSection?NCIAnalytics.siteSection+"_":"")+t.toLowerCase()+"|"+n.toLowerCase()},clickParams.LogToOmniture()},SectionLinkClick:function(a,i,e,c,n){clickParams=new NCIAnalytics.ClickParams(a,"nciglobal","o","SectionLinkClick"),clickParams.Events=[33],-1<c.search(/^how\sto\sapply/gi)&&clickParams.Events.push(105),clickParams.Evars={43:"Section Menu",45:e},clickParams.Props={66:(NCIAnalytics.siteSection?NCIAnalytics.siteSection+"_":"")+c.toLowerCase(),69:e,70:c,71:n,72:i},clickParams.LogToOmniture()},fontResizer:function(a,i,e){clickParams=new NCIAnalytics.ClickParams(a,"nciglobal","o","fontResizer"),e||(clickParams.Events=[36]),clickParams.Props={42:i,66:(NCIAnalytics.siteSection?NCIAnalytics.siteSection+"_":"")+"font-resize_"+(i?i.toLowerCase():"")},clickParams.LogToOmniture()},AccordionClick:function(a,i,e,c,n){clickParams=new NCIAnalytics.ClickParams(this,"nciglobal","o","LinkTracking");var t=i;e&&(t+="|"+e),c&&(t+="|"+c),n&&(t+="|"+n),clickParams.Props={41:t},clickParams.LogToOmniture()},HomePageDelighterClick:function(a,i,e){"hp_find"===i&&(clickParams=new NCIAnalytics.ClickParams(a,"nciglobal","o","HomePageFindDelighter"),clickParams.Props={5:"hp_find ct delighter|"+e,66:"delighter_findclinicaltrials"},clickParams.LogToOmniture())},RecordDelighterRailClick:function(a,i){var e=s.pageName;"livehelp"===i&&(clickParams=new NCIAnalytics.ClickParams(a,"nciglobal","o","DelighterLiveChat"),clickParams.Props={5:"rrail_chat with us|"+e},clickParams.LogToOmniture())},RecordProactiveChatPromptDisplay:function(a){var i=s.pageName;clickParams=new NCIAnalytics.ClickParams(a,"nciglobal","o","ProactiveChat"),clickParams.Props={5:"livehelp_proactive chat - display|"+i},clickParams.Events=[45],clickParams.LogToOmniture()},RecordProactiveChatPromptClick:function(a){var i=s.pageName;clickParams=new NCIAnalytics.ClickParams(a,"nciglobal","o","ProactiveChat"),clickParams.Props={5:"livehelp_proactive chat - launch|"+i},clickParams.Events=[44],clickParams.LogToOmniture()},RecordProactiveChatPromptDismissal:function(a){var i=s.pageName;clickParams=new NCIAnalytics.ClickParams(a,"nciglobal","o","ProactiveChat"),clickParams.Props={5:"livehelp_proactive chat - dismiss|"+i},clickParams.Events=[43],clickParams.LogToOmniture()},FeedbackFormClick:function(a,i){var e=s.pageName;clickParams=new NCIAnalytics.ClickParams(a,"nciglobal","o","FeedbackForm"),clickParams.Props={5:i+"|"+e},clickParams.LogToOmniture()},SimpleCTSLink:function(a,i,e){clickParams=new NCIAnalytics.ClickParams(a,"nciglobal","o","CTSLink"),clickParams.Props={5:i+"|"+e},clickParams.LogToOmniture()},CTSResultsClick:function(a,i,e){var c="clinicaltrials_basic";e&&(c="clinicaltrials_custom"),NCIAnalytics.CTSResultsWithFormClick(a,i,c)},CTSResultsWithFormClick:function(a,i,e){clickParams=new NCIAnalytics.ClickParams(a,"nciglobal","o","CTSLink"),clickParams.Events=[42],clickParams.Props={12:e,13:i},clickParams.Evars={12:e},clickParams.LogToOmniture()},SPLF_Lang:function(){},VideoSplashImageClick:function(a,i,e){clickParams=new NCIAnalytics.ClickParams(a,"nciglobal","o","OnThisPageClick"),clickParams.Props={66:"VideoStart_"+i,67:e},clickParams.Events=[51],clickParams.LogToOmniture()},BRPiconClick:function(a,i,e){clickParams=new NCIAnalytics.ClickParams(a,"nciglobal","o","OnThisPageClick"),clickParams.Props={66:"FileDownload_"+i,67:e},clickParams.Events=[52],clickParams.LogToOmniture()},BlogArchiveLinkClick:function(e,a){clickParams=new NCIAnalytics.ClickParams(e,"nciglobal","o","BlogArchiveDateClick"),urlParam=function(a){var i=new RegExp("[?&].*["+a+"]=([^&#]*)").exec(e.href);return null==i?"":i[1]||0};var i=urlParam("[year]"),c=urlParam("[month]");clickParams.Props={66:"Blog_"+s.prop44+"_"+NCIAnalytics.blogLocation()+"_Archive",67:a,50:i+(c?":"+c:"")},clickParams.Events=[55],clickParams.LogToOmniture()},BlogSubscribeClick:function(a,i){clickParams=new NCIAnalytics.ClickParams(a,"nciglobal","o","BlogSubscribeClick"),clickParams.Props={66:"Blog_"+s.prop44+"_"+NCIAnalytics.blogLocation()+"_Subscribe",67:i},clickParams.Events=[58],clickParams.LogToOmniture()},BlogArchiveAccordionClick:function(a,i,e){clickParams=new NCIAnalytics.ClickParams(a,"nciglobal","o","BlogAccordionAction");var c="";c=e?"_Collapse:Archive":"_Expand:Archive",clickParams.Props={66:"Blog_"+s.prop44+"_"+NCIAnalytics.blogLocation()+c,67:i},clickParams.LogToOmniture()},BlogBodyLinkClick:function(a,i,e){clickParams=new NCIAnalytics.ClickParams(a,"nciglobal","o","BlogBodyLinkClick");var c="_BodyLink";clickParams.Props={50:i,66:"Blog_"+s.prop44+"_"+NCIAnalytics.blogLocation()+c,67:e},clickParams.Events=[56],clickParams.LogToOmniture()},glossifiedTerm:function(a,i,e){var c=new NCIAnalytics.ClickParams(a,"nciglobal","o","glossifiedTerm");c.Props={45:"Glossified Term",50:i,67:"D=pageName"},e&&(c.Props[66]="Blog_"+s.prop44+"_"+NCIAnalytics.blogLocation()+"_BodyGlossifiedTerm"),c.Events=[56],c.LogToOmniture()},BlogRelatedLinksClick:function(a,i,e,c){clickParams=new NCIAnalytics.ClickParams(a,"nciglobal","o","BlogRelatedLinkClick");var n="";n=NCIAnalytics.blogLocation()?(clickParams.Events=[57],"Blog_"+s.prop44+"_"+NCIAnalytics.blogLocation()+"_RelatedResource:"+c):(clickParams.Events=[59],s.prop44+"_RelatedResource:"+c),clickParams.Props={66:n,67:e,50:i},clickParams.LogToOmniture()},BlogCardClick:function(a,i,e,c){clickParams=new NCIAnalytics.ClickParams(a,"nciglobal","o","BlogFeatureCardClick"),clickParams.Props={66:"Blog_"+s.prop44+"_"+NCIAnalytics.blogLocation()+"_BlogCard:"+e,67:c,50:i},clickParams.Events=[54],clickParams.LogToOmniture()},FeaturedPostsClick:function(a,i,e,c){clickParams=new NCIAnalytics.ClickParams(a,"nciglobal","o","FeaturedPostsClick"),clickParams.Props={66:"Blog_"+s.prop44+"_"+NCIAnalytics.blogLocation()+"_FeaturedPosts:"+e,67:c,50:i},clickParams.Events=[54],clickParams.LogToOmniture()},CategoryClick:function(a,i,e,c){clickParams=new NCIAnalytics.ClickParams(a,"nciglobal","o","CategoryClick"),clickParams.Props={66:"Blog_"+s.prop44+"_"+NCIAnalytics.blogLocation()+"_Category:"+e,67:c,50:i},clickParams.Events=[55],clickParams.LogToOmniture()},OlderNewerClick:function(a,i,e){clickParams=new NCIAnalytics.ClickParams(a,"nciglobal","o","OlderNewerClick"),clickParams.Props={66:"Blog_"+s.prop44+"_"+NCIAnalytics.blogLocation()+"_"+i,67:e},"Post"==NCIAnalytics.blogLocation()&&(clickParams.Events=[55]),clickParams.LogToOmniture()},TableSortHeaderClick:function(a,i){clickParams=new NCIAnalytics.ClickParams(a,"nciglobal","o","SortTableHeaderClick"),clickParams.Props={5:"table_sort",67:i},clickParams.LogToOmniture()},ProfilePanelLinkClick:function(a,i,e){clickParams=new NCIAnalytics.ClickParams(a,"nciglobal","o","ProfilePanelLinkClick"),clickParams.Props={66:"InstitutionCard_"+e+"_"+i,67:"D=pageName"},clickParams.LogToOmniture()},blogLocation:function(){return document.querySelector("body.cgvblogpost")?"Post":document.querySelector("body.cgvblogseries")?"Series":document.querySelector("body.cgvtopicpage")?"Category":""},buildPageDetail:function(){var a=document.location.hash,i="";return a=a.replace(/#?(section|link)\//g,""),a=a.replace(/#/g,""),a&&(selector=document.querySelector("#"+a+" h2"),selector&&(i=selector.textContent.toLowerCase())),i&&0!=i.indexOf("/")&&(i="/"+i),i},startPageLoadTimer:function(){window.pageLoadedAtTime=(new Date).getTime()}},timer;if("complete"===document.readyState||"loading"!==document.readyState&&!document.documentElement.doScroll?NCIAnalytics.startPageLoadTimer():document.addEventListener("DOMContentLoaded",NCIAnalytics.startPageLoadTimer),"/grants-training"===trimmedPathname){var grantsTrainingLinks=document.querySelectorAll("#content a[href*='grants-training']"),linksArray=[].slice.call(grantsTrainingLinks);function setTimeToClick(a){var i=a.target.href;if(destinationSiteSection="",oga_pattern.test(i)?destinationSiteSection="oga":cct_pattern.test(i)&&(destinationSiteSection="cct"),destinationSiteSection&&window.pageLoadedAtTime){var e=a.target.textContent.toLowerCase().substring(0,89).trim(),c=(new Date).getTime();NCIAnalytics.GlobalLinkTrack({sender:this,label:destinationSiteSection?destinationSiteSection+"_"+e:e,timeToClickLink:Math.round((c-window.pageLoadedAtTime)/1e3),eventList:"timetoclick"})}}linksArray.forEach(function(a){a.addEventListener("click",setTimeToClick)})}function buildPageOverride(a){var i="",e="",c=a.hash,n=a.page;return i=n||"",c=c.replace(/^\#?section\//i,""),e=NCIAnalytics.buildPageDetail(),e=e||c,e=e.replace(/^\//,""),i+=e?"/"+e:"",i}function changeMonitor(a){var i=a.name,e=a.value;if(window[i]!=e){var c=!0;"hash"===i&&-1<e.indexOf("#link/")&&(c=!1),c&&a.callback&&a.callback(),window[i]=e}}function attachEvents(a){var i=a.element,e=a.event,c=a.action;i.addEventListener?i.addEventListener(e,c):i.attachEvent&&i.attachEvent("on"+e,c)}NCIAnalytics.cookieWrite=function(a,i,e){var c=e?new Date:"";c&&(c.setDate(c.getDate()+e||0),c=c.toUTCString());var n=window.location.hostname;n=n.split("."),n=n.splice(n.length-2,2),n=n.join(".");var t=[];t.push(a+"="+encodeURI(i)),t.push("path=/"),t.push("domain="+n),c&&t.push("expires="+c),document.cookie=t.join(";")},NCIAnalytics.cookieRead=function(a){if(0<document.cookie.length){var i=document.cookie.indexOf(a+"=");if(-1!=i){i=i+a.length+1;var e=document.cookie.indexOf(";",i);return-1==e&&(e=document.cookie.length),decodeURI(document.cookie.substring(i,e))}}return""},NCIAnalytics.getScrollDetails=function(a){var e=NCIAnalytics.previousPageMaxVerticalTrackingString||"",i="";page=s.pageName+"",a&&(1!=a.updateOnly&&(e=NCIAnalytics.cookieRead("nci_scroll"),NCIAnalytics.cookieWrite("nci_scroll","")),!0===a.reset&&(NCIAnalytics.maxVerticalScroll=0,NCIAnalytics.maxPageHeight=0,NCIAnalytics.scrollDetails_orig=""),a.source,a.pageOverride&&(page=a.pageOverride)),page=page.replace(/www\.cancer\.gov/i,"").replace(/\s/gi,"-").toLowerCase();var c=NCIAnalytics.maxVerticalScroll||0,n=NCIAnalytics.maxPageHeight||0,t=window.innerHeight,r=window.pageYOffset,l=(o=document.body,m=document.documentElement,k=Math.max(o.scrollHeight,o.offsetHeight,m.clientHeight,m.scrollHeight,m.offsetHeight),k),o,m,k;NCIAnalytics.maxVerticalScroll=c<r?r:c,NCIAnalytics.maxPageHeight=n<l?l:n;var P=NCIAnalytics.maxVerticalScroll+t;function g(a){var i=a||{};return i.viewportHeight=t,i.fullPageHeight=l,i.verticalScrollDistance=r,i.maxVerticalScroll=NCIAnalytics.maxVerticalScroll,i.maxPageHeight=NCIAnalytics.maxPageHeight,i.totalPageViewed=P,i.percentAboveFoldAtLoad=percentAboveFoldAtLoad===1/0?100:percentAboveFoldAtLoad,i.percentOfTotalPageViewed=percentOfTotalPageViewed===1/0?100:percentOfTotalPageViewed,i.previousPageMaxVerticalTrackingString=e,i}if(percentAboveFoldAtLoad=Math.round(t/l*100),percentOfTotalPageViewed=Math.round(P/NCIAnalytics.maxPageHeight*100),NCIAnalytics.scrollDetails=g(),NCIAnalytics.cookieWrite("nci_scroll",NCIAnalytics.scrollDetails.percentOfTotalPageViewed+"pct|"+NCIAnalytics.scrollDetails.percentAboveFoldAtLoad+"pct|"+NCIAnalytics.maxPageHeight+"px|"+page),NCIAnalytics.scrollDetails_orig&&""!=NCIAnalytics.scrollDetails_orig||(NCIAnalytics.scrollDetails_orig=g()),a&&!0===a.sendCall){var u=document.location.hash||"";null!=u.match(/^(#link|#section)/)&&NCIAnalytics.GlobalLinkTrack({previousPageMaxVerticalTrackingString:NCIAnalytics.scrollDetails.previousPageMaxVerticalTrackingString})}return NCIAnalytics.scrollDetails},attachEvents({element:window,event:"load",action:function(){NCIAnalytics.getScrollDetails({source:"window.load",pageOverride:buildPageOverride({page:s.pageName,hash:document.location.hash})})}}),attachEvents({element:window,event:"scroll",action:function(){clearTimeout(timer),timer=setTimeout(function(){NCIAnalytics.getScrollDetails({updateOnly:!0,source:"window.scroll",pageOverride:buildPageOverride({page:s.pageName,hash:document.location.hash})})},150)}}),attachEvents({element:window,event:"hashchange",action:function(){changeMonitor({name:"hash",value:document.location.hash,callback:function(){setTimeout(function(){NCIAnalytics.getScrollDetails({source:"hashMonitor",reset:!0,sendCall:!0,pageOverride:buildPageOverride({page:s.pageName,hash:document.location.hash})})},100)}})}}),NCIAnalytics.isVarEmpty=function(a){return null==a||""===a},NCIAnalytics.getQueryString=function(a,i){var e="",c,n;if(c=i?i.slice(i.indexOf("?")+1):window.location.search.substring(1),subStringArray=c.split("&"),queryParamArray=a.split(","),0<subStringArray.length)for(var t=0,r=subStringArray.length;t<r;t++){paramValue=subStringArray[t].split("=");for(var l=0,s=queryParamArray.length;l<s;l++)if(paramValue[0].toLowerCase()==queryParamArray[l].toLowerCase())return e=paramValue[1]?unescape(paramValue[1]):"",e=e.replace(/\+/g," "),e=e.replace(/^\s+|\s+$/g,""),e}return e},NCIAnalytics.crossVisitParticipation=function(a){var i=a.cookieValue?a.cookieValue.replace("'",""):"",e=NCIAnalytics.cookieRead(a.cookieName)?NCIAnalytics.cookieRead(a.cookieName).split(","):"",c=a.expire,n;if(i){if("none"==e||NCIAnalytics.isVarEmpty(e))return newCookieArray=[i],NCIAnalytics.cookieWrite(a.cookieName,newCookieArray,c),i;var t=e[0];t!=i&&(e.unshift(i),e.length>=a.returnLength&&(e.length=a.returnLength),NCIAnalytics.cookieWrite(a.cookieName,e,c))}return n=e?e.reverse().join(a.delimiter):"",n},NCIAnalytics.urs={config:{campaignPrefixDelimiter:"_",internalDomains:["cancer.gov","nci.nih.gov","smokefree.gov"],searchEngines:["alibaba.com","aol.","ask.com","baidu.com","bing.com","duckduckgo.com","google.","msn.com","search.yahoo.","yandex."],socialNetworks:["facebook.com","flickr.com","instagram.com","linkedin.com","pinterest.com","plus.google.com","reddit.com","t.co","tumblr.com","twitter.com","yelp.com","youtube.com"],govDomains:[".gov"],eduDomains:[".edu"],pattEmail:/^(e(b|m)_)|((eblast|email)\|)/i,pattPaidSocial:/^psoc_/i,pattSocial:/^((soc|tw|fb)_|(twitter|facebook)\||sf\d{8}$)/i,pattSem:/^(sem|ppc)_/i,pattAffiliate:/^aff_/i,pattPartner:/^ptnr_/i,pattDisplay:/^bn_/i,pattDr:/^dr_/i,pattInternal:/^int_/i,channelStackDepth:5,channelStackDelimiter:">",channelStackExpire:180,channelStackCookie:"nci_urs_stack"},getStacked:function(a){var i=a.ursCookie,e=a.channel,c="";return e&&(c=NCIAnalytics.crossVisitParticipation({cookieName:i,cookieValue:e,returnLength:this.config.channelStackDepth,delimiter:this.config.channelStackDelimiter,expire:this.config.channelStackExpire})),c},getPrefix:function(a,i){var e="";return i=i||"_",a&&(e=a.split(i)[0]),e},getSeoStatus:function(a,i,e){var a=a,c=!1,n=-1<e.indexOf(".google."),t=-1<e.indexOf("search.yahoo.com"),r=-1<e.indexOf(".yandex.");return n||t||r?c=!0:e&&-1<i.indexOf(a)&&(c=!0),c},get:function(a){var i="",e="",c="",n=ppcKeyword="",t=g="",r=!1,l=a.campaign?a.campaign:"",s=a.referrer?a.referrer:document.referrer?document.referrer:"",o=(m=s,k={domain:"",subDomain:"",tld:""},m&&(k.domain=m.split("/")[2].split("."),k.subDomain=k.domain.join("."),k.domain=2<k.domain.length?k.domain.slice(1,k.domain.length):k.domain,k.tld=k.domain[k.domain.length-1],k.domain=k.domain.join(".")),k),m,k,P=o.tld,t=o.domain,g=o.subDomain;return l||s||t?-1<l.search(this.config.pattDisplay)?(i="display",e=l):-1<l.search(this.config.pattAffiliate)?(i="affiliate",e=l):-1<l.search(this.config.pattPartner)?(i="partner",e=l):-1<l.search(this.config.pattDr)?(i="dr",e=l):-1<l.search(this.config.pattEmail)?(i="email",e=l,/^eblast\|/i.test(l)&&(this.config.campaignPrefixDelimiter="|")):-1<l.search(this.config.pattSocial)?(i="social",e=l):-1<l.search(this.config.pattPaidSocial)?(i="paid_social",e=l):-1<l.search(this.config.pattSem)?(i="paid_search",e=l,s&&(ppcKeyword=NCIAnalytics.getQueryString("q,query,search",s)),ppcKeyword=ppcKeyword||"not provided|"+(t||i)):-1<l.search(this.config.pattInternal)?(i="internal",e=l):l?(i="unknown",e=l):s&&(-1<this.config.internalDomains.indexOf(t)||-1<this.config.internalDomains.indexOf(g))?(i="internal-dnt",e=""):s&&-1<this.config.socialNetworks.indexOf(t)||"plus.google.com"===g?(i="social",e="[soc]_"+t):this.getSeoStatus(t,this.config.searchEngines,s)?(i="organic_search",e="[seo]_"+t,n=NCIAnalytics.getQueryString("q,query,search,text",s),n=n||"not provided|"+(t||i)):s&&"gov"===P&&this.config.internalDomains.indexOf(t)<0?(i="government_domains",e="[gov]_"+t):s&&"edu"===P?(i="education_domains",e="[edu]_"+t):s&&this.config.govDomains.indexOf(t)<0&&(i="referring_domains",e="[ref]_"+t):(i="direct-dnt",e=l),c=this.getPrefix(e,this.config.campaignPrefixDelimiter),"unknown"===i&&(i=c),""!=e&&"organic_search"!=i&&(n="not organic search"),""!=e&&"paid_search"!=i&&(ppcKeyword="not paid search"),{campaign:l,referrer:s,refDomain:t,value:e,prefix:c,stacked:this.getStacked({channel:c,ursCookie:this.config.channelStackCookie}),trafficType:i,seoKeyword:n,ppcKeyword:ppcKeyword}}};</script><script type="text/javascript" src="Adult%20Central%20Nervous%20System%20Tumors%20Treatment%20(PDQ%C2%AE)%E2%80%94Health%20Professional%20Version%20-%20National%20Cancer%20Institute_files/4407.js" async="async"></script><!--BEGIN QUALTRICS SITE INTERCEPT-->
<script type="text/javascript">
(function(){var g=function(e,h,f,g){
this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null};
this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "};
this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0};
this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g+ "&t=" + (new Date()).getTime();document.body&&document.body.appendChild(a)}};
this.start=function(){var a=this;window.addEventListener?window.addEventListener("load",function(){a.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){a.go()})}};
try{(new g(100,"r","QSI_S_SI_blNAE3KoV3SLMWh","https://zn88jixcivzfb3vpp-nci.siteintercept.qualtrics.com/WRSiteInterceptEngine/?Q_SIID=SI_blNAE3KoV3SLMWh&Q_LOC="+encodeURIComponent(window.location.href))).start()}catch(i){}})();
</script><div id="SI_blNAE3KoV3SLMWh"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div>
<!--END SITE INTERCEPT--><!--BEGIN QUALTRICS SITE INTERCEPT-->
<script type="text/javascript">
	document.addEventListener("DOMContentLoaded", function(event) {
    // Only do this on the following pages:
    // Article pages
    // Blog posts
    // General Pages
    // Factsheets
    var pageType = document.body.getAttribute('data-cde-contenttype');
    if( pageType == 'cgvarticle' ||
        pageType == 'cgvblogpost' ||
        pageType == 'ncigeneral' ||
        pageType == 'cgvfactsheet'){
      var pageHelpfulDiv = document.createElement('div');
      
      pageHelpfulDiv.id="PageHelpfulSurvey";
      
      var surveyAnchor = document.getElementById('cgvDate');
      if(!surveyAnchor){
          surveyAnchor = document.getElementById('blog-cards');        
      }
      if(!surveyAnchor){
        surveyAnchor = document.getElementById('cgvSlPagination');
      }
      
      surveyAnchor.parentNode.insertBefore(pageHelpfulDiv, surveyAnchor.nextSibling);
    }
			//Qualtrics Zone code blurb
        var g=function(e,h,f,g){
        this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null};
        this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "};
        this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0};
        this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g+ "&t=" + (new Date()).getTime();document.body&&document.body.appendChild(a)}};
        this.start=function(){var a=this;window.addEventListener?window.addEventListener("load",function(){a.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){a.go()})}};
        try{(new g(100,"r","QSI_S_ZN_88jixcivZFB3vpP","//zn88jixcivzfb3vpp-nci.siteintercept.qualtrics.com/WRSiteInterceptEngine/?Q_ZID=ZN_88jixcivZFB3vpP&Q_LOC="+encodeURIComponent(window.location.href))).start()}catch(i){}

    });
    
</script><div id="ZN_88jixcivZFB3vpP"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div>
<!--END SITE INTERCEPT-->
    



      <div id="modal-1" class="modal-slide modal" aria-hidden="true">
        <div tabindex="-1" class="modal__overlay" data-modal-close="">
          <div class="modal__container" role="dialog" aria-modal="true" aria-labelledby="modal-1-title">
            <button class="modal__btn-close" aria-label="Close modal" data-modal-close=""></button>
            <div id="modal-1-content" class="modal__content">
              <div class="spinkit spinner"><div class="dot1"></div><div class="dot2"></div></div>
            </div>
            <button class="modal__btn-close modal__btn-close--bottom" aria-label="Close modal" data-modal-close=""></button>
          </div>
        </div>
      </div><ul id="ui-id-1" tabindex="0" class="ui-menu ui-widget ui-widget-content ui-front ui-autocomplete sitewide-search-menu" style="display: none;"></ul><div role="status" aria-live="assertive" aria-relevant="additions" class="ui-helper-hidden-accessible"></div><script type="text/javascript" src="Adult%20Central%20Nervous%20System%20Tumors%20Treatment%20(PDQ%C2%AE)%E2%80%94Health%20Professional%20Version%20-%20National%20Cancer%20Institute_files/a_002.js"></script><script type="text/javascript" src="Adult%20Central%20Nervous%20System%20Tumors%20Treatment%20(PDQ%C2%AE)%E2%80%94Health%20Professional%20Version%20-%20National%20Cancer%20Institute_files/a.js"></script><script src="Adult%20Central%20Nervous%20System%20Tumors%20Treatment%20(PDQ%C2%AE)%E2%80%94Health%20Professional%20Version%20-%20National%20Cancer%20Institute_files/CoreModule.js" defer="defer"></script></body></html>